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Like all sciences, chemistry has unique place in our pattern of understanding of the 
universe. It is the science of molecules. But the organic chemsitry is something more. It 
literally creates itself as it grows. Of course we need to study the molecules of nature both 
because they are interesting in their own right and because their functions are important to our 
daily lives. Organic chemistry often studies the life by making new moleculs that give 
information not available from the molecules actually present in living things. Natural 
products continue to play an important role in discovery and development of new 
pharmaceuticals, as clinically useful drugs, as starting materials to produce synthetic drugs, or 
as lead structures from which a synthetic drug can be designed.1 Menthol is the famous 
example of flavouring compound extracted from the essential oil of spearmint. At the same 
time, synthetic compounds not related to natural products play an increasingly important role 
for drug discovery. Continuous improvements in synthetic methodology have provided a 
convenient access to a vast array of synthetic substances. 
Natural products often represent important lead structures for the development of new 
antibiotics.2 In fact, a number of natural products exhibit antibiotic activity. Since the 
discovery of penicillin, a large number of antibiotics has been isolated from scores of 
microorganisms.3 The discovery of new important anti-infective compounds includes both 
plant and animal sources. For example, astemisinin, a sesquiterpene with endoperoxide 
moiety, was isolated from Astemisia annua, a Chinese medicinal plant, which has been used 
in China for centuries for treatment of malaria. The development of new drugs includes 
synthetic and semi-synthetic studies, microbial transformations, the biological screening and 
the study of the mechanism of action. 
Natural products have also provided the most important success in the chemotherapy of 
cancer disease. A number of anticancer drugs represent unmodified natural products isolated 
from plants or microorganisms:5 this includes bleomycin, doxorubicin, mitomycin, paclitaxel 
(TaxolTM); examples of semi-synthetic derivatives of natural products, which are important 
anticancer drugs are, for example, ironotecan (a camptothecin derivative), etoposide or 
tenoposide (a podophyllotoxin derivative). Currently, both a semi-synthetic derivative with 
improved water solubility, docetaxel (TaxoteneTM) and paclitaxel (TaxolTM) are approved 
and used clinically in the treatment of ovarian breast cancers. 
Many important drugs have been developed by a combination of natural product and 
synthetic chemistry. In this context, combinatorial chemistry provides an ever-increasing pool 
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for evaluation of therapeutic potential; advances in molecular biology will provide insights 
into the biological processes and, hence, possible targets for the treatment of disease. 
Bioactive natural products can serve as probes to study these molecular and pharmacological 
processes.6 
My studies are focused on the development of new and reliable synthetic strategies and 
their application to the preparation of natural products analogues, and pharmacologically 
active carba- and heterocycles.  
In the present thesis, the synthesis of natural product analogues is studied. These 
structures include salicylates, dibenzo[b,d]pyran-6-ones, fluoroarenes, fluorenones, 




























A significant part of the present dissertation has been recently published. The work presented 
in this dissertation is concerned with the synthesis of highly functionalized salicylates and 
dibenzo[b,d]pyran-6-ones, based on [3+3] cyclizations of 1,3-bis(silyloxy)-1,3-butadienes and 
cyclization reactions of 1,3-bis(silyloxy)-1,3-butadienes with dimethyl allene-1,3-
dicarboxylate and arylsulfonyl cyanides 
 
Synthesis of Homophthalates, 2-(Arylsulfonyl)pyridines,6-(Thien-2-yl)salicylates, 
Dibenzo[b,d]pyran-6-ones, Trifluoromethyl- and Fluoro-Substituted Biaryls by 
[4+2] and [3+3] Cyclizations of 1,3-Bis(silyloxy)-1,3-butadienes 
 
1. One-pot Synthesis of Salicylates based on [3+3] cyclizations of 1,3-
Bis(trimethylsilyloxy)-1,3-butadienes and comprison of Regioselectivities. This chapter 
includes the synthesis of novel alkyl-substituted 1,3-bis(silyl enol ethers) 5a-v based on the 
known procedures. The synthesis of ether-substituted 1,3-bis(silyl enol ethers) is also 
presented in this chapter. The 1,3-bis(silyl enol ethers) are used as starting materials for the 
synthesis of 6-(thien-2-yl)- and 6-(fur-2-yl)salicylates 10a-o, 13a-d and 4-aryl- and 4-hetaryl-
6-(trifluoromethyl)salicylates 16a-o. In the last, the regioselectivities are compared on the 
basis of methyl- and trifluoromethyl-substituted derivatives 
 
2. Synthesis of Biaryls and Dibenzo[b,d]pyran-6-ones based on a [3+3] Cyclization 
Strategy. Dibenzo[b,d]pyran-6-ones are present in many natural products such as alternariol, 
autumnariol, autumnariniol and altenuisol. In this chapter, the synthesis of functionalized 
biaryls 20a-i is carried out by using the [3+3] cyclization strategy, which are then transformed 
into the dibenzo[b,d]pyran-6-ones 21a-j by BBr3 mediated lactonization.  
 
3. Regioselective Synthesis of Fluorinated Biaryls, 6H-Benzo[c]chromen-6-ones and 
Fluorenones based on Formal [3+3] Cyclizations of 1,3-Bis(trimethylsilyloxy)-1,3-
butadienes. This chapter includes the synthesis of fluorinated salicylates 26a-w, by [3+3] 
cyclization methodology. These salicylates 26a-f are then transformed into the fluorinated 
dibenzo[b,d]pyran-6-ones 27a-f by BBr3 mediated lactonization. Moreover, some salicylates 




4. Synthesis of 4-Hydroxy- and 2,4-Dihydroxy-homophthalates by [4+2] Cycloaddition of 
1,3-Bis(trimethylsilyloxy)-1,3-butadienes with Dimethyl Allene-1,3-dicarboxylate. In this 
chapter, the the synthesis of various homophthalates 33a-ab based on the cycloaddition of 
dimethyl allene-1,3-dicarboxylate with various 1,3-bis(silyl enol ethers) is carried out.  
 
5. Synthesis of Functionalized 2-(Arylsulfonyl)-4-hydroxypyridines by Heter-Diels-Alder 
Reaction of 1,3-Bis(trimethylsilyloxy)-1,3-butadienes with Arylsulfonyl Cyanides. This 
chapter deals with the synthesis of 5-alkyl-, 5-halide-, 5-aryloxy- and 5-thioaryloxy-2-
(arylsulfonyl)-4-hydroxypyridines 35a-n by the hetero-Diels-Alder reaction of substituted 
1,3-bis(trimethylsilyloxy)-1,3-butadienes with arylsulfonyl cyanides, thus introducing the 
substitution pattern at carbon C-3 (or C-5) of the of pyridine using one-pot methodology. 
 
7. Experimental part 




















1. One-Pot Synthesis of Salicylates based on Regioselective [3+3] 
Cyclizations of 1,3-Bis(trimethylsilyloxy)-1,3-butadienes and comparison of 
Regioselectivities 
 




One-pot cyclization of 1,3-dicarbonyl compounds with electrophiles provide a convenient 
approach to various heterocyclic and carbacyclic ring systems. 1,3-dicarbonyl compounds can 
react in two ways, free dianions and masked dianions. Dinaion is a specie having two negative 
charges. Free dianions are generated by reaction of 1,3-dicarbonyl compounds with a strong 
base, such as LDA or n-BuLi.7 To avoid the high basicity and reactivity of free dianions, these 
are masked by using some masking agents. 1,3-Bis(silyl enol ethers) commonly known as 
masked dianions, are considered as the synthetic equivalent of the  corresponding 1,3-
dicarbonyl compounds.8 The regioselectivity observed for reactions of free and masked 
dianions is the same in most of the cases. The terminal carbon atom of 1,3-dicarbonyl 
compounds is functionalized by reaction of the corresponding dianions with one equivalent of 
an electrophile E+, to produce monoanion, which is trapped by the addition of second 
electrophile. The cyclization reactions of dianions follow the two general mechanistic 
pathways 7 (Scheme 1-1, Schem 1-2). 
 
Mechanism type A: the dianion can react with monofunctional electrophiles with 
transposition of a negative charge from the dianion to the electrophile. This carbanion attacks 
an E+ centre of the former dianion moiety (e.g. the ester group) to give a cyclic monoanion 

















Scheme 1-1: Possible mechanism for cyclization reactions of 1,3-dicarbonyl dianions. Nu 




Mechanism type B: the dianion can also react as a dinucleophile with a dielectrophile. A 
















Scheme 1-2: Possible mechanism for cyclization reactions of 1,3-dicarbonyl dianions.  E = 
electrophile center 
 
Cyclization reactions of dianions with dielectrophiles are synthetically important. In 
addition, 1,2-dielectrophiles are often rather labile, and reactions with nucleophiles can often 
lead to polymerization, decomposition, formation of open-chained products, elimination or 
SET-process. These limitations can be overcome by two methods: a) a proper tuning of the 
reactivity of dianion and dieletrophile and b) the use of eletroneutral dianion equivalents 
(masked dianions) in Lewis acid catalyzed reactions.7 
 
Recent studies proved that 1,3-bis(silyl enol ethers) can be considered as equivalents of the 
corresponding 1,3-dicarbonyl dianions.8 The chemistry of bis silyl enol ethers has been 
developed during the last two decades.8d It is, for example, known that silyl enol ethers can 
condense with various carbonyl compounds in the presence of Lewis acids.9 These Lewis-
acid-mediated reactions10 (e. g. alkylation and aldol condensation) provide useful alternatives 
to classical enolate chemistry. In cyclization reactions, 1,3-bis(silyl enol ethers) can react as 
1,3-dinucleophiles or, similar to the well-known Danishefsky diene,11 as functionalized 
butadienes. 1,3-Bis(silyl enol ethers) undergo reactions with electrophiles at the terminal 
carbon atom followed by reaction of the central carbon or the oxygen atom. Silyl enol ethers 
can be cleaved with nucleophiles such as MeLi, LiNH2 or R4N+F- to give enolates. They can 
be reacted with halides or pseudohalides,12 Whereas enolates can be alkylated only by primary 
or secondary halides, enol silyl ethers can be alkylated by tertiary halides.13  
 
The preparation of 1,3-bis(silyl enol ethers) mainly follows the procedures reported by 
Chan and Molander. These syntheses rely on the preparation of 1,3-mono(silyl enol ethers) 
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which are subsequently transformed into 1,3-bis(silyl enol ethers) by deprotonation with LDA 
and subsequent silylation.14 
 
In this chapter, I present the synthesis of various 1,3-bis(silyl enol ethers) following the 
procedure of Chan, Molander and Simchen. 
 
1.1.2. Results and discussion 
 
Following the procedures of Chan and Molander, 1,3-bis(trimethylsilyloxy)-1,3-butadienes 
5a-g were prepared from the respective 1,3-dicarbonyl compounds 3a-g in two steps, which 
were commercially available. Treatment of the -ketoesters with NEt3, Me3SiCl afforded 1,3-
mono(silyl enol ethers) 4a-g. Deprotonation of the latter with LDA and subsequent addition 














Scheme 1-3: Synthesis of 1,3-bis(silyl enol ethers) 5a-g; i) 1) NEt3 (1.5 equiv.); 2) 
Me3SiCl (1.5 equiv.), C6H6, 20 °C, 12 - 48 h; ii) 1) LDA (1.5 equiv.), THF, 0 °C, 2 h; 2) 
Me3SiCl (1.5 equiv.), –78  20 °C, 6 - 12 h. 
 
The synthesis of alkyl-substituted-1,3-bis(silyl enol ether) derivatives, which require the 
synthesis of the respective -ketoesters 3h-i was carried out with the collaboration of Yawer 
et al. It is known that the regioselectivities of the reactions of monoanions and dianions 
generally differ widely. 1,3-Dicarbonyl monoanions are generally alkylated at the central 
carbon or at the oxygen atom, whereas the formation of dianions allows the functionalization 
of the terminal carbon atom. Based on this, the 4-alkyl-3-oxobutanoates 3h-i were prepared 
by reactions of the dianion of ethyl acetoacetate 2a with the respective alkylhalides 1a-b. 
These compounds were transformed, according to a known procedure,8 into the desired 1,3-
bis(silyl enol ethers) 5h-i via the respective 1,3-mono(silyl enol ethers) 4h-i (Scheme 1-4, 






























Scheme 1-4: Synthesis of alkyl-substituted 1,3-bis(silyl enol ethers) derivatives 5h-i; i: 1) 
2.5 LDA, THF, 0 °C, 1 h; 2) 1a-b, –78  20 °C; ii: Me3SiCl (1.5 equiv.), NEt3 (1.5 equiv.), 
C6H6, 20 °C, 48 h; iii: 1) LDA (1.5 equiv.), THF, –78 °C, 1 h; 2) Me3SiCl (1.5 equiv.), 20 °C, 
–78  20 °C. 
 
In addition, the synthesis of aryloxy-1,3-bis(trimethylsilyloxy)-1,3-butadienes and their 
application has also been studied. The novel aryloxy- and thioaryloxy-1,3-
bis(trimethylsilyloxy)-1,3-butadienes 5j-o were prepared from the corresponding esters 4j-o 
(Scheme 1-5, Table 1-1) by a known procedure.8 These esters 4j-o, ethyl 4-
aryloxyacetoacetates 4j-m, ethyl 2-aryloxyacetoacetate 4n and 2-thioaryloxyacetoacetate 4o 
were prepared by base mediated reaction of ethyl 4-chloroacetoacetate 2b and ethyl 2-




































X = O, S
 
 
Scheme 1-5: Synthesis of aryloxy- and thioaryloxy-1,3-bis(silyl enol ether) derivatives 5j-
o; i: KOH, DMSO, 5 h, 20 °C ; ii: K2CO3, acetone, 2 h, reflux (for X = O); NEt3, CH2Cl2, 30 
min, 0 °C (for X = S); iii: Me3SiCl (1.8 equiv.), NEt3 (1.6 equiv.), C6H6, 20 °C, 72 h; iv: 1) 
LDA (1.5 equiv.), THF, –78 °C, 1 h; 2) Me3SiCl (1.5 equiv.), 20 °C, –78  20 °C. 
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    Table 1-1: 1,3-Bis(silyl enol ethers) 5a-o  
5 R1 R2 R3 
a H H Me 
b Me H Me 
c Et H Et 
d H Cl Et 
e H F Et 
f H Et Me 
g Me Cl Me 
h nHex H Me 
i nOct H Me 
j OPh H Et 
k O(3-MeC6H4) H Et 
l O(2-MeC6H4) H Et 
m O(4-MeC6H4) H Et 
n H O(3,5-Me2C6H3) Et 
o H SPh Me 
                    
1.1.3. Conclusions 
 
The applications of known procedures allowed the synthesis of novel 1,3-bis(silyl enol 
ethers). These masked dianions will be used in the cyclization reactions for synthesis 
heterocycles and aromatic rings - important building blocks of natural product analogues. 
 




A diketone is a molecule containing two ketone groups. 1,3-Diketones, such as 
acetylacetone, are particularly prone to form stable enols or enolates because of conjugation 
of the enol or enolate with the other carbonyl group, and the stability gained in forming a six-
membered ring, (hydrogen bonded in the case of the enol or containing the counter ion in the 
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case of the enolate). The masked dianions of 1,3-diketone are of my particular interest. Here 
in, I wish to report the exciting chemistry of substituted masked dianions of 1,3-diketones. 
The masking of 1,3-diketone was done using a well known procedure, established by Simchen 
et al.16 Some substituted 1,3-diketones were also synthesized by the known methods. 15 
 
1.2.2. Results and discussion 
 
Following the procedure of Simchen et al.16 2,4-bis(trimethylsilyloxy)-3-chlro-1,3-
pentadiene 5p was prepared from the respective 3-chloropentane-2,4-dione 2d in one step, 
which was commercially available. Treatment of 3-chloropentane-2,4-dione with 
triethylamine and trimethylsilyl-trifluormethansulfonate (TMSOTf) afforded silyl enol ether 









Scheme 1-6: Synthesis of 2,4-bis(trimethylsilyloxy)-1,3-pentadiene 5p; i: NEt3 
(2.1 equiv.), Me3SiOTf (2.1 equiv.), Et2O, 0 °C, 12 h. 
 
3-(Thioaryloxy)- and 3-(aryloxy)pentane-2,4-diones 5q-v were prepared, following a 
known procedure,15 by reaction of 3-chloropentane-2,4-dione 2d with thiophenols and 
phenols respectively 1h-k (Scheme 1-7, Table 1-2). The silylation of 3q-v afforded the 3-
(thioaryloxy)- and 3-(aryloxy)-2,4-bis(trimethylsilyloxy)-1,3-pentadiene 5q-v, following the 


























Scheme 1-7: Synthesis of 5q-v; i: method A: pyridine, MeOH, 0  20 °C, 6 h ; method B: 
piperidine, CH2Cl2, MeOH, 0  20 °C, 6 h (for X = S); K2CO3, acetone, 2 h, reflux (for X = 
O); ii: NEt3 (2.1 equiv.), Me3SiOTf (2.1 equiv.), Et2O, 0 °C, 12 h 
 
         Table 1-2: 1,3-Bis(silyl enol ethers) 5p-v  
5 R1 R2 R3 
p H Cl Me 
q H SPh Me 
r H S(3-MeC6H4) Me 
s H S(4-MeC6H4) Me 
t H O[4-(EtO)C6H4] Me 
u H O(3-MeC6H4) Me 
v H O(4-MeC6H4) Me 
 
All of the 1,3-bis(silyl enol ethers) prepared could be stored at suitable conditions (-20 oC, 




The application of the known procedures allowed the syntheses of novel 2,4-
bis(trimethylsilyloxy)-1,3-pentadienes. These masked dianions are used in the cyclization 
reactions for synthesis of heterocycles and aromatic rings - important building blocks of 
natural product analogues.
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1.3. One-Pot Synthesis of 6-(Thien-2-yl)salicylates based on Regioselective [3+3]  




Heterocyclic biaryls are of considerable pharmacological relevance and represent 
important lead structures in medicinal chemistry.17 In this context, highly functionalized 2-
(thien-2-yl)benzene derivatives are of special interest. For example, 6-(thien-2-yl)salicylates 
have been reported to show an in vitro inhibitory activity on guinea-pig detrusor muscle 
contraction at electrical field stimulation.18 2-(Thien-2-yl)benzoates are CAAX 
peptidomimetics and represent potent inhibitors of farnesyltransferase (Ftase).19 
 
2-(Thien-2-yl)benzoates have been prepared by Grignard reaction of 1-bromo-2-(thien-2-
yl)benzene with carbon dioxide20 and by Stille21 or Suzuki reactions22 of 2-halobenzoates or 
related transition metal-catalyzed cross-coupling reactions.23 The scope of these methods is 
often limited by the fact that sterically encumbered substrates often fail to undergo transition 
metal-catalyzed reactions or the yields are low. Besides, the synthesis of highly substituted 
and functionalized starting materials is often a difficult task. Based on original work reported 
by Chan and coworkers,8a I have been working on the synthesis of arenes based on formal 
[3+3] cyclizations of 1,3-bis(silyl enol ethers).24, 25 Recently, Langer et al, eported the first 
application of this concept to heterocyclic substrates (i. e. pyridines).26  
 
Due to the pharmacological relevance of the products, herein, I report synthesis of arenes 
containing an electron-rich heterocyclic moiety, based on [3+3] cyclization methodology. 
From a preparative viewpoint, the chemistry reported offers a convenient and regioselective 
approach to functionalized and sterically encumbered 6-(thien-2-yl)- and 6-(fur-2-
yl)salicylates. In fact, the products are not readily available by other methods and have only 
scarcely been reported so far.23 Noteworthy, the required starting materials, 3-(thien-2-yl)- and 
3-(fur-2-yl)-1,3-diones, are readily available. 
 
1.3.2. Result and Discussion 
 
The 3-(thien-2-yl)- and 3-(fur-2-yl)-1,3-diones 8a-d were prepared by LDA-mediated 
reaction of ketones 6a-c with (thien-2-yl)-and (fur-2-yl)carboxylic acid chloride 7a,b. The 
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silylation of 8a-d afforded the silyl enol ethers 9a-d. The TiCl4-mediated [3+3] cyclization of 
9a-d with 1,3-bis(silyl enol ethers) 5 (Scheme 1-3 and 1-4, Table 1-1), prepared from the 
corresponding 1,3-dicarbonyl compounds in two steps,8c afforded the 6-(thien-2-yl)salicylates 


























































X = S, O
 
 
Scheme 1-8: Synthesis of salicylates 10a-o; i: LDA (1.5 equiv.), THF; ii: 1) NEt3 (1.6 





                         Table 1-3: Synthesis of salicylates 10a-o  
5 9 10 X R1 R3 R4 % (10) a 
a a a S H Me Me 32 
b a b S Me Me Me 33 
c a c S Et Et Me 35 
h a d S nHex Me Me 30 
i a e S nOct Me Me 34 
a b f S H Me Et 35 
b b g S Me Me Et 34 
c b h S Et Et Et 30 
h b i S nHex Me Et 30 
a c j S H Me nPr 40 
b c k S Me Me nPr 47 
c c l S Et Et nPr 42 
h c m S nHex Me nPr 32 
a d n O H Me Et 32 
b d o O Me Me Et 30 
                          aYields of isolated products 
 





Figure 1-1: ORTEP-plot of 10b 
 
All products were formed with very good regioselectivity. During the optimization of this 
reaction, the (high) concentration and the temperature played an important role. The 
cyclization and the regioselectivity can be explained as follows. The cyclization of 9 with 5 
presumably proceeds by TiCl4 mediated isomerization of 9 by shift of the silyl group 
(intermediate A), TiCl4 mediated attack of the terminal carbon atom of 5 onto the carbon 
located next to substituent R1 to give intermediate B (conjugate addition), cyclization 
(intermediate C), and subsequent aromatization (Scheme 1-8). This mechanism has been 
previously suggested8a by Chan et al. for the cyclization of 5a with 1-phenyl-1-
(trimethylsilyloxy)but-1-en-3-one. However, a TiCl4-mediated attack of 5a onto the carbonyl 
group of 9a and subsequent cyclization by an SN mechanism with displacement of the 
Cl3TiO-group cannot be excluded.  
 
The 1-alkanoyl-1-(thien-2-oyl)cyclopropanes 12 were prepared by reaction of 8b with 1,2-
dibromoethane 11 (Scheme 1-9). The TiCl4-mediated reaction of 1,3-bis(trimethylsilyloxy)-
1,3-butadienes 5 (Scheme 1-3 and 1-4, Table 1-1), with 12 afforded the 6-(thien-2-
yl)salicylates 13a-d containing a remote chloride group (Scheme 1-9, Table 1-4). The 


























































Scheme 1-9: Synthesis of salicylates 13a-d; i: K2CO3 (4.0 equiv.). DMSO; ii: TiCl4, 
CH2Cl2, –78  20 °C, 20 h. 
 
             Table 1-4: Synthesis of salicylates 13a-d                                                  
5 13 R1 R3 % (13) a Regioisomeric ratio 
Major / Minor 
a a H Me 42 100 / 0 
b b Me Me 40 95 / 5 
c c Et Et 34 80 / 20 
d d nHex Me 32 66 / 33 
      a Isolated yields 
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Two isomers were formed for salicylates 13 (Figure 1-2). The regioselectivity of the 
isomers were confirmed by COSY and Correlation experiments and the regioisomeric ratio 
was calculated from the integration of two isomers in 1H NMR spectroscopy. The isomer 















Figure 1-2: Regioisomers of salicylates 13 
 
In the COSY measurement of 13a, H–H interactions were found between singlet of the 
aromatic proton and quartet of the ethyl group resonating at 6.95 (s, 1 H, CHAr) and 2.92 (q, 3J 
= 7.4 Hz, 2 H, CH2CH3) respectively (Figure 1-3). Similarly the COSY measurement of 13b 
showed H–H interactions between triplet of the ethyl group and singlet of the methyl group 
resonating at 1.13 (t, 3J = 7.4 Hz, 3 H, CH2CH3) and 1.88 (s, 3 H, CH3) respectively. Also  
H–H interactions were found between singlet of methyl and quartet of ethyl group of 13b 
resonating at 1.88 (s, 3 H, CH3) and 2.86 (q, 3J = 7.5 Hz, 2 H, CH2CH3) respectively (Figure 
1-3). These interactions confirm that R1 and ethy group are present at adjacent carbon atoms, 
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In conclusion, a variety of sterically encumbered 6-(thien-2-yl)- and 6-(fur-2-yl)salicylates 
has been regioselectively prepared by Lewis acid mediated [3+3] cyclization of 1,3-bis(silyl 
enol ethers) with novel 3-(thien-2-yl)- and 3-(fur-2-yl)-3-silyloxy-2-en-1-ones and with 1-
alkanoyl-1-(thien-2-oyl)cyclopropanes. These reactions show that arenes containing an 
electron-rich heterocyclic moiety can be successfully prepared by application of formal [3+3] 
cyclizations of 1,3-bis(silyl enol ethers). 
 
1.4. Synthesis of 4-Aryl- and 4-Hetaryl-6-(trifluoromethyl)salicylates by Regioselective 





The trifluoromethyl group is a very important substituent in organic and medicinal 
chemistry.28 Whereas the size of a methyl and a trifluoromethyl group are comparable, the 
latter possesses a highly electron-withdrawing effect. Therefore, the replacement of a CH3- by 
a CF3-group in a molecule results in a great change of its electronic properties and reactivity. 
The trifluoromethyl group of drugs plays an important role in drug-receptor interactions and 
in the in vivo transport. In addition, the high chemical and biological stability of the CF3-
group allows to avoid unwanted metabolic transformations. Trifluoromethyl-substituted 
arenes and hetarenes show an excellent solubility in fluorous biphase systems and 
supercritical carbon dioxide. Therefore, they are increasingly important ligands in catalytic 
reactions carried out in these solvent systems.29 Noteworthy, trifluoromethyl-substituted 
arenes are present, due to their electronic bias, in several organocatalysts which have been 
recently developed. 30 
 
Trifluoromethyl-substituted arenes and hetarenes are available by three strategies: a) the 
fluorination of suitable substrates (‘fluorination method’); b) introduction of the CF3-group 
into suitable organic substrates (‘trifluoromethylation method’); c) cyclization reactions of 
CF3-containing organic substrates (‘building block method’). A variety of CF3-substituted 
heterocycles have been prepared by trifluoromethylation.31 However, syntheses of benzene 
derivatives are rare. Trifluoromethylation reactions include, for example, the SF4-mediated 
transformation of carboxylic acids into CF3-groups, the transformation of CX3- into CF3-
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groups and the reaction of aryl halides with trifluoromethylcopper. However, the latter is 
rather unstable and rapidly decomposes in case of slow substitution reactions of ‘difficult’ 
substrates. In fact, the preparative scope of trifluoromethylation methods is often limited to 
specific substrates. In addition, the synthesis of the required highly substituted aromatic 
starting materials can be a difficult task. 
 
The ‘building block method’ provides an increasingly important alternative to 
trifluoromethylation reactions. (Trifluoromethyl)phenols have been prepared based on 
sequential cyclizations,32 reactions of metalated (trifluoromethyl)arenes with electrophiles,33 
and Diels-Alder reactions.34 3,5-Bis(trifluoromethyl)anilines are available by cyclization of 
enamines with 1,1,1,5,5,5-hexafluoroacetylacetone.35 Cyclocondensation reactions of ,-
unsaturated trifluoromethylketones allow a convenient approach to CF3-substituted 
heterocycles.36 However, the synthesis of functionalized benzene derivatives has only scarcely 
been reported to date.37 Some years ago, Chan and co workers developed8a an elegant 
approach to phenols based on formal [3+3] cyclizations24 of 1,3-bis(trimethylsilyloxy)-1,3-
butadienes.25 Recently, Langer et al  has reported the synthesis of CF3-substituted phenols by 
cyclization of 1,3-bis(trimethylsilyloxy)-1,3-butadienes with 4-ethoxy-1,1,1-trifluoro-3-en-2-
ones and 1,1,1-trifluoro-4-(silyloxy)pent-3-en-2-one.38  
 
Herein, I want to explore what is, to the best of my knowledge, the first cyclization 
reactions of 1,3-bis(silyl enol ethers) with 1-aryl-1-trimethylsilyloxy-3-(trifluoromethyl)prop-
1-en-3-ones based on [3+3] cyclization strategy. These reactions provide a convenient 
approach to various 4-aryl- and 4-hetaryl-6-(trifluoromethyl)salicylates. These products are 
not readily available by other methods. 
 
1.4.2. Results and discussion 
 
The 1-aryl-1-trimethylsilyloxy-3-(trifluoromethyl)prop-1-en-3-ones 15a-c were prepared 
by silylation of the corresponding 1,3-diketones 14a-c, which were commercially available. 
The TiCl4-mediated cyclization of 1,3-bis(trimethylsilyloxy)-1,3-butadienes 5 with 15a 
afforded the 4-phenyl-6-(trifluoromethyl)salicylates 16a-e (Scheme 1-10, Table 1-5). The 4-
(2-thienyl)-6-(trifluoromethyl)salicylates 16f-j (Scheme 1-10, Table 1-5) were prepared by 
cyclization of 5 with 15b. The cyclization of 5 with 15c gave the novel 4-(2-furyl)-6-
(trifluoromethyl)salicylates 16k-o (Scheme 1-10, Table 1-5). All cyclization reactions 
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proceeded with an excellent regioselectivity. Noteworthy, formal [3+3] cyclizations of 1,3-
bis(silyl enol ethers) with 1-aryl- and 1-hetaryl-1-silyloxy-3-(trifluoromethyl)prop-1-en-3-

















































Scheme 1-10: Synthesis of salicylates 16a-o; i: 1) NEt3 (1.6 equiv.), Me3SiCl (1.8 equiv.), 
C6H6, 20 °C, 72 h; ii: TiCl4, CH2Cl2, –78  20 °C 
 















                                    Table 1-5: Synthesis of salicylates 16a-o 
5 15 16 Ar R1 R3 % (16)a 
a a a Ph H Me 48 
b a b Ph Me Me 51 
c a c Ph Et Et 37 
h a d Ph nHex Me 56 
i a e Ph nOct Me 60 
a b f 2-Thienyl H Me 35 
b b g 2-Thienyl Me Me 45 
c b h 2-Thienyl Et Et 44 
h b i 2-Thienyl nHex Me 34 
i b j 2-Thienyl nOct Me 37 
a c k 2-Furyl H Me 40 
b c l 2-Furyl Me Me 41 
c c m 2-Furyl Et Et 35 
h c n 2-Furyl nHex Me 30 
i c o 2-Furyl nOct Me 35 
                                     a Yields of isolated products 
 
 
The regioselectivity of all products was confirmed by the two dimensional NMR 
spectroscopy (COSY and Correlation). The structures of 16b, 16f and 16k were 
















Figure 1-4: ORTEP-plot of 16k 
                   
Noteworthy, the cyclization of 1,3-bis(silyl enol ethers) 5 with alkyl- and CF3-substituted 
silyl enol ethers 9 and 15 proceeded with different regioselectivity. This might be explained 
due to the electron withdrawing effect of CF3 group, and also by comparison of the resonance 
structures of the cations formed by reaction of TiCl4 with silyl enol ethers 9 and 15 (Scheme 
1-11). In case of the CF3-substituted silyl enol ethers 15, it can be expected that resonance 
structure A1 is predominant over A2 due to the -donating effect of the methyl group. The aryl 
moiety is expected to be twised out of plane. In contrast, D2  is expected to be more stable than 
D1 due to the cation-destabilizing effect of the CF3-group (Figure 1-5). The reactions 
presumably proceed, under kinetic reaction control, by attack of the terminal carbon atom of 5 






















Scheme 1-11: Regioselectivity of the cyclization of 5 with 9a and 15a: i, TiCl4, CH2Cl2, 



























Figure 1-5: Resonance structures of intermediates A and D derived from reaction of TiCl4 




In conclusion, I developed a convenient and regioselective synthesis of 4-aryl- and 4-
hetaryl-6-(trifluoromethyl)salicylates by formal [3+3] cyclizations of 1,3-bis(silyloxy)-1,3-









Functionalized biaryls containing a 3-arylsalicylate substructure occur in a variety of 
pharmacologically relevant natural products. The simple biaryl cynandione has been isolated 
from many plant sources and shows a considerable in vitro activity against hepatocytes, 
human bladder carcinoma T-24 cells, epidermoid carcinoma KB cells, and human hepatoma 
PLC/PRF/5 cells.39 A natural product, isolated from the roots of such as bulbine-knipholone 
contains an anthraquinone moiety, showing antiplasmodial activity.40 Other compounds, e. g. 
secalonic acid A or globulixanthone E, contain a bixanthenyl substructure.41 Biaryls are also 
present in many flavones (e. g. bartramiaflavone, robustaflavone, dichamanetin).42 For 
example, robustaflavone which is a naturally occurring compound, is an inhibitor of hepatitis 
B virus replication in vitro.42 The natural product anastatin A, which contains a hydroxylated 














Figure 2-1: A natural product containing biaryl moiety 
 
Functionalized dibenzo[b,d]pyran-6-ones (‘biaryl lactones’) occur in a number of natural 
products such as alternariol, autumnariol, autumnariniol and altenuisol; 44 dibenzo[b,d]pyran-
6-ones containing an additional lactone bridge are present in ellagic and coruleoellagic acid.45 
Benzo[d]naphthopyran-6-ones occur in antibiotics and antitumor compounds isolated from 
Streptomyces; this includes, for example, defucogilvocarcin V, gilvocarcins, chrysomycins 
and ravidomycins.46 Some structures, which were isolated from the culture broth of a 
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streptomycete as antitumor substances, were determined as 6H-benzo[d]naphtho[1,2-b]pyran-
6-one.47a Ravidomycin was extracted from Streptomyces ravidus and is mainly active against 
Gram-positive bacteria including mycobacteria. Ravidomycin also exhibits potent antitumor 
activity against lymphocytic leukemia, tumor and mammary tumor.47b The 6H-dibenzo[b,d]-
pyran-6-one moiety is also present in compounds extracted from Pteropi faeces (the species 
of Trogopterus xanthipes Milne-Edwards). These compounds show hyaluronidase inhibitory 
activity.47c 
 
Many different methods for the synthesis of biaryllactones have been reported. A classic 
method for the synthesis of dibenzo[b,d]pyran-6-ones relies on the cyclization of o-
bromobenzoic acid with phenols. However, the scope of this method is limited to highly 
activated substrates and the yields are often rather low.46 Harris and Hay prepared 9-O-
methylalternariol by condensation of dilithiated 2,4-pentanedione with a protected salicylate 
and subsequent domino cyclization.48 Bringmann et al. developed an approach to 
dibenzo[b,d]pyran-6-ones by intramolecular Pd(II) catalyzed coupling reactions of ester-
linked aryl bromides and phenols.49 Snieckus and co-workers reported a versatile and efficient 
synthesis of dibenzo[b,d]pyran-6-ones by sequential directed ortho metalation 
(DOM)Suzuki cross-coupling reactions.46 This approach relies on the preparation of amide-
substituted boronic acids by DOM of benzoic amides. Suzuki cross-coupling reactions of the 
products with aryl bromides afforded biaryls which were transformed into the target 
molecules by lactonization. Some years ago, Langer et al. have reported the synthesis of 
biaryl lactones by domino ‘retro-Michael-aldol-lactonization’ reactions.50 In this method, the 
regioselective condensation of 1,3-bis(trimethylsilyloxy)-1,3-butadiens with benzopyrylium 
triflates afforded functionalized 2,3-dihydrobenzopyrans, masked tetraketides, which 
underwent a domino reaction upon treatment with base. Recently, Nguyen V.T.H. et al. 
reported the synthesis of dibenzo[b,d]pyran-6-ones based on sequential [3+3] 
cyclizationSuzuki cross-coupling reactions.51 This approach relies on the [3+3] cyclization 
of 1,3-bis-silyl enol ethers with 3-silyloxyalk-2-en-1-ones, a methodology developed by Chan 
and co-workers (vide supra).8,52 The functionalized salicylates prepared were transformed into 
their corresponding aryl triflates which were coupled with boronic acids by Suzuki 




Herein, I wish to report what is, to the best of my knowledge, a new and simple 
methodology for the synthesis of dibenzo[b,d]pyran-6-ones. My approach is based on [3+3] 
cyclizations of 1,3-bis(silyl enol ethers) with 1-(2-methoxyphenyl)-1-(trimethylsilyloxy)alk-1-
en-3-ones. The salicylates prepared were directly transformed into dibenzo[b,d]pyran-6-ones 
















Figure 2-2: Some natural products containing dibenzo[b,d]pyran-6-ones moiety 
 
2.2. Results and discussion 
 
(2-Methoxybenzoyl)acetone 18a and (2-methoxybenzoyl)butan-2-one 18b were prepared, 
by LDA mediated reaction of acetone 6a and pentan-2-one 6c with 2-methoxybenzoyl 
chloride 17, respectively. The silylation of 18a,b afforded the silyl enol ethers 19a,b. The 
[3+3] cyclization of 1-(2-methoxyphenyl)-1-(trimethylsilyloxy)alk-1-en-3-ones 19a,b with 
1,3-bis(silyl enol ethers) 5 afforded the biaryls 20a-i with excellent regioselectivity.54 The 
regioselectivity can be explained by TiCl4 mediated isomerization of 19a,b by shift of the 
trimethylsilyl group from one oxygen atom to the other (intermediate A), TiCl4 mediated 
attack of the terminal carbon atom of the 1,3-bis(silyl enol ether) onto the carbon located next 
to substituent R1 to give (intermediate B) (conjugate addition), cyclization (intermediate C), 
and subsequent aromatization. Treatment of biaryls 20a-i with BBr3 and subsequent addition 































































Scheme 2-1: Synthesis of dibenzo[b,d]pyran-6-ones 21a-i; i: LDA (1.5 equiv. ), THF; ii: 
1) NEt3 (1.6 equiv.), Me3SiCl (1.8 equiv.), C6H6, 20 °C, 72 h; iii: TiCl4, CH2Cl2, –78  20 
°C; iv: 1) BBr3 (4 equiv.), CH2Cl2, 0  20 °C, 18 h, 2) KOtBu, H2O, 15 min, 20  °C 
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                            Table 2-1: Synthesis of dibenzo[b,d]pyran-6-ones 21a-i  
5 20,21 R1 R4 % (20)a % (21)a 
a a H Me 47 92 
b b Me Me 27 69 
c c Et Me 34 62 
h d nHex Me 26 65 
i e nOct Me 52 60 
a f H nPr 22 77 
b g Me nPr 21 73 
c h Et nPr 30 71 
h i nHex nPr 32 62 
                                           a Yields of isolated products,  
 
The structure of all products was established by spectroscopic methods. The structure of 
21c was independently confirmed by X-ray crystal structure analysis (Figure 2-3).116 
 
Figure 2-3: ORTEP-plot of 21c with 50% probability of the thermal ellipsoids 
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2.3. Conclusions 
A new methodology for the synthesis of dibenzo[b,d]pyran-6-ones based on [3+3] 
cyclizations of 1,3-bis(silyl enol ethers) has been reported. Known syntheses of 
dibenzo[b,d]pyran-6-ones rely on the transition metal catalyzed coupling of two appropriate 
benzene derivatives and are, thus, limited by the availability of the later. The synthesis of 
functionalized and heavily substituted benzene derivatives was a difficult task. In contrast to 
known methods, the methodology reported herein involves the assembly of one of the two 
benzene moieties during the synthesis. Therefore, products can be prepared which are not 
readily available by other methods. Notably, this strategy outlined herein, bases on [3+3] 
cyclizations as the key step. The overall yields of the dibenzo[b,d]pyran-6-ones are mainly 
limited by the [3+3] cyclization step which mostly proceeds only in moderate yield. However, 























3. Regioselective Synthesis of Fluorinated Biaryls, 6H-Benzo[c]chromen-6-
ones and Fluorenones based on Formal [3+3] Cyclizations of 1,3-Bis(Silyl 
Enol Ethers) 
 




Fluoro group represents, due to its unique stereoelectronic properties, a very important 
substituent in organic and medicinal chemistry.29 While the size of the fluoro group is 
comparable to a hydrogen atom, its high electronegativity results in a dramatic change of the 
electronic situation and of the reactivity of the molecule. This plays an important role in drug-
receptor interactions. Notably, the increased lipophilicity of fluoro-substituted molecules also 
improves their transport in vivo. It is noteworthy that, due to the high chemical and biological 
stability of the fluoro group, undesirable metabolic transformations are often avoided. 
Therefore, the synthesis of fluoro-substituted arenes and hetarenes plays an important role in 
drug discovery.29,55 A great variety of pharmaceuticals, such as well known ciprofloxacin, 
ofloxacin, or norfloxacin, contain a fluoroarene moiety.56 Aryl fluorides are also present in 
natural products. This includes, for example, 4-fluoro-zaragozic acid A or fluorinated 
carbazole alkaloids.57 Organic fluoro compounds show a very good solubility in fluorophilic 
solvents. Therefore, they are used as ligands58 for catalytic reactions in fluorous biphase 
systems and supercritical carbon dioxide.59 The unique electronic properties of fluorinated 
arenes are used also for applications in organocatalysis.60,61  
 
Aryl fluorides are available by reaction of arenes with strong electrophilic fluorination 
agents (such as fluorine or xenon fluorides).62 However, these reagents are difficult to obtain 
or handle, dangereous or (in some cases) very expensive. Selectfluor represents an ‘easy-to-
handle’, commercially available electrophilic fluorination agent.63 However, the fluorination 
of non-activated arenes was reported to be unsuccessful (low conversion).63,64 The 
fluorination of (activated) anisol has been reported to proceed with 72% conversion. 
However, a 1:1 regioisomeric mixture of 2- and 4-fluoromethoxyphenol was formed.64 The 
reaction of Selectfluor with phenols has been reported to give 4-fluorocyclohexadienones.65 
The functionalization of simple fluorinated arenes, such as 4-fluorophenol, by electrophilic 
substitution reactions has been widely explored.66 However, these transformations are often 
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low-yielding and proceed with low regioselectivity. In addition, the synthesis of heavily 
substituted benzene derivatives is not an easy task. A different approach to aryl fluorides 
relies on cyclization reactions of fluorinated synthetic building blocks. For example, Shi et al. 
reported the synthesis of aryl fluorides based on [4+2] cycloaddition reactions of 2-fluoro-1-
methoxy-3-trimethylsilyloxy-1,3-butadiene, 2-fluoro-3-methoxy-buta-1,3-diene and related 
dienes with alkenes or alkynes.67,68  
 
Herein, I wish to report a convenient approach, which is based on the formal [3+3] 
cyclization of 1,3-bis(silyl enol ethers) with 1,3-dielectrophiles, first reported by Chan and 
coworkers,8 provides an efficient way to the various functionalized arenes.24,25 Recently, I 
reported the application of this method to the synthesis of aryl fluorides based on [3+3] 
cyclizations of 1,3-bis(silyl enol ethers) with 2-fluoro-3-silyloxy-2-en-1-ones.69 Herein, I 
report full details of these studies. With regard to the preliminary communication, I extended 
the preparative scope also. In addition, I report the application of this methodology to the 
synthesis of fluorinated 6H-benzo[c]chromen-6-ones (biaryl lactones, dibenzo[b,d]pyran-6-
ones) and fluorenones. The chemistry outlined herein offers a convenient and regioselective 
approach to a variety of functionalised and sterically encumbered aryl fluorides which are not 























Figure 3-1: Some pharmaceuticals containing fluoroarene moiety 
 
3.1.2. Results and discussion 
 
 The compounds 23a,b70 have already been reported as 18a,b in the second chapter. The 
LDA mediated reaction of ketones 6a,c with acid chlorides 22c-h afforded the 1,3-diketones 
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23c-h. 2-Fluoro-1,3-diones are available by reaction of 1,3-diketones with fluorine,71 N-
fluorobis(trifluoromethyl)-sulfonimide,72 and selectfluor.73 My starting point was the synthesis 
of a variety of novel 2-fluoro-1,3-diones which were required for further studies. The reaction 
of selectfluor with 1,3-diketones 23a-h afforded the 2-fluoro-1,3-diones 24a-h which were 
transformed, by reaction with Me3SiCl/NEt3, into the 2-fluoro-3-silyloxy-2-en-1-ones 25a-h 
(Scheme 3-1, Table 3-1). The TiCl4 mediated cyclization of 1,3-bis(silyl enol ethers) 5a-c8c 
with 2-fluoro-3-silyloxy-2-en-1-ones 25a-h afforded the novel fluorinated biaryls 26a-w 




















Scheme 3-1: Synthesis of fluorinated sily enol ethers 25a-h; i: LDA (1.5 equiv.), THF; i: 
Selectfluor, CH3CN; reflux, 4 h; iii: NEt3 (1.6 equiv.), Me3SiCl (1.8 equiv.), C6H6, 20 °C, 72h.  
 
             Table 3-1: Synthesis of 2-fluoro-3-silyloxy-2-en-1-ones 25a-h 
23,24,25 R4 R5 % (23) a % (24) a % (25) a 
a Me 2-(MeO)C6H4 37 72 99 
b nPr 2-(MeO)C6H4 73 90 79 
c Me 2-MeC6H4 33 65 44 
d Me 2-ClC6H4 25 42 80 
e Me 4-ClC6H4 38 58 70 
f Me 4-FC6H4 36 46 82 
g Me 1-Naph 43 37 71 
h nPr 2-Naph 62 64 74 
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          Table 3-2. Synthesis of salicylates 26a-w 
5 25 26 R1 R3 R4 R5 % (26) a 
a a a H Me Me 2-(MeO)C6H4 44 
b a b Me Me Me 2-(MeO)C6H4 54 
c a c Et Et Me 2-(MeO)C6H4 44 
a b d H Me nPr 2-(MeO)C6H4 35 
b b e Me Me nPr 2-(MeO)C6H4 34 
c b f Et Et nPr 2-(MeO)C6H4 55 
a c g H Me Me 2-MeC6H4 44 
b c h Et Et Me 2-MeC6H4 40 
a d i H Me Me 2-ClC6H4 26 
b d j Me Me Me 2-ClC6H4 38 
c d k Et Et Me 2-ClC6H4 38 
a e l H Me Me 4-ClC6H4 30 
b e m Me Me Me 4-ClC6H4 32 
c e n Et Et Me 4-ClC6H4 44 
a f o H Me Me 4-FC6H4 32 
b f p Me Me Me 4-FC6H4 40 
c f q Et Et Me 4-FC6H4 35 
a g r H Me Me 1-Naph 31 
b g s Me Me Me 1-Naph 37 
c g t Et Et Me 1-Naph 42 
a h u H Me nPr 2-Naph 30 
b h v Me Me nPr 2-Naph 34 
c h w Et Et nPr 2-Naph 35 
               a Isolated yields 
 
The best yields were obtained when the reaction was carried out in high concentration. 
The use of Me3SiOTf or BF3OEt2, rather than TiCl4, was unsuccessful (no conversion or 
decomposition, respectively). Notably, products 26a-w were formed with excellent 
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regioselectivity. The formation of the opposite regioisomer could not be detected. The results 
can be explained by the following mechanism:8c,25 Silyl enol ethers 25 undergo a TiCl4 
mediated 1,5-silyl shift to give intermediate A. The TiCl4 mediated conjugate addition of the 
1,3-bis(silyl enol ethers) 5 onto A gave intermediate B (Mukaiyama-Michael reaction). The 
cyclization proceeds by attack of the central carbon of 5 onto the carbonyl group 
(Mukaiyama-aldol reaction). Aromatization by an elimination reaction (before or during the 
aqueous work-up) leads to the final product. The yields seem to mainly depend on the quality 
of the starting materials and on the handling of each individual experiment. 
 
The structures of 26m and 26n were independently confirmed by X-ray crystal structure 






Figure 3-2: ORTEP-plot of 26m 
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In conclusion, a variety of regioselective functionalized aryl fluorides, has been 
synthesized based on one-pot [3+3] cyclization of 1,3-bis(silyl enol ethers) with 2-fluoro-3-
silyloxy-2-en-1-ones. These products are not readily available by other methods. 
 




As the biological relevance of 6H-Benzo[c]chromen-6-ones (dibenzo[b,d]pyran-6-ones, 
biaryl lactones)44a,44c,45,74-78 has already been discussed in previous chapter. Recently, Langer 
et al. reported the synthesis of 6H-benzo[c]chromen-6-ones by reaction of 1,3-bis(silyl enol 
ethers) with benzopyrylium triflates.79 As we have reported the recent approach to 6H-
benzo[c]chromen-6-ones relies on the [3+3] cyclizations of 1,3-bis(silyl enol ethers) with 1-
(2-methoxyphenyl)-1-(trimethylsilyloxy)alk-1-en-3-ones and subsequent lactonization.70 
Herein, I wish to extend the scope of this methodology to the synthesis of 10-fluoro-6H-
benzo[c]chromen-6-ones. The synthesis of this type of fluorinated core structure has, to the 
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best of my knowledge, not yet been reported.  
 
3.2.2. Results and discussion 
 
Treatment of biaryls 26a-f with BBr3 and subsequent addition of an aqueous solution of 
potassium tert-butanolate (KOtBu) afforded the novel fluorinated dibenzo[b,d]pyran-6-ones 
27a-f (Scheme 3-3, Table 3-3). The formation of the products proceeded by cleavage of the 
arylmethyl ether and subsequent base-medaited lactonization. The structure of 27d was 















26a-f 27a-f  
 
Scheme 3-3: Synthesis of dibenzo[b,d]pyran-6-ones 27a-f; i: BBr3 (4.0 equiv.), CH2Cl2, 0 
 20 °C, 18 h, ii) KOtBu (1M), H2O, 15 min, 20 °C 
                          
                              Table 3-3: Synthesis of dibenzo[b,d]pyran-6-ones 27a-f 
26 R1 R3 R4 % (27)a 
a H Me Me 91 
b Me Me Me 84 
c Et Et Me 75 
d H Me nPr 47 
e Me Me nPr 55 
f Et Et nPr 67 









In conclusion, a variety of fluorinated 6H-benzo[c]chromen-6-ones has been synthesized, 
based on regioselective [3+3] cyclizations of 1,3-bis(silyl enol ethers) with 2-fluoro-3-
silyloxy-2-en-1-ones. This approach provides a convenient pathway to synthesis of various 






1-Hydroxyfluorenones are interesting lead structures in medicinal chemistry and are also 
present in nature (e. g. in the natural products dengibsin, dengibsinin, and dendroflorin).80 
Fluorinated fluorenones81 are of specific interest in current medicinal chemistry.  For example, 
it was shown that 4-fluorofluorenones possess antagonistic in vitro activity to human 
progesterone receptor B (hPR-B) in cotransfected CV-1 cells (IC50 = 158 nM).82 Fluorenones 
have already been prepared, for example, by intramolecular Friedel–Crafts acylations of 
biaryls.83 Snieckus and co-workers reported the synthesis of fluorenones based on remote 
aromatic metalation.84 Some years ago, the synthesis of fluorenones using a Suzuki 
coupling/intramolecular Friedel–Crafts acylation sequence has been reported.85 Recently, 
Reim et al. reported an efficient synthetic approach to fluorenones based on a ‘[3+3] 
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cyclization/Suzuki crosscoupling/Friedel–Crafts acylation’ strategy.86 Chan et al. reported the 
synthesis of 1-hydroxy-3-methylfluorenone by reaction of methyl 6-phenylsalicylate with 
concentrated sulfuric acid.8a  
 
Herein, I report an approach to synthesis of fluorenones and fluorinated fluorenones based 













Figure 3-5: Some natural products containing fluorenones. 
 
3.3.2. Results and discussion 
 
3-silyloxy-2-en-1-ones 28a, was prepared by reaction of 1,3-diketone 23f with  
Me3SiCl/NEt3 (Scheme 3-4, Table 3-4). The TiCl4 mediated formal [3+3] cyclization of 28a 
with 1,3-bis(silyl enol ethers) 5a,c – prepared from the corresponding 1,3-dicarbonyl 
compounds in one or two steps8c– afforded the novel fluorinated biaryls 29a,b in moderate to 
good yields. Treatment of the latter with concentrated sulfuric acid afforded the fluorenones 






























Scheme 3-4: Synthesis of fluorenones 30a,b; i: NEt3 (1.6 equiv.), Me3SiCl (1.8 equiv.), 
C6H6, 20 °C, 72 h.  ii: TiCl4, CH2Cl2, –78  20 °C. iii: H2SO4, 20 °C, 1 h. 
 
 Table 3-4: Synthesis of fluorenones 30a,b 
5 29 30 R1 R3 R4 % (29)a % (30)a 
a a a H Me Me 44 68 
c a b Et Et Me 49 76 
 a Isolated yields; 
 
The novel 1-hydroxy-4-fluorofluorenones 31a-d were obtained in good yields by simple 
























Scheme 3-5: Synthesis of fluorenones 31a-d; conditions: i: concd. H2SO4, 20 °C, 3 h 
                       
                     Table 3-5: Synthesis of fluorenones 31a-d 
26 31 X R1 R3 R4 % (31) a 
l a Cl H Me Me 77 
m b Cl Me Me Me 75 
p c F Me Me Me 74 
q d F Et Et Me 69 




In conclusion, I reported the synthesis of a variety of functionalized fluorenones and 
















4. Synthesis of 4-Hydroxy- and 2,4-Dihydroxy-homophthalates by [4+2] 





A cycloaddition is a pericyclic chemical reaction, in which two  bonds are lost and two  
bonds are gained, the resulting reaction is a cyclization reaction. This refers to the Diels-Alder 
a [4 + 2] cycloaddition, which proceeds between a conjugated diene and a dienophile to form 
a cyclic system.87 The diene component in the Diels-Alder reaction can be open-chain or 
cyclic and it can have many different kinds of substituents.88 The dienophile is usually an 
electron deficient specie, mostly having the electron withdrawing group conjugated to 
unsaturated system. Different types of dienes and dienophiles are being used for the 
cycloaddition reactions. Here in, the masked dianions and allene as a diene and dienophile 
respectively, are of my particular interest. The synthesis and chemistry of masked dianions 
has already been discussed in the previous chapters. Allenes represent versatile synthetic 
building blocks in inter- and intramolecular [4+2] cycloadditions.89 Synthesis of ()-
Epibatidine and its derivatives has been carried out from chiral allene-1,3-dicarboxylate 
esters.90 The [4+2] cycloaddition of 1,3-bis(silyl enol ethers) with allenes has been reported to 
give functionalized phenols. For example, (R)-(+)-lasiodiplodin was prepared based on the 
cyclization of a cyclic allenylester with 1,1-dimethoxy-3-trimethylsilyloxy-1,3-butadiene.91 
The reaction of allenylphenylsulfone with Danishefsky’s diene afforded 3-methyl-4-
(phenylsulfonyl)-phenol.92 Roush and Murphy were the first to report the cycloaddition of 1-
methoxy-1,3-bis(trimethylsilyloxy)-1,3-butadiene with dimethyl allene-1,3-dicarboxylate.93 
Some years ago, Langer et al, has reported the synthesis of various homophthalates based on 
the cycloaddition of dimethyl allene-1,3-dicarboxylate with various 1,3-bis(silyl enol 
ethers).94 Later on, this methodology was successfully applied to the synthesis of an analogue 
of lactonamycin95 and of the N7-C25 fragment of psymberin (Scheme 1).96  
 





















































4.2. Results and discussion 
 
The reaction of 1-ethoxy-1,3-bis(trimethylsilyloxy)-1,3-butadiene 5a (Table 1-1), 
prepared from ethyl acetoacetate in two steps8a,8c,24 with dimethyl allene-1,3-dicarboxylate 32, 
available from dimethyl acetone-1,3-dicarboxylate,97 afforded the homophthalate 33a up to 
42% yield (Scheme 4-1, Table 4-1). The best yield was obtained when a mixture of the 
starting materials (neat) was stirred for 20 h at 20 °C. Subsequently, to the mixture was added 
an ethanolic solution of triethylammonium fluoride.98 The formation of 33a can be explained 
by [4+2] cycloaddition to give intermediate A, cleavage of the Si-O bonds upon addition of 
triethylammonium fluoride, and subsequent aromatization by extrusion of ethanol 
intermediate B, enolization and migration of the exocyclic double bond. The yield decreased 
when the reaction was carried out at elevated temperature (40 or 80 °C), or when the reaction 
was carried in a toluene solution (room temperature or reflux). The yield also decreased when 
the reaction time was decreased (no complete conversion) or increased (decomposition). The 
stoichiometry also played an important role. The use of an excess of the dienophile did not 





































Scheme 4-1: Possible mechanism of the formation of 33a 
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Noteworthy, the selective elimination of ethanol (formation of a 3-hydroxyphenol) rather 
than water (formation of a 3-ethoxyphenol) was observed. The relatively low yield can be 
explained by partial decomposition of the quite sensitive diene, due to the long reaction time. 
 
The cycloaddition of 32 with 1-alkoxy-, 1-aryloxy- and 1-thioaryloxy-1,3-
bis(trimethylsilyloxy)-1,3-butadienes 5, prepared in two steps from the corresponding -
ketoesters, afforded the 2,4-dihydroxyhomophthalates 33a-t (Scheme 4-2, Table 4-1). A wide 
range of products – including fluoro-, chloro-, alkyl-, methoxy-, benzyloxy-, aryloxy-, 
arylthio-substituted derivatives – were successfully prepared. Moderate to good yields were 
obtained for all products (except for 33s). Noteworthy, the reaction conditions were optimized 





















Scheme 4-2: Synthesis of 2,4-dihydroxyhomophthalates 33a-t; i: neat 20-80 °C, 12-18 h. 
ii HNET3F, H2O 












                    Table 4-1: Synthesis of 2,4-dihydroxyhomophthalates 31a-t 
33 R1 R2 R3 % (33) a 
a H H Et 42 
b H Et Et 52 
c H Cl Et 64 
d H F Et 70 
e H SPh Me 50 
f Me H Me 51 
g Me Cl Me 47 
h Et H Et 40 
i Allyl H Et 50 
j nBu H Et 38 
k nHex H Me 52 
l nOct H Me 56 
m Bn H Et 32 
n OMe H Me 34 
o OPh H Et 58 
p O(3-MeC6H4) H Et 48 
q O(2-MeC6H4) H Et 50 
r O(4-MeC6H4) H Et 54 
s OBn H Et 16 
t SPh H Et 41 
                               a Isolated yields 
 
The cycloaddition of 32 with 1,3-bis(trimethylsilyloxy)-1,3-butadienes 5, available from 
the corresponding 1,3-diketones, afforded the 4-hydroxyhomophthalates 33u-ab (Scheme 4-3, 
Table 4-2). A wide range of products – including chloro-, alkyl- and aryloxy- substituted 
derivatives – were successfully prepared. All products were formed in moderate yields 
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Scheme 4-3: Synthesis of 4-hydroxyhomophthalates 33u-ab; i: neat 20-80 °C, 12-18 h. ii 
HNET3F, H2O 
 
                        Table 4-2: Synthesis of 4-dihydroxyhomophthalates 33u-ab 
33 R1 R2 R3 % (33)a 
u H H Me 40 
v H H Ph 46 
w H Me Me 44 
x H CO2Me Me 20 
y H Cl Me 42 
z H O[4-(EtO)C6H4] Me 48 
aa H O(4-ClC6H4) Me 45 
ab H O[4-(NC)C6H4] Me 56 
                                    a Isolated yields 
                                
The regioselectivity of all products was confirmed by the two dimensional NMR 
spectroscopy (COSY and Correlation). The structures of 33b, 33c and 33d were 






















In conclusion, a variety of functionalized 4-hydroxy- and 2,4-dihydroxy-homophthalates 
has been prepared by reaction of 1,3-bis(trimethylsiloxy)-1,3-butadienes with dimethyl allene-











5. Synthesis of Functionalized 2-(Arylsulfonyl)-4-hydroxypyridines by 
Heter-Diels-Alder Reaction of 1,3-Bis(trimethylsilyloxy)-1,3-butadienes 




The pyridine ring appears in a range of bioactive compounds, both naturally occurring and 
synthetic, often in highly substituted form; examples include the lycopodium alkaloids such as 
lycodine,99 and the well-known proton pump inhibitor omeprazole, which is used to reduce 
the production of acid in the stomach. Thiopeptide antibiotics, a class of sulfur containing 
highly modified cyclic peptides, are of particular interest which are characterised by the 
presence of a heterocyclic centrepiece consisting of a tri- or tetra-substituted pyridine 
embedded in a macrocyclic array.100 Examples of these types of natural products are 
amythiamicin D101 and nosiheptide.102  
 
Hetero Diels-Alder reaction is of particular interest, as it allows synthesis of heterocyclic 
framework. In amythiamicin D, the pyridine core was successfully constructesd via a 
biomimetic hetero-Diels–Alder reaction of a 2-azabutadiene.101 Ghosez et al. reported a 
versatile method for the preparation of large range of pyridines and dihydropyridines, using 1-
azabutadienes in hetero-Diels-Alder reaction.103 The scope of the hetero-Diels–Alder reaction 
of 1-azabutadienes has been extended by the discovery of Boger and Blagg that N-sulfonyl-2-
(ethoxycarbonyl)-1-aza-1,3-butadienes participate in the [4+2] cycloadditions with electron 
rich dienophiles.104 The hetero-Diels–Alder reaction of aldehydes with Danishefsky’s diene or 
related silyl enol ethers has been widely used for the synthesis of pyran derivatives.103c,105 
Ding et al. has reported the synthesis of -lactones based on the enantioselective hetero-Diels-
Alder reaction of electron-rich 1,3-dimethoxy-1-(trimethylsiloxy)butadiene (Brassard’s diene) 
with aldehydes.106 In contrast, hetero-Diels–Alder reactions of nitriles are relatively rare, due 
to the low reactivity of nitriles as hetero-dienophiles.107 Some years ago, Breitmaier and 
Rüffer reported108 an efficient synthesis of functionalized pyridines by cyclization of buta-1,3-
dienes, including 2-siloxy)buta-1,3-dienes, with highly reactive tosyl cyanide.109 Pyridines 
have also been prepared by cyclization of pyran-2-ones with tosyl cyanide with extrusion of 
carbon dioxide.110 The 1,3-dipolar cycloaddition of diazomethane with tosyl cyanide has been 
reported to give 1,2,3-triazines.111 McClure et al. has reported the synthesis of 1-
azabicyclo[2.2.2]oct-1-enes by cyclization of 2-(siloxy)cyclohexa-1,3-dienes with tosyl 
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cyanide.112 Recently, Langer et al. reported the synthesis of 2-(arylsulfonyl)-4-
hydroxypyridines,113 which are of considerable pharmacological importance.114 
 
However, the presence of a hydroxyl group at carbon C-3 (or C-5) of the pyridine ring, as 
in nosiheptide, presents a different challenge.115 Herein, I report, to the best of my knowledge, 
a highly functionalized substitution pattern -for example alkyl, halide, aryloxy and 
thioaryloxy groups- at  carbon C-3 (or C-5) position of 4-hyroxypyridines based on hetero-
Diels–Alder reaction of 1,3-bis(trimethylsiloxy)buta-1,3-dienes (1,3-bis-silyl enol ethers)8,24,25 
with aryl cyanides. These reactions allow the convenient synthesis of 2-(arylsulfonyl)-4-
hydroxypyridines having a wide range of substitution pattern at carbon C-3 (or C-5), which is 
difficult to achieve by electrophillic substitution reactions of pyridine. The synthesis of highly 

















Figure 5-1: Some novel compounds containing pyridine moiety as central core 
5.2. Results and Discussion 
 
The reaction of aryl cyanides 34a,b with 1,3-bis(trimethylsiloxy)buta-1,3-dienes 5, readily 
available from substituted methyl acetoacetate or ethyl acetoacetate, afforded the substituted 
4-hydroxy-2-sulfonylpyridines 35a-h (Scheme 5-1, Table 5-1) in up to 62% yield. The best 
yields were obtained when a neat mixture of the starting materials was allowed to slowly 
warm from –78 °C to ambient temperature. A complex mixture was obtained when the 
reaction was carried out at elevated temperatures or when a solvent was added. An aqueous 
work-up using NH4Cl or HCl was necessary. The formation of 35 can be explained by [4+2] 
cycloaddition to give intermediate A and subsequent acid-mediated cleavage of the silyloxy 
group and aromatization. The reaction times were in the range of 48 to 96 h. In most cases, 
the reactions were carried out at –78  20 °C. Noteworthy, the yields of 4-hydroxy-2-
sulfonylpyridines pyridines 35 were very good. This can be explained by the cisoid 
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conformation of 1,3-bis(sily enol ethers) 5 , due to the presence of the substituent located at 
the central carbon atom. The reaction of 34a,b with 1,3-bis(sily enol ethers) containing a 
substituent located at the terminal carbon atom proved to be unsuccessful, presumably due to 
steric reasons. The employment of ethoxycarbonyl cyanide rather than 34a,b proved to be 
unsuccessful, due to its low reactivity; decomposition was observed under forcing conditions 




































Scheme 5-1: Synthesis of 2-(arylsulfonyl)-4-hydroxypyridines 35a–h; i: neat 78 °C to 60 














       Table 5-1: Synthesis of 2-(arylsulfonyl)-4-hydroxypyridines 35a-h  
5 34 35 R1 R2 R3 R4 % (35)a 
d a a  H Cl Et H 56 
e a b  H F Et H 59 
f a c  H Et Me H 60 
n a d  H O(2,3-Me2C6H3) Et H 61 
o a e  H SPh Me H 56 
d b f H Cl Et Me 48 
e b g  H F Et Me 54 
n b h   H O(2,3-Me2C6H3) Et Me 62 
           a Isolated yields 
 
The reaction of aryl cyanide 34a,b with 1,3-bis(trimethylsiloxy)buta-1,3-dienes 5, readily 
available from substituted 1,3-diketones, afforded the substituted 4-hydroxy-2-tosylpyridine 
35i-n (Scheme 5-2, Table 5-2) in up to 79% yield, following the same procedure as discussed 



























    Scheme 5-2: Synthesis of 2-(arylsulfonyl)-4-hydroxypyridines 35a–h; i: neat 78 °C to 60 
°C, 48 to 96 h. ii: aq. 1M NH4Cl 
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        Table 5-2: Synthesis of 2-(arylsulfonyl)-4-hydroxypyridines 35i-n 
5 34 35 R1 R2 R3 R4 % (35)a 
q a i H SPh CH3 H 53 
r a j H S(3-MeC6H4) CH3 H 79 
u b k H O(3-MeC6H4) CH3 CH3 58 
v b l H O(4-MeC6H4) CH3 CH3 57 
q b m H SPh CH3 CH3 64 
s b n H S(4-MeC6H4) CH3 CH3 51 
             a Isolated yields 
 
The structures of carbon C-3 (or C-5) substituted 2-(arylsulfonyl)-4-hydroxypyridines 
35a–n were confirmed by spectroscopic methods. The compound 35k was crystallized as a 
monohydrate of 2-methyl-3-(m-tolyloxy)-6-tosylpyridin-4-ol. The structures of 35i and 35k 















In conclusion, a variety of functionalized 5-alkyl-, 5-halide-, 5-aryloxy- and 5-
thioaryloxy- 2-(arylsulfonyl)-4-hydroxypyridines has been prepared by hetero-Diels-Alder 
reaction of 1,3-bis(trimethylsiloxy)-1,3-butadienes with arylsulfonyl cyanides. The products 













One-pot cyclization reactions of 1,3-bis(silyl enol ethers) with the different electrophiles 
provide a convenient approach for the synthesis of various complex carbacycles and 
heterocycles from simple starting materials. 6-Hetaryl-salicylates and 4-Aryl and 4-Hetaryl-
salicylates were prepared based on [3+3] cyclizations of 1,3-bis(sily enol ethers) in an 
efficient way. Dibenzo[b,d]pyran-6-ones were synthesized by formal [3+3] cyclization of 1,3-
bis(silyl enol ethers) with 1-(2-methoxyphenyl)-1-(trimethylsilyloxy)alk-1-en-3-ones and 
subsequent BBr3-mediated lactonization. Aryl fluorides were synthesized by [3+3] cyclization 
of 1,3-bis(silyl enol ethers) with 2-fluoro-3-silyloxy-2-en-1-ones. 1,3-Bis(silyl enol ethers) 
were used efficiently for the synthesis of highly functionalized homomphthalates and 4-
hydoxypyridines based on [4+2] cyclization reactions. 
 
Ein-Topf Cyclisierungensreaktionen von 1,3-Bis(silylenolethern) mit unterschiedlichen 
Elektrophilen ermöglicht einen bequemen Zugang zu einer großem Bandbreite von Carba- 
und Heterocyclen ausgehend von einfachen Startmaterialien. 6-Hetaryl-salicylate und 4-Aryl 
und 4-Hetaryl-salicylate wurde durch [3+3] Cyclisierungen von 1,3-Bis(silyenolethern) auf 
effiziente Weise hergestellt. Weiterhin wurden Dibenzo[b,d]pyran-6-one durch formale [3+3] 
Cyclisierungen von 1,3-Bis(silylenolethern) mit 1-(2-Methoxyphenyl)-1-
(trimethylsilyloxy)alk-1-en-3-onen und anschließende BBr3-vermittelte Lactonisierung 
synthetisiert. Arylfluoride wurden durch [3+3] Cyclisierungen von 1,3-Bis(silylenolethern) 
mit 2-Fluoro-3-silyloxy-2-en-1-onen hergestellt. 1,3-Bis(silylenolether) wurden weiterhin als 
Bausteine für die Synthese hochfunktionalisierter Homomphthalate und 4-Hydoxypyridine 


































































General Scheme: As the part of this work was carried out with 1,3-bis(silyl enol ethers) 












7. Experimental Section: 
 
7.1. General: Equipment, chemicals and work technique 
 
1H NMR Spectroscopy:  
Bruker: AM 250, Avance 250, AC 250 (250 MHz); ARX 300, Avance 300 (300 MHz); 
Varian VXR 500 S, Avance 500 (500 MHz);  = 0.00 ppm for Tetramethylsilane;  = 2.04 
ppm for Acetone d-6;  = 7.26 ppm for Deuterochloroform (CDCl3) and  = 2.50 ppm for 
DMSO- d6; Characterization of the signal fragmentations: s = singlet, d = doublet, dd = 
double of doublet, ddd = doublet of a double doublet, t = triplet, q = quartet, quint = quintet; 
sext = Sextet, sept = Septet, m = multiplet, br = broadly. Spectra were evaluated according to 
first order rule. All coupling constants are indicated as (J). 
 
13C NMR Spectroscopy:  
Bruker: AM 250, Avance 250, AC 250 (62.9 MHz); ARX 300, Avance 300 (75 MHz); Varian 
VXR 500 S, Avance 500 (125 MHz);  = 128.00 ppm for Acetone d-6;  = 77.00 ppm for 
CDCl3,  = 39.7 ppm for DMSO- d6. The multiplicity of the carbon atoms was determined by 
the DEPT 135 and APT technique (APT = Attached Proton Test) and quoted as CH3, CH2, 
CH and C for primary, secondary, tertiary and quaternary carbon atoms. Characterization of 
the signal fragmentations: quart = quartet the multiplicity of the signals was determined by the 
DEPT recording technology and/or the APT recording technology. 
 
Mass Spectroscopy:  
AMD MS40, AMD 402 (AMD Intectra),  Varian MAT CH 7, MAT 731. 
 
High Resolution mass spectroscopy:  
Finnigan MAT 95 or Varian MAT 311; Bruker FTCIR, AMD 402 (AMD Intectra). 
 
Infrared spectroscopy (IR):  
Bruker IFS 66 (FT IR), Nicolet 205 FT IR; Nicolet Protege 460, Nicolet 360 Smart 
Orbit  (ATR);  KBr ,KAP, Nujol, and ATR; Abbreviations for signal allocations: w = weak, 
m = medium, s = strong, br = broad. 
 
Elementary analysis:  
LECO CHNS-932, Thermoquest Flash EA 1112. 
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X-ray crystal structure analysis: B 
ruker X8Apex Diffractometer with CCD-Kamera (Mo-Ka und Graphit Monochromator, 
 = 0.71073 Å). 
 
Melting points:  
Micro heating table HMK 67/1825 Kuestner (Büchi apparatus); Meltingpoints are 
uncorrected. 
 
Column chromatography:  
Chromatography was performed over Merck silica gel 60 (0,063 -0,200 mm, 70 - 230 mesh) 
as normal and/or over mesh silica gel 60 (0,040 - 0,063 mm, 200 -400 mesh) as Flash 
Chromatography. All solvent were distilled before use. 
 
TLC:  
Merck DC finished foils silica gel 60 F254 on aluminum foil and Macherey finished 
foils Alugram® Sil G/UV254. Detection under UV light with 254 nm and/or 366 nm without 
dipping reagent, as well as with anisaldehyde sulfuric acid reagent (1 mL anisaldehyde 
consisting in 100 mL stock solution of 85% methanol, 14% acetic acid and 1% sulfuric acid). 
 
Chemicals and work technique: 
All solvents for using were distilled by standard methods. All reactions were carried out under 
an inert atmosphere, oxygen and humidity exclusion. All of the chemicals are standard, 
commercially available from Merck®, Aldrich®, Arcos® and others. The order of the 
characterized connections effected numerically, but does not correspond to the order in the 
main part of dissertation. 
 
7.2. Procedures and Spectroscopic Data
 
General procedure for the synthesis of 1,3-dicarbonyl compounds 8, 18, 23:  
To a stirred solution of LDA (75.0 mmol) in THF (1.2 mL/1.0 mmol of LDA) was added 
ketone 6 (50.0 mmol) at 78 °C. After the solution was stirred for 1 h, the acid chloride 7 
(60.0 mmol) was added. The temperature of the solution was allowed to rise to 20 °C during 
12 h. A saturated solution of NH4Cl was added, the layers were separated, and the aqueous 
layer was extracted with EtOAc (3 x 50 mL). The combined organic layers were dried 
(Na2SO4) and filtered, and the solvent was removed in vacuo. The residue was purified by 
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chromatography (silica gel, n-heptane/EtOAc = 30:1  20:1) to give 8. Compounds 6a-c 
were commercially available.  
 
1-Hydroxy-1-(2-thienyl)-1-penten-3-one (8b). 
Starting with THF (62.5 mL), LDA (75 mmol), 2-butanone 6b (3.606 
g, 50.0 mmol) and 2-thiophenecarbonyl chloride 7a (8.796 g, 60.0 
mmol), 8b was isolated as a yellowish oil (2.720 g, 30%). 1H NMR 
(300 MHz, CDCl3):  = 1.41 (t, 3J = 6.6 Hz, 3 H, CH2CH3), 2.60 (q, 
3J = 7.6 Hz, 2 H, CH2CH3), 6.22 (s, 1 H, CH), 7.317.33 (m, 1 H, CHHetar), 7.78 (dd, 3J = 4.9 
Hz, 4J = 1.1 Hz, 1 H, CHHetar), 7.887.90 (m, 1 H, CHHetar), 15.89 (s, 1 H, OH). 13C NMR (75 
MHz, CDCl3):  = 10.5 (CH2CH3), 31.0 (CH2CH3), 95.3 (CH), 128.5, 130.4, 132.6 (CHHetar), 
142.1 (CHetar), 182.1 (COH), 186.1 (CO). GC-MS (EI, 70 eV): m/z (%) = 182 ([M+], 62), 153 
(86), 126 (26), 111 (100), 97 (7), 83 (8), 69 (56), 56 (17), 53 (7), 45 (8), 39 (17), 29 (8). 
HRMS (EI): Calcd. for C9H10O2S [M+]: 182.03960; found: 182.03933. 
 
1-Hydroxy-1-(2-thienyl)-1-hexen-3-one (8c).  
Starting with THF (62.5 mL), LDA (75.0 mmol), 2-pentanone 6c 
(4.306 g, 50.0 mmol) and 2-thiophenecarboxylic acid chloride 2 
(8.796 g, 60.0 mmol), 3c was isolated as a yellowish oil (2.750 g, 
28%). 1H NMR (300 MHz, CDCl3):  = 0.86 (t, 3J = 7.4 Hz, 3 H, CH2CH2CH3), 1.531.61 
(m, 2 H, CH2CH2CH3), 2.21 (t, 3J = 7.2 Hz, 2 H, CH2CH2CH3), 5.91 (s, 1 H, CH), 6.977.00 
(m, 1 H, CHHetar), 7.46 (dd, 3J = 4.4 Hz, 4J = 0.9 Hz, 1 H, CHHetar), 7.567.57 (m, 1 H, 
CHHetar), 15.62 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 12.6 (CH2CH2CH3), 18.4 
(CH2CH2CH3), 38.2 (CH2CH2CH3), 94.8 (CH), 126.6, 129.1, 131.9 (CHHetar), 142.6 (CHetar), 
181.0 (COH), 189.1 (CO). GC-MS (EI, 70 eV): m/z (%) = 196 ([M+], 47), 181 (3), 168 (14), 
153 (100), 135 (4), 126 (34), 111 (90), 97 (7), 85 (7), 69 (53), 53 (5), 39 (18). HRMS (EI): 
Calcd. for C10H12O2S [M+]: 196.05525; found: 196.05469. 
 
General procedure for the synthesis of sily enol ethers 9, 15, 19, 25, 28: 
To a stirred benzene solution (2.5 mL/1.0 mmol of 8) of 8 (10.0 mmol) was added 
triethylamine (16.0 mmol). After the solution was stirred for 2 h, trimethylchlorosilane (18.0 
mmol) was added. After the solution was stirred for 72 h, the solvent was removed in vacuo 






under argon atmosphere. The filtrate was concentrated in vacuo to give silyl enol ethers 9. 
The compounds 14a-c were available commercially. 
 
1-(2-Thienyl)-1-[(trimethylsilyl)oxy]-1-penten-3-one (9b).  
Starting with benzene (30.0 mL), 8b (1.821 g, 10.0 mmol), 
triethylamine (1.619 g, 16.0 mmol) and trimethylchlorosilane (1.738 
g, 18.0 mmol), 9b was isolated as a reddish oil (2.162 g, 85%). 1H 
NMR (300 MHz, CDCl3):  = 0.20 (m, 9 H, Si(CH3)3), 0.98 (t, 3J = 
7.4 Hz, 3 H, CH2CH3), 2.68 (q, 3J = 7.6 Hz, 2 H, CH2CH3), 5.96 (s, 1 H, CH), 6.936.95 (m, 
1 H, CHHetar), 7.367.38 (m, 1 H, CHHetar), 7.427.44 (m , 1 H, CHHetar). 
 
1-(2-Thienyl)-1-[(trimethylsilyl)oxy]-1-hexen-3-one (9c).  
Starting with benzene (73.0 mL), 8c (4.799 g, 24.5 mmol), 
triethylamine (3.960 g, 39.1 mmol) and trimethylchlorosilane 
(4.780 g, 44.0 mmol), 9c was isolated as a yellowish oil (6.018 g, 
92%). 1H NMR (300 MHz, CDCl3):  = 0.27 (m, 9 H, Si(CH3)3), 0.90 (t, 3J = 7.2 Hz, 3 H, 
CH2CH2CH3), 1.53 (m, 2 H, CH2CH2CH3), 2.74 (t, 3J = 6.1 Hz, 2 H, CH2CH2CH3), 6.08 (s,1 
H, CH), 6.977.01 (m, 1 H, CHHetar), 7.437.45 (m, 1 H, CHHetar), 7.497.51 (m , 1 H, 
CHHetar). 13C NMR (75 MHz, CDCl3):  = 0.3 (Si(CH3)3), 12.8 (CH2CH2CH3), 18.4 
(CH2CH2CH3), 35.3 (CH2CH2CH3), 103.8 (CH), 127.5, 128.8, 132.0 (CHHetar), 147.3 (CHetar), 
174.8 (C), 181.7 (CO). 
 
General procedure for the synthesis of salicylates 10, 16, 20, 26, 29:  
To a CH2Cl2 solution (2 mL/1.0 mmol of 9) of 9 (1.0 mmol) was added 5 (1.1 mmol) and, 
subsequently, TiCl4 (1.1 mmol) at 78 °C. The temperature of the solution was allowed to 
warm to 20 °C during 14 h with stirring. To the solution was added hydrochloric acid (10%, 
20 mL) and the organic and the aqueous layer were separated. The latter was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried (Na2SO4), filtered and the 
filtrate was concentrated in vacuo. The residue was purifed by chromatography (silica gel, n-










Methyl 4-ethyl-2-hydroxy-6-(2-thienyl)benzoate (10f).  
Starting with 9b (0.448 g, 2.0 mmol), 5a (0.567 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 10f was isolated as a reddish viscous oil 
(0.184 g, 35%). 1H NMR (300 MHz, CDCl3):  = 1.15 (t, 3J = 7.4 
Hz, 3 H, CH2CH3), 2.53 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.50 (s, 3 H, 
OCH3), 6.69 (s, 1 H, CHAr), 6.77 (s, 1 H, CHAr), 6.81 (m, 1 H, 
CHHetar), 6.91 (dd, 3J = 5.1 Hz, 4J = 1.7 Hz, 1 H, CHHetar), 7.21 (dd, 3J = 4.9 Hz, 4J = 1.3 Hz, 1 
H, CHHetar), 10.55 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.6 (CH2CH3), 27.7 
(CH2CH3), 50.8 (OCH3), 109.0 (CCOOCH3Ar), 115.5 (CHAr), 122.8, 123.9 (CHHetar), 124.7 
(CHAr), 125.4 (CHHetar), 135.5, 142.7 (CAr), 149.7 (CHetar), 160.5 (COHAr), 170.0 (CO). IR 
(neat, cm1): 	~ = 2967 (s), 2872 (w), 1734 (w), 1664 (s), 1610 (s), 1568 (s), 1440 (s), 1360 
(s), 1265 (s), 1160 (m), 1098 (s), 1014 (m), 932 (m), 808 (m), 791 (m), 697 (s).GC-MS (EI, 
70 eV): m/z (%) = 262 ([M+], 43), 230 (100), 202 (26), 187 (24), 173 (7), 115 (10). HRMS 
(EI): Calcd. for C14H14O3S [M+]: 262.0582; found: 262.06562. 
 
Methyl 4-ethyl-2-hydroxy-3-methyl-6-(2-thienyl)benzoate (10g).  
Starting with 9b (0.448 g, 2.0 mmol), 5b (0.598 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 10g was isolated as a reddish viscous 
oil. (0.180 g, 34%). 1H NMR (300 MHz, CDCl3):  = 1.09 (t, 3J = 
7.6 Hz, 3 H, CH2CH3), 2.13 (s, 3 H, CH3), 2.54 (q, 3J = 7.4 Hz, 2 H, 
CH2CH3), 3.48 (s, 3 H, OCH3), 6.67 (s, 1 H, CHAr), 6.776.79 (m, 1 
H, CHHetar), 6.90 (dd, 3J = 4.9 Hz, 4J = 1.5 Hz, 1 H, CHHetar), 7.16 (dd, 3J = 5.1 Hz, 4J = 1.1 
Hz, 1 H, CHHetar), 10.87 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 11.0 (CH2CH3), 14.0 
(CH3), 26.8 (CH2CH3), 51.7 (OCH3), 109.0 (CCOOCH3Ar), 123.1 (CHAr), 123.5, 124.6, 126.3 
(CHHetar), 133.3, 139.7 (CAr), 144.4 (CHetar), 148.4 (CAr), 159.6 (COHAr), 171.6 (CO). IR 
(Nujol, cm1): 	~ = 1663 (s), 1607 (m), 1561 (m), 1261 (s), 1220 (m), 1196 (m), 1160 (m), 
1102 (w), 1043 (m), 1007 (m), 848 (m), 806 (m), 766 (w), 649 (s). MS (EI, 70 eV): m/z (%) = 
276 ([M+], 98), 244 (100), 216 (91), 201 (41), 187 (23), 173 (25), 115 (15), 97 (8), 69 (10), 55 















Ethyl 3,4-diethyl-2-hydroxy-6-(2-thienyl)benzoate (10h).  
Starting with 9b (0.448 g, 2.0 mmol), 5c (0.659 g, 2.2 mmol) and TiCl4 
(0.24 mL, 2.2 mmol), 10h was isolated as a reddish viscous oil (0.186 
g, 30%). 1H NMR (300 MHz, CDCl3):  = 0.82 (t, 3J = 7.0 Hz, 3 H, 
CH2CH3), 1.09 (t, 3J = 7.4 Hz, 3 H, CH2CH3), 1.12 (t, 3J = 7.6 Hz, 3 H, 
OCH2CH3), 2.56 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 2.64 (q, 3J = 7.4 Hz, 2 
H, CH2CH3), 3.96 (q, 3J = 7.0 Hz, 2 H, OCH2CH3), 6.67 (s, 1 H, CHAr), 6.766.78 (m, 1 H, 
CHHetar), 6.90 (dd, 3J = 5.1 Hz, 4J = 1.5 Hz, 1 H, CHHetar), 7.17 (dd, 3J = 5.1 Hz, 4J = 1.1 Hz, 1 
H, CHHetar), 10.99 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.5 (CH2CH3), 14.4 
(CH2CH3), 16.6 (OCH2CH3), 19.5 (CH2CH3), 26.4 (CH2CH3), 61.3 (OCH2CH3), 110.8 
(CCOOCH2CH3Ar), 124.2 (CHAr), 125.9, 126.1, 127.1 (CHHetar), 134.0, 139.7 (CAr), 144.8 
(CHetar), 148.1 (CAr), 160.4 (COHAr), 171.6 (CO). IR (neat, cm1): 	~ = 2968 (s), 2874 (m), 
1657 (s), 1606 (m), 1559 (m), 1463 (m), 1394 (s), 1322 (m), 1274 (s), 1242 (m), 1220 (s), 
1175 (s), 1109 (m), 1030 (m), 870 (w), 812 (m), 694 (s). MS (EI, 70 eV): m/z (%) = 304 
([M+], 47), 258 (100), 229 (31), 215 (52), 201 (6), 187 (7), 171 (13), 153 (6), 97 (11), 81(9), 
69 (14), 55 (13), 41 (11). HRMS (EI): Calcd. for C17H20O3S [M+]: 304.11277; found: 
304.11299. 
 
Methyl 4-ethyl-3-hexyl-2-hydroxy-6-(2-thienyl)-benzoate (10i).  
Starting with 9b (0.425 g, 1.7 mmol), 5h (0.628 g, 1.8 mmol) and 
TiCl4 (0.20 mL, 1.8 mmol), 10i was isolated as a reddish viscous 
oil (0.156 g, 30%). 1H NMR (300 MHz, CDCl3):  = 0.71 (t(br), 
3J = 7.0 Hz, 3 H, CH2(CH2)4CH3), 1.03 (t, 3J = 7.6 Hz, 3 H, 
CH2CH3), 1.081.14 (m, 8 H, CH2(CH2)4CH3), 2.46 (q, 3J = 7.2 
Hz, 2 H, CH2CH3), 2.48 (q, 3J = 8.1 Hz, 2 H, CH2(CH2)4CH3), 3.41 (s, 3 H, OCH3), 6.59 (m, 
1 H, CHAr), 6.70 (m, 1 H, CHHetar), 6.82 (dd, 3J = 6.4 Hz, 4J = 1.7 Hz, 1 H, CHHetar), 7.077.09 
(m, 1 H, CHHetar), 10.71 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 15.2 ((CH2)5CH3), 
20.9 (CH2CH3), 23.8, 27.2, 30.4, 30.7, 31.0, 33.1 (CH2), 53.0 (OCH3), 111.2 (CCOOCH3Ar), 
124.9 (CHAr), 125.9, 126.6, 127.6 (CHHetar), 130.4, 134.6 (CAr), 145.8 (CHetar), 149.3 (CAr), 
160.8 (COHAr), 172.8 (CO). IR (neat, cm1): 	~ = 2925 (s), 2854 (m), 1661 (s), 1606 (m), 1559 
(m), 1439 (s), 1396 (s), 1324 (m), 1263 (s), 1220 (s), 1197 (m), 1162 (m), 1125 (w), 849 (m), 
813 (w), 649 (m). GC-MS (EI, 70 eV): m/z (%) = 346 ([M+], 43), 314 (8), 285 (100), 271 (5), 
257 (8), 244 (55), 215 (13), 187 (4), 171 (12), 153 (4), 85 (8), 71 (11), 57 (15), 43 (13). 












Methyl 2-hydroxy-4-propyl-6-(2-thienyl)benzoate (10j).  
Starting with 9c (0.536 g, 2.0 mmol), 5a (0.568 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 10j was isolated as a reddish viscous 
oil (0.214 g, 40%). 1H NMR (300 MHz, CDCl3):  = 0.81 (t, 3J = 
7.4 Hz, 3 H, CH2CH2CH3), 1.451.58 (m, 2 H, CH2CH2CH3), 2.42 
(t, 3J = 7.8 Hz, 2 H, CH2CH2CH3), 3.46 (s, 3 H, OCH3), 6.62 (s, 1 
H, CHAr), 6.70 (s, 1 H, CHAr), 6.77 (m, 1 H, CHHetar), 6.86 (m, 1 H, CHHetar), 7.15 (d, 3J = 6.3 
Hz, 1H, CHHetar), 10.57 (s, 1 H, OHAr). 13C NMR (75 MHz, CDCl3):  = 13.7 (CH3), 23.6, 
37.7 (CH2), 51.7 (OCH3), 110.2 (CCOOMeAr), 117.1, 124.3 (CHAr), 124.9, 125.6, 126.4 
(CHHetar), 136.7, 143.7 (CAr), 149.2 (CHetar), 161.4 (COHAr), 171.0 (CO). IR (KBr, cm1): 	~ = 
3012 (w), 2844 (w), 1662 (s), 1499 (m), 1459 (s), 1378 (s), 1239 (s), 1106 (m), 1074 (m), 
1025 (m), 806 (m). MS (EI, 70 eV): m/z (%) = 276 ([M+], 60), 244 (100), 229 (5), 216 (97), 
187 (24), 160 (10), 115 (20). HRMS (EI): Calcd. for C15H16SO3 [M+]: 276.08147; found: 
276.08178. 
 
Methyl 2-hydroxy-3-methyl-4-propyl-6-(2-thienyl)-benzoate (10k).  
Starting with 9c (0.537 g, 2.0 mmol), 5b (0.604 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 10k was isolated as a reddish viscous 
oil (0.274 g, 47%). 1H NMR (300 MHz, CDCl3):  = 0.88 (t, 3J = 
7.4 Hz, 3 H, CH2CH2CH3), 1.461.49 (m, 2 H, CH2CH2CH3), 2.14 
(s, 3 H, CH3), 2.49 (t, 3J = 7.8 Hz, 2 H, CH2CH2CH3), 3.49 (s, 3 H, 
OCH3), 6.66 (s,1 H, CHAr), 6.78-6.79 (m, 1 H, CHHetar), 6.90 (dd, 3J = 5.1 Hz, 4J = 1.5 Hz, 
1H, CHHetar), 7.17 (dd, 3J = 5.1 Hz, 4J = 1.1 Hz, 1H, CHHetar), 10.88 (s, 1 H, OH). 13C NMR 
(75 MHz, CDCl3):  = 11.7 (CH2CH2CH3), 14.7 (CH3), 23.1 (CH2CH2CH3), 36.3 
(CH2CH2CH3), 52.2 (OCH3), 110.2 (CCOOMeAr), 124.8 (CHAr), 125.9, 126.8, 127.5 
(CHHetar), 133.5, 140.0 (CAr), 144.6 (CHetar), 147.5 (CAr), 160.1 (COHAr), 172.1 (CO). IR (neat, 
cm1): 	~ = 2957 (s), 2871 (m), 1662 (s), 1607 (m), 1562 (m), 1438 (s), 1397 (s), 1312 (m), 
1266 (s), 1198 (m), 1161 (m), 1011 (w), 849 (w), 807 (m), 747 (w), 697 (m). MS (EI, 70 eV): 
m/z (%) = 290 ([M+], 72), 258 (100), 229 (18), 215 (25), 202 (55), 187 (13), 171 (13), 158 (4), 














Ethyl 3-ethyl-2-hydroxy-4-propyl-6-(2-thienyl)-benzoate (6l).  
Starting with 9c (0.537 g, 2.0 mmol), 5c (0.659 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 10l was isolated as a reddish viscous oil 
(0.245 g, 42%). 1H NMR (300 MHz, CDCl3):  = 0.81 (t, 3J = 7.0 
Hz, 3 H, CH2CH2CH3), 0.89 (t, 3J = 7.2 Hz, 3 H, CH2CH3), 1.09 (t, 
3J = 7.4 Hz, 3 H, OCH2CH3), 1.491.56 (m, 2 H, CH2CH2CH3), 
2.50 (t, 3J = 7.8 Hz, 2 H, CH2CH2CH3), 2.64 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.96 (q, 3J = 7.0 
Hz, 2 H, OCH2CH3), 6.66 (s, 1 H, CHAr), 6.766.77 (m, 1 H, CHHetar), 6.88 (dd, 3J = 5.1 Hz, 
4J = 1.5 Hz, 1H, CHHetar), 7.16 (dd, 3J = 5.1 Hz, 4J = 1.1 Hz, 1H, CHHetar), 10.99 (s, 1 H, OH). 
13C NMR (75 MHz, CDCl3):  = 13.5 (CH2CH2CH3), 14.3 (CH2CH3), 14.6 (OCH2CH3), 19.6 
(CH2CH2CH3), 24.5 (CH2CH2CH3), 35.5 (CH2CH3), 61.3 (OCH2CH3), 110.8 
(CCOOCH2CH3Ar), 124.8 (CHAr), 125.0, 125.9, 126.7 (CHHetar), 131.0, 133.7 (CAr), 142.6 
(CHetar), 144.8 (CAr), 160.2 (COHAr), 171.6 (CO). GC-MS (EI, 70 eV): m/z (%) = 318 ([M+], 
62), 272 (100), 257 (64), 244 (18), 229 (45), 216 (7), 201 (7), 187 (5), 171 (14), 153 (4), 115 
(7), 97 (3), 77 (3). HRMS (EI): Calcd. for C18H22O3S [M+]: 318.12842; found: 318.12842. 
 
Methyl 3-hexyl-2-hydroxy-4-propyl-6-(2-thienyl)-benzoate (10m).  
Starting with 9c (0.537 g, 2.0 mmol), 5h (0.812 g, 2.2 mmol) and 
TiCl4 (0.24 mL, 2.2 mmol), 10m was isolated as a reddish 
viscous oil (0.273 g, 35%). 1H NMR (300 MHz, CDCl3):  = 
0.71 (t(br), 3J = 4.7 Hz, 3 H, CH2(CH2)4CH3), 0.81 (t, 3J = 7.2 
Hz, 3 H, CH2CH2CH3), 1.08 (m, 8H, CH2(CH2)4CH3), 1.391.47 
(m, 2H, CH2CH2CH3), 2.41 (t, 3J = 7.8 Hz, 2 H, CH2CH2CH3), 2.49 (t, 3J = 7.4 Hz, 2 H, 
CH2(CH2)4CH3), 3.41 (s, 3 H, OCH3), 6.57 (m, 1 H, CHAr), 6.696.71 (m, 1 H, CHHetar), 6.81 
(dd, 3J = 4.9 Hz, 4J = 1.5 Hz, 1 H, CHHetar), 7.10 (dd, 3J = 5.1 Hz, 4J = 1.1 Hz, 1 H, CHHetar), 
10.71 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.1 (CH2)5CH3), 13.2 (CH2CH2CH3), 
21.6, 23.0, 25.0, 28.5, 28.6, 30.7, 34.2 (CH2), 50.8 (OCH3), 108.9 (CCOOCH3Ar), 123.5 
(CHAr), 123.6, 124.4, 125.4 (CHHetar), 128.5, 132.1 (CAr), 143.3 (CHetar), 145.7 (CAr), 158.7 
(COHAr), 170.6 (CO). IR (neat, cm1): 	~ = 2927 (s), 2870 (m), 1663 (s), 1605 (m), 1559 (m), 
1437 (s), 1396 (s), 1268 (s), 1161 (s), 1114 (w), 1015 (w), 810 (m), 693 (s). MS (EI, 70 eV): 
m/z (%) = 360 ([M+], 79), 328 (35), 311 (21), 285 (100), 271 (13), 258 (73), 243 (28), 201 
(11), 171 (11), 97 (6), 83 (6), 57 (11). HRMS (CI, Positive): Calcd. for C21H29O3S ([M+1]+): 













General procedure for the synthesis of 12:  
To a stirred dimethylsulfoxide solution (1 mL/1.0 mmol of 8) of 8 (10.0 mmol) was added 
potassium carbonate (40.0 mmol) at room temperature. After the solution was stirred for 30 
min, 1,2-dibromoethane 11 (20.0 mmol) was added at 20 °C. After the solution was stirred for 
12 h, an excess amount of water was added to remove dimethylsulfoxide and the mixture was 
extracted with dichloromethane. The combined organic layers were dried (Na2SO4) and 
filtered. The filtrate was concentrated in vacuo. The residue was purified by chromatography 
(silica gel, n-heptane/EtOAc = 30:1  20:1) to give 12.  
 
1-[1-(2-Thienylcarbonyl)cyclopropyl]-1-ethanone (12a).  
Starting with dimethysulfoxide (17.8 mL), 8b (3.250 g, 17.840 
mmol), K2CO3 (9.863 g, 71.4 mmol) and 1,2-dibromoethane  11 
(6.704 g, 35.7 mmol), 12a was isolated as a reddish oil (3.417 g, 
91%). 1H NMR (300 MHz, CDCl3):  = 0.90 (t, 3J = 7.1 Hz, 3 H, 
CH2CH3), 1.34 (t, 3J = 3.1 Hz, 2 H, CH2), 1.43 (t, 3J = 3.2 Hz, 2 H, CH2), 2.42 (q, 3J = 7.3 Hz, 
2 H, CH2CH3), 7.05 (dd, 3J = 4.9 Hz, 4J = 1.1 Hz, 1 H, CHHetar), 7.567.58 (m, 1 H, CHHetar), 
7.607.62 (m, 1 H, CHHetar). 13C NMR (75 MHz, CDCl3):  = 7.4 (CH2CH3), 16.1 (2CH2), 
35.2 (CH2CH3), 41.6 (COCCO), 128.2, 133.6, 134.2 (CHHetar), 143.4 (CHetar), 188.7, 206.0 
(CO). IR (neat, cm1): 	~ = 2977 (w), 1700 (m), 1647 (s), 1512 (w), 1409 (s), 1315 (m), 1233 
(m), 1052 (m), 972 (w), 794 (w), 721 (s), 657 (w). GC-MS (EI, 70 eV): m/z (%) = 208 ([M+], 
16), 193 (10), 179 (22), 151 (9), 111 (100), 83 (8), 57 (13), 39 (13). HRMS (EI): Calcd. for 
C11H12O2S [M+]: 208.05507; found: 208.05475.  
 
General procedure for the synthesis of salicylates 13:  
To a CH2Cl2 solution (50 mL/1.0 mmol of  12) of 12 (1.0 mmol) was added 5 (1.1 mmol) and, 
subsequently, TiCl4 (1.1 mmol) at 78 °C. The temperature of the solution was allowed to 
warm to 20 °C during 14 h with stirring. To the solution was added hydrochloric acid (10%, 
20 mL) and the organic and the aqueous layer were separated. The latter was extracted with 
CH2Cl2 (3 x 20 mL). The combined organic layers were dried (Na2SO4), filtered and the 
filtrate was concentrated in vacuo. The residue was purifed by chromatography (silica gel, n-







Methyl 3-(2-chloroethyl)-4-ethyl-6-hydroxy-2-(thiophen-2-yl)benzoate (13a).  
Starting with 12a (0.312 g, 1.2 mmol), 5a (0.429 g, 1.6 mmol) and 
TiCl4 (0.570 mL, 3.0 mmol), 13a was isolated as a colourless solid 
(0.204 g, 42%). 1H NMR (250 MHz, CDCl3):  = 1.15 (t, 3J = 7.4 
Hz, 3 H, CH2CH3), 2.92 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.08 (t, 3J = 
7.5 Hz, 2 H, CH2CH2Cl), 3.36 (t, 3J = 8.1 Hz, 2 H, CH2CH2Cl), 3.92 
(s, 3 H, OCH3), 6.95 (s, 1 H, CHAr), 6.96 (s, 1 H, CHHetar), 7.03 (d, 3J = 5.1 Hz, 1 H, CHHetar), 
7.32 (dd, 3J = 5.1 Hz, 4J = 1.2 Hz, 1 H, CHHetar), 10.42 (s, 1 H, OH). 13C NMR (62 MHz, 
CDCl3):  = 15.9 (CH2CH3), 26.6 (CH2CH3), 32.9 (CH2CH2Cl), 43.4 (CH2CH2Cl), 52.5 
(OCH3), 112.6 (CCOOCH3Ar), 118.2 (CHAr), 126.1 (CHHetar), 126.8 (CAr), 126.9, 127.0 
(CHHetar), 141.1, 141.3 (CAr), 145.8 (CHetar), 159.4 (COHAr), 170.2 (CO). IR (neat, cm1): 	~ = 
2923 (w), 1661 (s), 1597 (w), 1569 (m), 1434 (s), 1337 (m), 1234 (s), 1203 (s), 1142 (m), 
1080 (m), 939 (w), 807 (m), 788 (m), 692 (s). MS (EI, 70 eV): m/z (%) = 326 ([M+], 37Cl, 8), 
324 ([M+], 35Cl, 21), 294 (37Cl, 17), 292 (35Cl, 49), 275 (6), 245 (37Cl, 5), 243 (35Cl, 100), 215 
(4), 187 (5), 171 (6), 119 (9), 97 (11), 83 (11), 69 (24), 57 (19). HRMS (EI): Calcd. for 
C16H17ClO3S ([M]+, 35Cl): 324.05796; found: 324.05780. 
 
Methyl 3-(2-chloroethyl)-4-ethyl-6-hydroxy-5-methyl-2-(thiophen-2-yl)benzoate (13b).  
Starting with 12a (0.312 g, 1.2 mmol), 5b (0.452 g, 1.7 mmol) and 
TiCl4 (0.570 mL, 3.0 mmol), 13b was isolated as a colourless 
viscous oil (0.200 g, 40%). 1H NMR (250 MHz, CDCl3):  = 1.13 (t, 
3J = 7.4 Hz, 3 H, CH2CH3), 1.88 (s, 3 H, CH3), 2.86 (q, 3J = 7.5 Hz, 
2 H, CH2CH3), 2.89 (t, 3J = 7.3 Hz, 2 H, CH2CH2Cl), 3.42 (t, 3J = 
6.5 Hz, 2H, CH2CH2Cl), 3.92 (s, 3 H, OCH3), 6.746.76 (m, 1 H, CHHetar), 7.05 (dd, 3J = 5.2 
Hz, 4J = 1.7 Hz, 1 H, CHHetar), 7.36 (d, 3J = 6.2 Hz, 1 H, CHHetar), 10.71 (s, 1 H, OH). 13C 
NMR (62 MHz, CDCl3):  = 12.7 (CH2CH3), 15.7 (CH3), 23.3 (CH2CH3), 32.8 (CH2CH2Cl), 
42.8 (CH2CH2Cl), 51.5 (OCH3), 112.0 (CCOOCH3Ar), 124.8, 125.7, 126.1 (CHHetar), 126.7, 
139.1, 139.9, 140.8 (CAr), 140.8 (CHetar), 157.1 (COHAr), 170.9 (CO). IR (neat, cm1): 	~ = 
2953 (w), 1642 (s), 1567 (w), 1434 (m), 1325 (m), 1236 (s), 1209 (s), 1122 (s), 1035 (m), 814 
(s), 716 (s), 666 (m), 554 (m). MS (EI, 70 eV): m/z (%) = 340 ([M+], 37Cl, 17), 338 ([M+], 
35Cl, 36), 308 (37Cl, 33), 306 (35Cl, 100), 289 (7), 271 (7), 257 (68), 243 (51), 229 (7), 214 (5), 
177 (10), 161 (7), 135 (6), 111 (8), 97 (12), 83 (13), 69 (21), 57 (24). HRMS (EI): Calcd. for 













Ethyl 3-(2-chloroethyl)-2,5-diethyl-6-hydroxy-4-(2-thienyl)benzoate (13c).  
Starting with 12a (0.312 g, 1.2 mmol), 5c (0.499 g, 1.6 mmol) and 
TiCl4 (0.570 mL, 3.0 mmol), 13c was isolated as a colourless oil 
(0.194 g, 34%). 1H NMR (250 MHz, CDCl3):  = 0.95 (t, 3J = 7.4 Hz, 
3 H, CH2CH3), 1.15 (t, 3J = 7.2 Hz, 3 H, CH2CH3), 1.38 (t, 3J = 7.1 
Hz, 3 H, OCH2CH3), 2.32 (q, 3J = 7.5 Hz, 2 H, CH2CH3), 2.67 (t, 3J = 
7.5 Hz, 2 H, CH2CH2Cl), 2.88 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.34 (t, 3J = 5.0 Hz, 2H, 
CH2CH2Cl), 4.40 (q, 3J = 7.1 Hz, 2 H, OCH2CH3), 6.77 (d, 3J = 4.6 Hz, 1 H, CHHetar), 7.04 
(dd, 3J = 5.1 Hz, 4J = 1.7 Hz, 1 H, CHHetar), 7.33 (d, 3J = 6.2 Hz, 1 H, CHHetar), 10.75 (s, 1 H, 
OH). 13C NMR (62 MHz, CDCl3):  = 13.0, 13.3, (CH2CH3), 15.1 (OCH2CH3), 18.3 
(CH2CH3), 23.3 (CH2CH2Cl), 32.9 (CH2CH3), 42.9 (CH2CH2Cl), 60.9 (OCH2CH3), 112.5 
(CCOOC2H5Ar), 124.6 (CHHetar), 125.3 (CAr), 125.9, 126.8 (CHHetar), 130.9, 138.8, 139.1 
(CAr), 140.8 (CHetar), 157.1 (COHAr), 170.5 (CO). IR (neat, cm1): 	~ = 2963 (w), 1651 (s), 
1589 (w), 1446 (w), 1396 (m), 1371 (s), 1277 (s), 1194 (s), 1121 (m), 1018 (m), 814 (w), 693 
(s). MS (EI, 70 eV): m/z (%) = 368 ([M+], 37Cl, 18), 366 ([M+], 35Cl, 55), 341 (15), 344 (56), 
322 (37Cl, 38), 320 (35Cl, 100), 287 (34), 271 (23), 257 (61), 243 (19), 228 (10), 213 (5), 177 
(94), 161 (60), 149 (40), 129 (22). HRMS (EI): Calcd. for C17H23ClO3S ([M]+, 35Cl): 
366.10509; found: 366.10404. 
 
Methyl 3-(2-chloroethyl)-4-ethyl-5-hexyl-6-hydroxy-2-(thiophen-2-yl)benzoate (13d).  
Starting with 12a (0.312 g, 1.2 mmol), 5h (0.587 g, 1.6 mmol) 
and TiCl4 (0.570 mL, 3.0 mmol), 13d was isolated as a 
colourless oil (0.186 g, 32%). 1H NMR (250 MHz, CDCl3):  = 
0.75 (t (br), 3J = 7.0 Hz, 3 H, CH2(CH2)4CH3), 1.10 (t, 3J = 7.3 
Hz, 3 H, CH2CH3), 1.141.16 (m, 8 H, CH2(CH2)4CH3), 
1.291.32 (m, 2 H, CH2(CH2)4CH3), 2.27 (q, 3J = 6.1 Hz, 2 H, CH2CH3), 2.85 (t, 3J = 6.2 Hz, 
2 H, CH2CH2Cl), 3.34 (t, 3J = 5.5 Hz, 2 H, CH2CH2Cl), 3.91 (s, 3 H, OCH3), 6.756.77 (m, 1 
H, CHHetar), 7.03 (dd, 3J = 5.2 Hz, 4J = 1.7 Hz, 1 H, CHHetar), 7.33 (d, 3J = 6.3 Hz, 1 H, 
CHHetar), 10.61 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 14.0 (CH2)5CH3), 16.0, 
(CH2CH3), 22.4, 23.1, 28.3, 29.8, 29.9, 31.3, 33.9, 43.9 (8CH2), 52.4 (OCH3), 112.3 
(CCOOC2H5Ar), 122.7 (CAr), 125.3, 125.8, 126.0 (CHHetar), 130.2, 138.7, 139.4 (CAr), 140.8 
(CHetar), 157.0 (COHAr), 170.9 (CO). IR (neat, cm1): 	~ = 2925 (w), 16582 (m), 1590 (w), 
1432 (m), 1316 (m), 1202 (m), 1124 (m), 1070 (w), 833 (w), 817 (w), 693 (m). GCMS (EI, 














359 (27), 313 (42), 285 (12), 243 (48), 227 (8), 184 (7), 112 (4). HRMS (EI): Calcd. for 
C22H29ClO3S  ([M]+, 35Cl): 408.15204; found: 408.15396. 
 
1,1,1-trifluoro-4-phenyl-4-[(trimethylsilyl)oxy]-3-buten-2-one (15a). 
Starting with benzene (60.0 mL), 14a (5.00 g, 24.6 mmol), 
triethylamine (3.927 g, 38.8 mmol) and trimethylchlorosilane (2.917 
g, 27.0 mmol), 15a was isolated as a reddish oil (5.729 g, 82%). 1H 
NMR (300 MHz, CDCl3):  = 0.20 (m, 9 H, Si(CH3)3), 6.56 (s, 1 H, CH), 7.297.34 (m, 3 H, CHAr), 
7.777.80 (m, 2 H, CHAr). 
 
1,1,1-Trifluoro-4-(2-thienyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (15b).  
Starting with benzene (45.0 mL), 14b (3.330 g, 15.0 mmol), 
triethylamine (2.429 g, 24.0 mmol) and trimethylchlorosilane (2.917 
g, 27.0 mmol), 15b was isolated as a reddish oil (3.175 g, 72%). 1H 
NMR (250 MHz, CDCl3):  = 0.24 (m, 9 H, Si(CH3)3), 6.53 (m, 1 H, 
CH), 7.04 (m, 1 H, CHHeter), 7.567.62 (m, 2 H, CHHeter).  
 
1,1,1-Trifluoro-4-(2-furyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (15c).  
Starting with benzene (45.0 mL), 14c (3.09 g, 15.0 mmol), 
triethylamine (2.429 g, 24.0 mmol) and trimethylchlorosilane (2.917 
g, 27.0 mmol), 15c was isolated as a reddish oil (3.169 g, 76%). 1H 
NMR (300 MHz, CDCl3):  = 0.27 (m, 9 H, Si(CH3)3), 6.44 (m, 1 H, 
CH), 6.59 (m, 1 H, CHHeter), 7.127.19 (m, 1 H, CHHeter), 7.497.54 (m, 1 H, CHHeter).  
 
Methyl 3-hydroxy-5-(trifluoromethyl)[1,1'-biphenyl]-4-carboxylate (16a). 
Starting with 15a (0.361 g, 1.5 mmol), 5a (0.426 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 16a was isolated as a colourless 
solid (0.213 g, 48 %); 1H NMR (300 MHz, CDCl3):  = 3.82 (s, 
3 H, OCH3), 7.24 (m, 1 H, CHPh), 7.27 (m, 2 H, CHPh), 7.32 
(m, 1 H, CHAr), 7.37 (m, 1 H, CHAr), 7.427.44 (m, 2 H, CHPh), 
10.55 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 52.8 (OCH3), 109.5 (CCOOCH3Ar), 
118.0 (q, 3JF, C = 6.8 Hz, CHAr), 116.7 (CHAr), 119.7 (CHPh), 123.3 (d, 1J = 269.7 Hz, CF3), 
127.1 (2CHPh), 129.0 (2CHPh), 130.7 (q, 2J = 31.6 Hz, CCF3Ar), 138.2 (CPh), 146.7 (CAr), 

















	~  = 1660 (s), 1619 (m), 1452 (s), 1343 (s), 1219 (m), 1136 (s), 966 (m), 882 (m), 694 (m). 
GC-MS (EI, 70 eV): m/z (%) = 296 ([M+], 49), 265 (27), 264 (100), 263 (22), 236 (43), 208 
(8), 188 (18), 139 (13), 118 (6). HRMS (EI): Calcd. for C15H11F3O3 : 296.06548; found: 
296.06510. 
 
Methyl 3-hydroxy-2-methyl-5-(trifluoromethyl)[1,1'-biphenyl]-4-carboxylate (16b). 
Starting with 15a (0.361 g, 1.5 mmol), 5b (0.426 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 16b was isolated as a reddish 
viscous oil (0.237 g, 51 %); 1H NMR (300 MHz, CDCl3):  = 
2.13 (s, 3 H, CH3), 3.91 (s, 3 H, OCH3), 7.15 (m, 1 H, CHPh), 
7.19 (m, 1 H, CHAr), 7.22 (m, 1 H, CHPh), 7.34 (m, 2 H, CHPh), 
7.36 (m, 1 H, CHPh), 11.09 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.6 (CH3), 52.8 
(OCH3), 108.6 (CCOOCH3Ar), 120.2 (q, 3JF, C = 6.8 Hz, CHAr), 123.5 (d, 1J = 269.0 Hz, CF3), 
127.4 (q, 2J = 31.6 Hz, CCF3Ar), 127.9 (CHPh), 128.3 (2CHPh), 128.8 (2CHPh), 130.0 (CPh), 
139.7, 146.9 (CAr), 160.6 (COHAr), 170.2 (CO). 19F NMR (235 MHz, CDCl3):  =  58.0 
(CF3). IR (Neat, cm-1): 	~  = 2995 (w), 1681 (m), 1609 (w), 1439 (m), 1335 (m), 1274 (s), 
1122 (s), 1017 (s), 886 (s), 700 (s). GC-MS (EI, 70 eV): m/z (%) = 310 ([M+], 68), 279 (27), 
278 (80), 277 (100), 257 (9), 250 (36), 231 (7), 201 (24), 181 (57), 152 (24), 152 (24), 115 
(5). HRMS (EI): Calcd. for C16H13F3O3 : 310.08113; found: 310.08062. 
 
Ethyl 2-ethyl-3-hydroxy-5-(trifluoromethyl)[1,1'-biphenyl]-4-carboxylate (16c). 
Starting with 15a (0.360 g, 1.5 mmol), 5h (0.495 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 6c was isolated as a reddish 
viscous oil (0.187 g, 37 %). 1H NMR (250 MHz, CDCl3):  = 
1.00 (t, 3J = 7.4 Hz, 3 H, CH2CH3), 1.32 (t, 3J = 7.1 Hz, 3 H, 
OCH2CH3), 2.54 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 4.36 (q, 3J = 7.2 
Hz, 2 H, OCH2CH3), 7.09 (s(br), 1 H, CHAr), 7.15 (m, 1 H, CHPh), 7.167.19 (m, 2 H, CHPh), 
7.307.33 (m, 2 H, CHPh), 11.13 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 12.4 
(CH2CH3), 12.6 (OCH2CH3), 19.8 (CH2CH3), 62.2 (OCH2CH3), 108.3 (CCOOCH2CH3Ar), 
119.5 (q, 3JF, C = 6.6 Hz, CHAr), 122.5 (d, 1JF, C = 269.0 Hz, CF3), 125.4 (q, 2J = 31.6 Hz, 
CCF3Ar), 126.7 (CHPh), 127.2 (2CHPh), 127.5 (2CHPh), 134.2 (CPh), 139.0, 145.7 (CAr), 159.1 
(COHAr), 168.7 (CO). 19F NMR (235 MHz, CDCl3):  = 57.8 (CF3). GC-MS (EI, 70 eV): 
m/z (%) = 338 ([M+], 59), 293 (26), 292 (79), 291 (100), 264 (46), 249 (24), 223 (5), 195 (21), 












Methyl 2-hexyl-3-hydroxy-5-(trifluoromethyl)[1,1'-biphenyl]-4-carboxylate (16d). 
Starting with 15a (0.360 g, 1.5 mmol), 5h (0.563 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 16d was isolated as a reddish 
viscous oil (0.319 g, 56 %). 1H NMR (250 MHz, CDCl3):  = 
0.64 (t(br), 3J = 7.0 Hz, 3 H, CH2(CH2)4CH3), 0.991.34 (m, 8 
H, CH2(CH2)4CH3), 2.44 (t, 3J = 8.0 Hz, 2 H, CH2(CH2)4CH3), 
3.81 (s, 3 H, OCH3), 7.01 (m, 1 H, CHAr), 7.08 (m, 1 H, CHPh), 7.11 (m, 1 H, CHPh), 7.23 (m, 
2 H, CHPh), 7.25 (m, 1 H, CHPh), 10.91 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 13.9 
(CH3), 22.4, 27.3, 29.0, 29.3, 31.3 (CH2), 52.7 (OCH3), 109.0 (CCOOCH3Ar), 120.5 (q, 3JF, C 
= 6.5 Hz, CHAr), 123.5 (d, 1JF, C = 269.0 Hz, CF3), 127.4 (q, 2F, C = 31.6 Hz, CCF3Ar), 127.8 
(CHPh), 128.2 (2CHPh), 128.6(2CHPh), 134.2 (CPh), 140.0, 147.0 (CAr), 160.4 (COHAr), 170.2 
(CO). 19F NMR (235 MHz, CDCl3):  = 57.8 (CF3). IR (Capillary, cm-1): 	~  = 2927(w), 
2856 (w), 1671 (m), 1610 (w), 1439 (m), 1336 (m), 1280 (s), 1200 (m), 1177 (s), 1030 (w), 
947 (m), 885 (m), 770 (m), 701 (s). GC-MS (EI, 70 eV): m/z (%) = 380 ([M+], 55), 349 (31), 
348 (100), 347 (49), 331 (13), 278 (40), 277 (62), 250 (28), 229 (5), 201 (23), 181 (28), 152 
(16). HRMS (EI): Calcd. for C21H23O3F3: 380.15938; found: 380.15976. 
 
Methyl 3-hydroxy-2-octyl-5-(trifluoromethyl)[1,1'-biphenyl]-4-carboxylate (16e). 
Starting with 15a (0.360 g, 1.5 mmol), 5i (0.563 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 16e was isolated as a reddish 
viscous oil (0.367 g, 60 %). 1H NMR (250 MHz, CDCl3):  = 
0.77 (t(br), 3J = 6.9 Hz, 3 H, CH2(CH2)6CH3), 1.081.39 (m, 12 
H, CH2(CH2)6CH3), 2.25 (t, 3J = 7.8 Hz, 2 H, CH2(CH2)6CH3), 
3.90 (s, 3 H, OCH3), 7.10 (m, 1 H, CHAr), 7.16 (m, 1 H, CHPh), 7.19 (m, 1 H, CHPh), 7.32 (m, 
2 H, CHPh), 7.25 (m, 1 H, CHPh), 10.99 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 13.0 
(CH3), 21.6, 26.3 (CH2), 28.0 (3CH2), 28.6, 30.8 (CH2), 51.7 (OCH3), 108.0 (CCOOCH3Ar), 
119.5 (q, 3JF, C = 6.8 Hz, CHAr), 122.4 (d, 1JF, C = 269.0 Hz, CF3), 125.8 (q, 2JF, C = 31.6 Hz, 
CCF3Ar), 126.7, 126.9, 127.0, 127.2, 127.5 (CHPh), 133.2 (CPh), 139.0 (CAr), 146.0 (CAr), 
159.4 (COHAr), 169.2 (CO). 19F NMR (235 MHz, CDCl3):  = 58.6 (CF3). IR (Neat, cm-1): 
	~  = 2961 (w), 2854 (w), 1672 (w), 1374 (w), 1257 (s), 1087 (m), 1012 (s), 791 (s). GC-MS 
(EI, 70 eV): m/z (%) = 408 ([M+], 43), 377 (32), 37 (100), 359 (12), 333 (7), 278 (41), 277 
(59), 250 (25), 229 (5), 201 (19), 181 (18), 152 (13). HRMS (EI): Calcd. for C23H27O3F3: 













Methyl 2-hydroxy-4-(2-thienyl)-6-(trifluoromethyl)benzoate  (16f).  
Starting with 15b (0.442 g, 1.5 mmol), 5a (0.430 g, 1.6 mmol) 
and TiCl4 (0.18 mL, 1.6 mmol), 16f was isolated as a colourless 
solid (0.160 g, 35%), m.p = 126128 oC. 1H NMR (250 MHz, 
CDCl3):  = 3.92 (s, 3 H, OCH3), 7.05 (dd, 3J = 5.1 Hz, 4J= 1.4 
Hz, 1 H, CHHeter), 7.337.35 (m, 2 H, CHHeter), 7.377.39 (m, 1 H, CHAr), 7.47 (m, 1 H, 
CHAr), 10.86 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 52.8 (OCH3), 109.2 
(CCOOCH3Ar), 116.6 (d, 3JF, C = 6.8 Hz, CHAr), 117.8 (CHAr), 123.1 (d, 1JF, C = 269.7 Hz, 
CF3), 125.7, 127.5, 128.5 (CHHeter), 130.5 (d, 2JF, C = 31.6 Hz, CCF3Ar), 139.7 (CHeter), 141.2 
(CAr), 162.4 (COHAr), 169.3 (CO). 19F NMR (235 MHz, CDCl3):  =  59.0 (CF3). IR (neat, 
cm-1): 	~  = 2964 (w), 2857 (w), 1672 (m), 1614 (w), 1440 (m), 1422 (m), 1326 (m), 1228 (w), 
1127 (m), 1030 (m), 923 (m), 869 (m), 717 (m). GC-MS (EI, 70 eV): m/z (%) = 302 ([M+], 
81), 270 (100), 242 (41), 223 (9), 214 (40), 194 (4), 169 (4), 145 (16), 121 (13). HRMS (EI): 
Calcd. for C13H9O3F3S : 302.02190; found: 302.02202. 
 
Methyl 2-hydroxy-3-methyl-4-(2-thienyl)-6-(trifluoromethyl)benzoate (16g).  
Starting with 15b (0.442 g, 1.5 mmol), 5b (0.452 g, 
1.6 mmol) and TiCl4 (0.18 mL, 1.6 mmol), 16g was isolated 
as a colourless solid (0.215 g, 45%), m.p = 7274 oC. 1H 
NMR (250 MHz, CDCl3):  = 2.30 (s, 3 H, CH3), 3.92 (s, 3 
H, OCH3), 7.04 (d, 4J H, F = 2.2 Hz, 1 H, CHAr), 7.07 (m, 1 
H, CHHeter), 7.30 (m, 1 H, CHHeter), 7.36 (m, 1 H, CHHeter), 
11.16 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 12.8 (CH3), 51.8 (OCH3), 107.7 
(CCOOCH3Ar), 119.8 (d, 3JF, C = 6.8 Hz, CHAr), 122.3 (d, 1JF, C = 271.5 Hz, CF3), 125.8 
(CHHeter), 126.0 (d, 2JF, C = 31.5 Hz, CCF3Ar), 126.3, 126.9 (CHHeter), 128.8, 138.3 (CAr), 139.6 
(CHeter), 159.7 (COHAr), 169.0 (CO). 19F NMR (235 MHz, CDCl3):  =  58.6 (CF3). IR (neat, 
cm-1): 	~  = 2962 (w), 2853 (w), 1683 (m), 1606 (w), 1436 (m), 1315 (m), 1275 (s), 1112 (s), 
1013 (m), 937 (m), 882 (m), 687 (s). GC-MS (EI, 70 eV): m/z (%) = 316 ([M+], 66), 284 (29), 
256 (100), 237 (5), 207 (11), 187 (10), 159 (8), 134 (4), 115 (6). HRMS (EI): Calcd. for 
















Ethyl 3-ethyl-2-hydroxy-4-(2-thienyl)-6-(trifluoromethyl)benzoate (16h).  
Starting with 15b (0.442 g, 1.5 mmol), 5c (0.499 g, 1.6 mmol) 
and TiCl4 (0.18 mL, 1.6 mmol), 16h was isolated as a yellow oil 
(0.230 g, 44%). 1H NMR (250 MHz, CDCl3):  = 1.12 (t, 3J = 
7.4 Hz, 3 H, CH2CH3), 1.34 (t, 3J = 7.1 Hz, 3 H, OCH2CH3), 
2.74 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 4.38 (q, 3J = 7.1 Hz, 3 H, 
OCH2CH3), 7.03 (m, 1 H, CHHeter), 7.04 (d, 4J H, F = 1.4 Hz, 1 H, CHAr), 7.26 (m, 1 H, 
CHHeter), 7.337.35 (m, 1 H, CHHeter), 11.19 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 
14.1, 14.2 (CH3), 21.0 (CH2CH3), 62.5 (OCH2CH3), 109.5 (CCOOCH2CH3Ar), 121.2 (d, 3JF, C 
= 7.5 Hz, CHAr), 123.3 (d, 1JF, C = 271.5 Hz, CF3), 126.6 (CHHeter), 127.0 (d, 2JF, C = 31.5 Hz, 
CCF3Ar), 127.3, 127.4 (CHHeter), 136.0, 138.8 (CAr), 140.5 (CHeter), 160.6 (COHAr), 169.6 
(CO). IR (neat, cm-1): 	~  = 2930 (w), 2874 (w), 1666 (m), 1608 (w), 1463 (w), 1372 (m), 
1288 (s), 1231 (m), 1137 (s), 1013 (m), 932 (m), 883 (w), 696 (s). GC-MS (EI, 70 eV): m/z 
(%) = 344 ([M+], 45), 298 (15), 270 (100), 255 (4), 222 (4), 207 (6), 171 (5). HRMS (EI): 
Calcd. for C16H15O3F3S : 344.07413; found: 344.07710. 
 
Methyl 3-hexyl-2-hydroxy-4-(2-thienyl)-6-(trifluoromethyl)benzoate (16i).  
Starting with 15b (0.442 g, 1.5 mmol), 5h (0.568 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 16i was isolated as a colourless 
viscous oil (0.196 g, 34 %). 1H NMR (250 MHz, CDCl3):  = 
0.79 (t(br), 3J = 6.6 Hz, 3 H, CH2(CH2)4CH3), 1.181.51 (m, 8 
H, CH2(CH2)4CH3), 2.69 (t, 3J = 8.2 Hz, 2 H, CH2(CH2)4CH3), 
3.92 (s, 3 H, OCH3), 7.02 (m, 1 H, CHAr), 7.047.06 (m, 1 H, CHHeter), 7.26 (m, 1 H, CHHeter), 
7.35 (dd, 3J = 4.8 Hz, 4J = 1.3 Hz, 1 H, CHHeter), 11.05 (s, 1 H, OH). 13C NMR (62 MHz, 
CDCl3):  = 13.0 (CH3), 21.5, 26.6, 28.3, 28.4, 30.4 (CH2), 51.8 (OCH3), 108.2 
(CCOOCH3Ar), 120.2 (q, 3JF, C = 8.2 Hz, CHAr), 122.4 (d, 1JF, C = 250.4 Hz, CF3), 125.7(CAr), 
125.6, 126.2, 126.4 (CHHeter), 134.0, 138.1 (CAr), 139.5 (CHeter), 159.5 (COHAr), 169.1 (CO). 
19F NMR (235 MHz, CDCl3):  =  58.7 (CF3). IR (neat, cm-1): 	~  = 2928(w), 2849 (w), 1672 
(m), 1601 (w), 1439 (m), 1356 (m), 1298 (s), 1198 (m), 1124 (s), 1047 (w), 940 (m), 810 (m), 
701 (s). GC-MS (EI, 70 eV): m/z (%) = 386 ([M+], 100), 354 (25), 337 (11), 326 (94), 315 (8), 
297 (14), 283 (59), 256 (54), 235 (7), 207 (28), 187 (7), 158 (14). HRMS (EI): Calcd. for 
















Methyl 2-hydroxy-3-octyl-4-(2-thienyl)-6-(trifluoromethyl)benzoate (16j).  
Starting with 15b (0.442 g, 1.5 mmol), 5i (0.614 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 1.6 mmol), 16j was isolated as a colourless 
viscous oil (0.231 g, 37 %), m.p = 4950 oC. 1H NMR (250 
MHz, CDCl3):  = 0.58 (t(br), 3J = 6.9 Hz, 3 H, 
CH2(CH2)6CH3), 0.951.26 (m, 12 H, CH2(CH2)6CH3), 2.47 (t, 
3J = 8.1 Hz, 2 H, CH2(CH2)6CH3), 3.70 (s, 3 H, OCH3), 6.80 (m, 1 H, CHAr), 6.83 (m, 1 H, 
CHHeter), 7.04 (m, 1 H, CHHeter), 7.13 (dd, 3J = 6.3 Hz, 4J = 1.3 Hz, 1 H, CHHeter), 10.82 (s, 1 
H, OH). 13C NMR (75 MHz, CDCl3):  = 14.0 (CH3), 22.6, 27.6, 29.1, 29.2, 29.4, 29.7, 31.8 
(CH2), 52.8 (OCH3), 109.2 (CCOOCH3Ar), 121.3 (q, 3JF, C = 6.7 Hz, CHAr), 123.3 (d, 1JF, C = 
271.5 Hz, CF3), 126.5 (d, 2JF, C = 31.5 Hz, CCF3Ar), 126.6, 127.2, 127.4 (CHHeter), 135.0, 
139.1 (CAr), 140.5 (CHeter), 160.5 (COHAr), 170.1 (CO). 19F NMR (235 MHz, CDCl3):  =   
58.7 (CF3). IR (Neat, cm-1): 	~  = 2915(w), 2848 (w), 1669 (m), 1604 (w), 1440 (m), 1338 
(m), 1286 (m), 1197 (m), 1125 (s), 1048 (w), 946 (m), 852 (w), 698 (s). GC-MS (EI, 70 eV): 
m/z (%) = 414 ([M+], 100), 382 (30), 365 (12), 297 (16), 284 (33), 283 (63), 269 (74), 256 
(48), 235 (7), 207 (24), 158 (12). HRMS (EI): Calcd. for C21H25O3F3S: 414.14710; found: 
414.14684. 
 
Methyl 2-hydroxy-4-(2-furanyl))-6-(trifluoromethyl)benzoate (16k).  
Starting with 15c (0.556 g, 2.0 mmol), 5a (0.567 g, 2.2 mmol) 
and TiCl4 (0.24 ml, 2.2 mmol), 16k was isolated as a colourless 
solid (0.231 g, 40 %), m.p = 116118 oC. 1H NMR (250 MHz, 
CDCl3):  = 3.91 (s, 3 H, OCH3), 6.45 (q, 4JH, F = 1.7 Hz, 1 H, 
CHAr), 6.78 (dd, 3J = 4.1 Hz, 4J = 0.6 Hz, 1 H, CHHeter), 7.37 (m, 
1 H, CHHeter), 7.47 (m, 1 H, CHAr), 7.52 (m, 1 H, CHHeter), 10.84 (s, 1 H, OH). 13C NMR (75 
MHz, CDCl3):  = 52.8 (OCH3), 108.9, 112.2 (CHHeter), 114.7 (q, 3JF, C = 6.7 Hz, CHAr), 115.6 
(CHAr), 117.7 (CCOOCH3Ar), 123.1 (d, 1JF, C = 271.5 Hz, CF3), 131.0 (d, 2JF, C = 32.2 Hz, 
CCF3Ar), 135.6 (CAr), 144.0 (CHHeter), 151.2 (CHeter), 162.4 (COHAr), 169.4 (CO). 19F NMR 
(235 MHz, CDCl3):  =  59.0 (CF3). IR (neat, cm-1): 	~  = 2921 (w), 2852 (w), 1660 (m), 
1621 (w), 1440 (m), 1335 (m), 1290 (m), 1212 (m), 1126 (m), 1016 (m), 904 (m), 802 (m), 
760 (m). GC-MS (EI, 70 eV): m/z (%) = 286 ([M+], 81), 254 (100), 226 (69), 207 (10), 198 
(23), 169 (16), 151 (21), 129 (4), 113 (8), 75 (5). HRMS (EI): Calcd. for C13H9O4F3: 














Methyl 4-(2-furanyl)-2-hydroxy-3-methyl-6-(trifluoromethyl)benzoate (16l).  
Starting with 15c (0.4176 g, 1.5 mmol), 5b (0.452 g, 1.6 mmol) 
and TiCl4 (0.18 ml, 2.2 mmol), 16l was isolated as a red solid 
(0.186 g, 41 %), m.p = 7982 oC. 1H NMR (300 MHz, CDCl3): 
 = 2.38 (s, 3 H, CH3), 3.91 (s, 3 H, OCH3), 6.48 (dd, 3J = 5.2 
Hz, 4J = 1.8 Hz, 1 H, CHHeter), 6.656.67 (m, 1 H, CHHeter), 7.50 (m, 1 H, CHAr), 7.60 (m, 1 H, 
CHHeter), 11.21 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 12.5 (CH3), 51.8 (OCH3), 107.1 
(CCOOCH3Ar), 110.8, 110.9 (CHHeter), 116.4 (q, 3JF, C = 6.8 Hz, CHAr), 122.4 (d, 1JF, C = 271.5 
Hz, CF3), 124.6 (CAr), 126.4 (d, 2JF, C = 32.2 Hz, CCF3Ar), 133.6 (CAr), 142.1 (CHHeter), 150.3 
(CHeter), 159.8 (COHAr), 169.1 (CO). 19F NMR (235 MHz, CDCl3):  =   58.8 (CF3). IR 
(neat, cm-1): 	~  = 2921 (w), 2850 (w), 1798 (m), 1658 (m), 1438 (m), 1338 (m), 1282 (s), 
1120 (s), 1018 (m), 936 (m), 804 (m), 754 (m). GC-MS (EI, 70 eV): m/z (%) = 300 ([M+], 
100), 268 (78), 248 (80), 219 (9), 192 (10), 164 (26), 133 (11), 115 (21). HRMS (EI): Calcd. 
for C14H11O4F3: 300.06039; found: 300.05967. 
 
Ethyl 3-ethyl-4-(2-furanyl)-2-methyl-6-(trifluoromethyl)benzoate (16m).  
Starting with 15c (0.556 g, 2.0 mmol), 5c (0.652 g, 2.2 mmol) and 
TiCl4 (0.24 ml, 2.2 mmol), 16m was isolated as a red solid 
(0.226 g, 35 %). 1H NMR (300 MHz, CDCl3):  = 1.18 (t, 3J = 7.4 
Hz, 3 H, CH2CH3), 1.34 (t, 3J = 7.2 Hz, 3 H, OCH2CH3), 2.87 (q, 
3J = 7.2 Hz, 2 H, CH2CH3), 4.38 (q, 3J = 7.2 Hz, 2 H, OCH2CH3), 6.47 (q, 3JH, F = 5.1 Hz, 1 
H, CHAr), 6.63 (m, 1 H, CHHeter), 7.50 (m, 1 H, CHHeter), 7.54 (m, 1 H, CHHeter), 11.27 (s, 1 H, 
OH). 13C NMR (62 MHz, CDCl3):  = 12.0 (CH2CH3), 12.5 (OCH2CH3), 19.6 (CH2CH3), 
61.5 (OCH2CH3), 107.8 (CCOOCH2CH3Ar), 109.9, 110.8 (CHHeter), 117.0 (q, 3JF, C = 6.8 Hz, 
CHAr), 122.4 (d, 1JF, C = 269.1 Hz, CF3), 126.4 (d, 2JF, C = 32.2 Hz, CCF3Ar), 132.7, 133.0 
(CAr), 142.2 (CHHeter), 150.3 (CHeter), 159.9 (COHAr), 168.7 (CO). 19F NMR (235 MHz, 
CDCl3):  =  58.1 (CF3). IR (neat, cm-1): 	~  = 2924 (w), 2853 (w), 1671 (m), 1439 (m), 1336 
(m), 1282 (s), 1200 (m), 1131 (s), 1047 (m), 954 (w), 886 (w), 770 (w), 701 (s). GC-MS (EI, 
70 eV): m/z (%) = 328 ([M+], 61), 282 (29), 254 (100), 234 (7), 207 (7), 177 (7), 128 (7). 

















Methyl 4-(2-furanyl)-3-hexyl-2-methyl-6-(trifluoromethyl)benzoate (16n).  
Starting with 15c (0.556 g, 2.0 mmol), 5h (0.751 g, 2.2 mmol) 
and TiCl4 (0.24 ml, 2.2 mmol), 16n was isolated as a viscous oil 
(0.222 g, 30 %). 1H NMR (250 MHz, CDCl3):  = 0.84 (t, 3J = 
6.8 Hz, 3 H, CH2(CH2)4CH3), 1.23-1.54 (m, 8H, 
CH2(CH2)4CH3), 2.80 (t, 3J = 7.6 Hz, 2 H, CH2(CH2)4CH3), 3.89 (s, 3 H, OCH3), 6.46 (q, 4JH, 
F = 1.8 Hz, 1 H, CHAr), 6.58 (m, 1 H, CHHeter), 7.48 (m, 1 H, CHHeter), 7.53 (m, 1 H, CHHeter), 
11.14 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 13.0 (CH3), 21.6, 26.2, 27.5, 28.6, 30.5 
(CH2), 51.7 (OCH3), 107.4 (CCOOCH3Ar), 109.9, 110.8 (CHHeter), 177.0 (q, 3JF, C = 6.8 Hz, 
CHAr), 122.4 (d, 1JF, C = 269.1 Hz, CF3), 126.3 (d, 2JF, C = 31.6 Hz, CCF3Ar), 131.7, 133.3 
(CAr), 142.1 (CHHeter), 150.3 (CHeter), 159.8 (COHAr), 169.1 (CO). 19F NMR (235 MHz, 
CDCl3):  =  59.0 (CF3). IR (neat, cm-1): 	~  = 2917 (w), 2849 (w), 1672 (m), 1439 (m), 1336 
(m), 1282 (s), 1202 (m), 1133 (s), 948 (w), 880 (w), 739 (w). GC-MS (EI, 70 eV): m/z (%) = 
370 ([M+], 100), 338 (24), 321 (11), 310 (42), 281 (32), 267 (68), 240 (28), 219 (31), 211 (6), 
183 (14), 164 (11), 133 (15), 115 (8). HRMS (EI): Calcd. for C19H21O4F3: 370.13865; found: 
370.13811. 
 
Methyl 4-(2-furanyl)-3-hexyl-2-methyl-6-(trifluoromethyl)benzoate (16o).  
Starting with 15c (0.556 g, 2.0 mmol), 5i (0.812 g, 2.2 mmol) 
and TiCl4 (0.24 ml, 2.2 mmol), 16o was isolated as a 
colourless solid (0.280 g, 35 %). 1H NMR (300 MHz, CDCl3): 
 = 0.79 (t, 3J = 6.8 Hz, 3 H, CH2(CH2)6CH3), 1.461.54 (m, 
12 H, CH2(CH2)6CH3), 2.80 (t, 3J = 7.6 Hz, 2 H, 
CH2(CH2)6CH3), 3.89 (s, 3 H, OCH3), 6.44 (q, 4JH, F = 4.1 Hz, 1 H, CHAr), 6.57 (dd, 3J = 4.1 
Hz, 4J = 0.8 Hz, 1 H, CHHeter), 7.47 (m, 1 H, CHHeter), 7.52 (m, 1 H, CHHeter), 11.12 (s, 1 H, 
OH). 13C NMR (62 MHz, CDCl3):  = 14.0 (CH3), 22.6, 27.2, 28.6, 29.2, 29.3, 29.9, 31.8 
(CH2), 52.7 (OCH3), 108.4 (CCOOCH3Ar), 110.9, 111.8 (CHHeter), 118.1 (q, 3JF, C = 6.8 Hz, 
CHAr), 123.4 (d, 1JF, C = 269.0 Hz, CF3), 127.4 (q, 2JF, C = 31.0 Hz, CCF3Ar), 132.8, 134.3 
(CAr), 143.1 (CHHeter), 151.4 (CHeter), 160.9 (COHAr), 170.1 (CO). 19F NMR (235 MHz, 
CDCl3):  =   58.8 (CF3). IR (neat, cm-1): 	~  = 2917 (w), 2849 (w), 1672 (m), 1439 (m), 
1336 (m), 1282 (s), 1202 (m), 1133 (s), 948 (w), 880 (w), 739 (w). GC-MS (EI, 70 eV): m/z 
(%) = 398 ([M+], 100), 366 (42), 338 (8), 267 (76), 219 (37), 183 (12), 133 (11). HRMS (EI): 















4-Hydroxy-4-(2-methoxyphenyl)-3-buten-2-one (18a).  
Starting with THF (62.5 mL), LDA (75 mmol), acetone 6a (2.904 g, 
50.0 mmol) and 2-methoxy anisoyl chloride  17 (10.235 g, 60.0 mmol), 
18a was isolated as a yellowish oil (3.550 g, 37%). 1H NMR (250 MHz, 
CDCl3):  = 1.99 (s, 3 H, CH3), 3.69 (s, 3 H, OCH3), 6.28 (s, 1 H, CH), 
6.76 (dd, J = 8.5 Hz, J = 0.9 Hz, 1 H, Ar), 6.84 (ddd, J = 7.3 Hz, J = 7.3 Hz, J = 0.9 Hz, 1 H, 
Ar), 7.22 (ddd, J = 8.5 Hz, J = 8.2 Hz, J = 1.8 Hz, 1 H, Ar), 7.70 (dd, J = 7.6 Hz, J = 1.8 Hz, 1 
H, Ar), 15.3 (s(br), 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 26.1 (CH3), 55.4 (OCH3), 
101.9, 111.6, 120.9, 130.8, 133.1 (CH), 134.8, 158.4, 181.3, 194.6 (C). IR (Nujol, cm-1): 	~  = 
3076 (w), 3005 (w) 2962 (w), 1721 (m), 1603 (s), 1490 (s), 1250 (s), 1164 (m), 1022 (m), 989 
(m), 755 (m), 533 (w). MS (EI, 70 eV): m/z (%) = 192 ([M]+, 12), 174 (10), 161 (54), 136 
(10), 135 (100), 120 (5), 105 (4), 92 (11), 77 (25), 63.1 (5), 51 (5), 43 (11). HRMS (EI): 
Calcd. for C11H12O3 : 192.07810; found: 192.07797. Anal. calcd. for C11H12O3:  C 68.73, H 
6.29; found: C 69.16, H 6.52. 
 
1-Hydroxy-1-(2-methoxyphenyl)-1-hexen-3-one (18b).  
Starting with THF (5 mL), LDA (6.0 mmol), 2-Pentanone 6c 
(0.344 g, 4.0 mmol) and 2-methoxy anisoyl chloride 17 (0.818 g, 
4.8 mmol), 18a was isolated as a yellowish oil (0.647 g, 73%, 
mixture of keto-enol tautomers). 1H NMR (300 MHz, CDCl3):  
= 0.86 (t, J = 7.2 Hz, 3 H, CH3), 1.53-1.61 (m, 2 H, CH2), 2.26 (t, J = 7.3 Hz, 2 H, CH2), 3.74 
(s, 3 H, OCH3), 6.32 (s, 1 H, CH), 6.80 (m, 1 H, Ar), 6.88 (dd, J = 7.6 Hz, J = 0.9 Hz, 1 H, 
Ar), 7.27 (ddd, J = 8.5 Hz, J = 8.4 Hz, J = 1.9 Hz, 1 H, Ar), 7.74 (dd, J = 7.8 Hz, J = 1.9 Hz, 1 
H, Ar), 16.2 (s(br), 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 12.7 (CH3), 18.2, 40.2 (CH2), 
54.5 (OCH3), 100.3, 110.6, 119.6 (CH), 123.2 (C), 128.7, 131.9 (CH), 157.3, 180.5, 196.3 
(C). IR (Nujol, cm-1): 	~  = 2963 (m), 2935 (m), 2874 (w), 2839 (w), 1718 (w), 1668 (w), 1604 
(s), 1490 (s), 1465 (m), 1293 (m), 1250 (s), 1165 (m), 1067 (w), 1067 (w), 1023 (m), 805 (w), 
754 (m). MS (EI, 70 eV): m/z (%) = 220 ([M]+, 7), 202 (4), 189 (23), 177 (24), 135 (100), 120 
(3), 105 (2), 92 (8), 77 (17), 63.1 (3),  43 (5). HRMS (EI): Calcd. for C13H16O3 : 220.10940; 










4-(2-Methoxyphenyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (19a).   
Starting with benzene (37 mL), 18a (2.854 g, 14.9 mmol), triethylamine 
(2.406 g, 23.8 mmol) and trimethylchlorosilane (2.905 g, 26.7 mmol), 
19b was isolated as a yellow oil (2.893 g, 73%, mixture of E/Z-
isomers). 1H NMR (250 MHz, CDCl3):  = 0.21 (s, 9 H, 3CH3), 2.31 (s, 
3 H, CH3), 3.78 (s, 3 H, OCH3), 6.16 (s, 1 H, CH), 6.84-6.86 (m, 1 H, Ar), 6.90 (dd, J = 8.7 
Hz, J = 1.1 Hz, 1 H, Ar), 7.28-7.30 (m, 1 H, Ar), 7.51 (dd, J = 8.7 Hz, J = 2.1 Hz, 1 H, Ar). 
13C NMR (75 MHz, CDCl3):  = 0.16 (3 CH3), 21.9 (CH3), 55.1 (OCH3), 101.3, 111.0, 119.8, 
130.5, 131.5 (CH), 132.7, 157.2, 169.7, 191.3 (C). 
 
1-(2-Methoxyphenyl)-1-[(trimethylsilyl)oxy]-1-hexen-3-one (19b).  
Starting with benzene (55 mL) of 18b (5.0 g, 22.7 mmol), 
triethylamine (3.675 g, 36.3 mmol) and trimethylchlorosilane 
(4.439 g, 40.8 mmol),  19b was isolated as a yellowish oil (5.024 
g, 75%, mixture of E/Z-isomers). 1H NMR (300 MHz, CDCl3):  
= 0.23 (s, 9 H, 3CH3), 0.90 (m, 3 H, CH3), 1.51-1.59 (m, 2 H, CH2), 2.72 (t, J = 7.6 Hz, CH3), 
3.75 (s, 3 H, OCH3), 6.15 (s, 1 H, CH), 6.82-6.83 (m, 1 H, Ar), 6.89 (dd, J = 6.3 Hz, J = 0.5 
Hz, 1 H, Ar), 7.26-7.28 (m, 1 H, Ar), 7.53 (dd, J = 8.3 Hz, J = 1.8 Hz, 1 H, Ar). 13C NMR (75 
MHz, CDCl3):  = 0.5 (3 CH3), 13.9 (CH3), 20.3, 36.2 (CH2), 55.6 (OCH3), 101.3, 109.3 
(CH), 111.0 (C), 120.2, 120.6, 131.6 (CH), 157.4, 173.3, 191.0 (C). 
 
Ethyl 3-hydroxy-2'-methoxy-5-methyl[1,1'-biphenyl]-2-carboxylate (20a).  
Starting with 19a (0.582 g, 2.2 mmol), 5a (0.659 g, 2.4 mmol) and 
TiCl4 (0.455 g, 2.4 mmol), 20a was isolated (0.293 g, 47%) as a 
colorless solid (mp = 91-93 ºC). 1H NMR (250 MHz, CDCl3):  = 0.78 
(t, J = 7.2 Hz, 3 H, CH3), 2.34 (s, 3 H, CH3), 3.70 (s, 3 H, OCH3), 3.97 
(q, J = 7.3 Hz, 2 H, OCH2CH3), 6.87-6.58 (m, 1 H, Ar), 6.80-6.81 (m, 
1 H, Ar), 6.85 (dd, J = 8.1 Hz, J = 1.2 Hz, 1 H, Ar), 6.99 (ddd, J = 7.3 
Hz, J = 7.6 Hz, J = 1.2 Hz, 1 H, Ar), 7.15 (dd, J = 7.3 Hz, J = 1.5 Hz, 1 H, Ar), 7.32 (ddd, J = 
8.6 Hz, J = 7.3 Hz, J = 1.8 Hz, 1 H, Ar), 10.93 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 
13.5, 22.2 (CH3), 55.6 (OCH2CH3), 60.8 (OCH3), 109.9, 117.2, 120.5 (CH), 122.8 (C) 124.2, 
128.4, 129.5 (CH), 140.8, 145.0, 151.6, 156.4, 161.4,171.2 (C). IR (KBr, cm-1): 	~  = 3432(m), 









871 (w), 759 (m). MS (EI, 70 eV): m/z (%) = 286 (M+, 40), 255 (2), 240 (100), 211 (15), 197 
(22), 169 (11), 152 (7), 141 (7), 115 (9), 77 (2). HRMS (EI): Calcd. for C17H18O4 : 
286.11996; found: 286.120041. 
 
Methyl 3-hydroxy-2'-methoxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (20b).  
Starting with 19a (0.529 g, 2.0 mmol), 5b  (0.604 g, 2.2 mmol) and  
TiCl4 (0.411 g, 2.2 mmol), 20b was isolated (0.117 g, 27%) as a 
yellow viscous oil. 1H NMR (250 MHz, CDCl3):  = 2.09 (s, 3 H, 
CH3), 2.18 (s, 3 H, CH3), 3.36 (s, 3 H, OCH3), 3.38 (s, 3 Hz, 3 H, 
OCH3), 6.60 (s, 1 H, Ar), 6.86 (dd, J = 8.2 Hz, J = 0.9 Hz, 1 H, Ar), 
6.99 (ddd, J = 8.1 Hz, J = 7.3 Hz, J = 0.9 Hz, 1 H, Ar), 7.19 (dd, J = 7.3 Hz, J = 1.8 Hz, 1 H, 
Ar), 7.31 (ddd, J = 8.2 Hz, J = 7.3 Hz, J = 1.8 Hz, 1 H, Ar), 11.07 (s, 1 H, OH). 13C NMR (62 
MHz, CDCl3):  = 20.5, 30.3 (CH3), 51.4, 55.4 (OCH3), 109.6, 120.4, 124.2 (CH), 125.5 (C) 
128.2, 129.3 (CH), 132.2, 137.0, 143.2, 147.6, 156.1, 158.9, 171.9 (C). IR (KBr, cm-1): 	~  = 
3000 (m), 2954 (m), 2951 (m), 2854 (m), 1657 (s), 1611 (m), 1439 (s), 1393 (s), 1269 (s), 
1242 (s), 1195 (m), 1025 (s), 918 (w), 807 (m), 761 (s), 637 (w), 578 (w). MS (EI, 70 eV): 
m/z (%) = 286 (M+, 35), 254 (64), 239 (100), 223 (40), 211 (22), 181 (27), 165 (16), 152 (16), 
131 (27), 115 (12), 77 (18). HRMS (EI): Calcd. for C17H18O4 : 286.11996; found: 
286.119424. 
 
Methyl 4-ethyl-3-hydroxy-2'-methoxy-5-methyl[1,1'-biphenyl]-2-carboxylate (20c).  
Starting with 19a (0.582 g, 2.2 mmol), 5c (0.692 g, 2.4 mmol) and  
TiCl4 (0.411 g, 2.2 mmol),  20c was isolated (0.226 g, 34%) as a 
colorless solid (mp = 123-125oC). 1H NMR (250 MHz, CDCl3):  = 
1.12 (t, J = 7.9 Hz, 3 H, CH3), 2.28 (s, 3 H, CH3), 2.68 (q, J = 5.8 
Hz, 2 H, CH2), 3.42 (s, 3 Hz, OCH3), 3.65 (s, 3 H, OCH3),  6.53 (s, 
1 H, Ar), 6.80 (dd, J = 8.5 Hz, J = 1.2 Hz, 1 H, Ar), 6.94 (ddd, J = 8.5 Hz, J = 7.6 Hz, J = 1.2 
Hz, 1 H, Ar), 7.14 (dd, J = 7.3 Hz, J = 1.5 Hz, 1 H, Ar), 7.24 (ddd, J = 8.4 Hz, J = 6.2 Hz, J = 
2.1 Hz, 1 H, Ar), 10.92 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 13.2 (CH3), 19.7 
(CH2), 19.8 (CH3), 51.6, 55.6 (OCH3), 109.7, 120.6 (CH), 123.5 (C), 124.7,  128.4, 129.5 
(CH), 130.0, 137.3, 142.6, 144.3, 156.3, 159.0, 172.1 (C). IR (Nujol, cm-1): 	~  = 3433 (w), 
2954 (m), 2927 (m), 2870 (w), 1659 (s), 1605 (m), 1438 (s), 1278 (s), 1239 (s), 1197 (m), 
1102 (m), 1026 (m), 812 (m), 756 (s), 639 (w), 575 (w). GC-MS (EI, 70 eV): m/z (%) = 300.2 









(12), 115 (7), 77 (5). HRMS (EI): Calcd. for C18H20O4 : 300.13561; found: 300.135117. 
 
Ethyl 4-hexyl-3-hydroxy-2'-methoxy-5-methyl[1,1'-biphenyl]-2-carboxylate (20d). 
 Starting with the 19a (0.582 g, 2.2 mmol), 5h (0.861 g, 2.4 
mmol), TiCl4 (0.448 g, 2.4 mmol), 20d was isolated (0.216 g, 
26%) as a yellow oil. 1H NMR (250 MHz, CDCl3):  = 0.69 (t, J 
= 7.0 Hz, 3 H, CH3), 0.83 (t, J = 6.4 Hz, 3 H, CH3), 1.17-1.28 
(m, 8 H, CH2), 2.24 (s, 3 H, CH3), 2.59 (t, J = 8.2 Hz, 2 H CH2), 
3.62 (s, 3 H, OCH3), 3.89 (q, J = 7.3 Hz, 2 H, OCH2CH3)  6.57 (s, 1 H, Ar), 6.84 (dd, J = 7.3 
Hz, J = 0.9 Hz, 1 H, Ar), 6.97 (ddd, J = 7.3 Hz, J = 6.4 Hz, J = 0.9 Hz, 1 H, Ar), 7.16 (dd, J = 
7.3 Hz, J = 1.8 Hz, 1 H, Ar), 7.29 (ddd, J = 7.3 Hz, J = 6.4 Hz, J = 1.8 Hz, 1 H, Ar), 10.08 (s, 
1 H, OH). 13C NMR (62 MHz, CDCl3):  = 12.9, 14.0, 19.7 (CH3), 22.6, 26.3, 29.6, 31.2, 31.8 
(CH2), 55.3 (OCH3), 60.5 (OCH2CH3), 109.6 (CH), 110.4 (C), 120.3, 124.3 (CH), 127.9 (C), 
128.7,  129.3 (CH), 132.5, 137.2, 142.4, 156.2, 159.1, 171.5 (C). IR (Nujol, cm-1): 	~  = 2955 
(m), 2926 (s), 2856 (m), 1656 (s), 1610 (m), 1462 (m), 1389 (m), 1270 (s), 1244 (m), 1180 
(m), 1109 (m), 1029 (m), 750 (m). GC-MS (EI, 70 eV): m/z (%) = 370 (M+, 64), 324 (45), 309 
(68), 307 (35), 254 (60), 253 (54), 239 (100),  223 (43), 181 (15), 115 (4), 77 (2). HRMS (EI): 
Calcd. for C23H30O4 : 370.21386; found: 370.213501. 
 
Ethyl 3-hydroxy-2'-methoxy-5-methyl-4-octyl[1,1'-biphenyl]-2-carboxylate (20e). 
Starting with 19a (0.582 g, 2.2 mmol), 5i (0.928 g, 2.4 mmol), 
and TiCl4 (0.455 g, 2.4 mmol), 20e was isolated (0.457 g, 52%) 
as a yellow oil. 1H NMR (250 MHz, CDCl3):  = 0.74 (t, J = 7.3 
Hz, 3 H, CH3), 0.86 (t(br), J = 7.5 Hz, 3 H, CH3), 1.23-1.37 (m, 
12 H, CH2), 2.30 (s, 3 H, CH3), 2.64 (t, J = 7.6 Hz, 2 H, CH3), 
3.67 (s, 3 H, OCH3), 3.94 (q, J = 6.7 Hz, 2 H, OCH2CH3),  6.58 
(s, 1 H, Ar), 6.85 (dd, J = 7.9 Hz, J = 1.2 Hz, 1 H, Ar), 6.98 (ddd, J = 7.3 Hz, J = 6.9 Hz, J = 
0.9 Hz, 1 H, Ar), 7.17 (dd, J = 7.3 Hz, J = 1.8 Hz 1 H, Ar), 7.29 (ddd, J = 8.2 Hz, J = 7.7 Hz, 
J = 1.8 Hz, 1 H, Ar), 10.99 (s, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 12.9, 14.1, 19.8 
(CH3), 22.6, 26.9, 28.8, 29.3, 29.5, 30.1, 31.9 (CH2), 55.3 (OCH3), 60.5 (OCH2CH3), 109.6 
(CH), 110.4 (C), 120.2, 124.2 (CH), 127.9 (C), 128.7, 129.3 (CH), 132.5, 137.2, 142.4, 156.2, 
159.1, 171.5 (C). IR (KBr, cm-1): 	~  = 2954 (s), 2926 (s), 2855 (w), 1657 (m), 1610 (m), 1490 
(m), 1490 (w), 1389 (m), 1373 (m), 1274 (s), 1243 (m), 1180 (s), 1109 (m), 1036 (m), 750 










(61), 253 (58), 239 (100), 223 (42), 211 (9), 181 (14), 115 (3), 77 (2), 43 (7). HRMS (EI): 
Calcd. for C25H34O4 : 398.24516; found: 398.24515. 
 
Methyl 3-hydroxy-2'-methoxy-5-propyl[1,1'-biphenyl]-2-carboxylate (20f).  
Starting with 19b (0.585 g, 2.0 mmol), 5a  (0.568 g, 2.2 mmol) and 
TiCl4 (0.414 g, 2.2 mmol),  20f  was isolated (0.134 g, 22%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3):  = 0.82 (t, J = 7.3 Hz, 3 
H, CH3), 1.53 (m, 2 H, CH2), 2.43 (t, J = 7.4 Hz, 2 H, CH2), 3.34 
(s, 3 H, OCH3), 3.56 (s, 3 H, OCH3), 6.46-6.47 (m, 1 H, Ar), 6.68 
(m, 1 H, Ar), 6.72 (dd, J = 8.1 Hz, J = 0.4 Hz, 1 H, Ar), 6.85 (ddd, J = 8.5 Hz, J = 7.4 Hz, J = 
0.9 Hz, 1 H, Ar), 7.05 (dd, J = 7.4 Hz, J = 1.8 Hz, 1 H, Ar), 7.15 (ddd, J = 8.1 Hz, J = 8.1 Hz, 
J = 1.9 Hz, 1 H, Ar), 10.60 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 12.8 (CH3), 22.7, 
37.0 (CH2), 50.4, 54.4 (OCH3), 108.8 (CH), 109.8 (C), 115.3, 119.4, 122.5, 127.4, 128.4 
(CH), 132.9, 139.3, 148.5, 155.1, 160.0, 170.4 (C). IR (Nujol, cm-1): 	~  = 2961 (m), 2934 (m), 
2873 (w), 1665 (s), 1610 (s), 1570 (s), 1491 (m), 1437 (m), 1359 (w), 1269 (s), 1248 (s), 1025 
(m), 807 (w), 753 (m). GC-MS (EI, 70 eV): m/z (%) = 300 (M+, 42), 269 (23), 268 (100), 240 
(43), 197 (12), 152 (6), 115 (5), 91 (2), 77 (2). HRMS (EI): Calcd. for C18H20O4 : 300.13561; 
found: 300.13695. 
 
Methyl 3-hydroxy-2'-methoxy-4-methyl-5-propyl[1,1'-biphenyl]-2-carboxylate (20g). 
Starting with 19b (0.585 g, 2.0 mmol), 5b  (0.598 g, 2.2 mmol) and 
TiCl4 (0.414 g, 2.2 mmol), 20g was isolated (0.137 g, 21%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3):  = 0.90 (t, J = 7.4 Hz, 3 
H, CH3), 1.49-1.56 (m, 2 H, CH2), 2.20 (s, 3 H, CH3), 2.54 (t, J = 
7.5 Hz, 2 H, CH2), 3.40 (s, 3 H, OCH3), 3.62 (s, 3 H, OCH3), 6.52 
(s, 1 H, Ar), 6.77 (dd, J = 8.0 Hz, J = 0.9 Hz, 1 H, Ar), 6.91 (ddd, J 
= 7.4 Hz, J = 7.4 Hz, J = 0.9 Hz, 1 H, Ar), 7.11 (dd, J = 7.4 Hz, J = 1.7 Hz, 1 H, Ar), 7.20 
(ddd, J = 8.1 Hz, J = 7.4 Hz, J = 1.7 Hz, 1 H, Ar), 10.98 (s, 1 H, OH). 13C NMR (75 MHz, 
CDCl3):  = 10.2, 13.1 (CH3), 22.2, 35.0 (CH2), 50.4, 54.4 (OCH3), 108.7 (CH), 109.2 (C), 
119.4, 122.5 (CH), 122.6 (C),  127.2, 128.4 (CH), 131.4, 135.9, 146.3, 155.2, 158.2, 170.9 
(C). IR (Nujol, cm-1): 	~  = 2957 (s), 2929 (s), 2871 (m), 1663 (m), 1610 (m), 1584 (w), 1491 
(m), 1437 (m), 1267 (s), 1243 (s), 1169 (m), 1029 (m), 810 (m), 752 (m). GC-MS (EI, 70 eV): 
m/z (%) = 314 (M+, 59), 282 (100), 267 (52),  251 (28), 239 (61), 211 (11), 181 (14), 115 (6), 











Ethyl 4-ethyl-3-hydroxy-2'-methoxy-5-propyl[1,1'-biphenyl]-2-carboxylate (20h).  
Starting with 19b (0.585 g, 2.0 mmol), 5c (0.660 g, 2.0 mmol) and 
TiCl4 (0.414 g, 2.2 mmol), 20h was isolated (0.203 g, 29%) as a 
yellow oil. 1H NMR (300 MHz, CDCl3):  = 0.59 (t, J = 7.2 Hz, 3 
H, CH3), 0.81 (t, J = 7.4 Hz, 3 H, CH3), 1.02 (t, J = 7.4 Hz, 3 H, 
CH3), 1.40-1.48 (m, 2 H, CH2), 2.43 (t, J = 7.2 Hz, 2 H, CH2), 2.56 
(q, J = 7.4 Hz, 2 H, CH2), 3.51 (s, 3 H, OCH3), 3.79 (q, J = 7.0 Hz, 2 H, OCH2CH3), 6.40 (s, 1 
H, Ar), 6.64-6.66 (m, 1 H, Ar), 6.78 (ddd, J = 7.4 Hz, J = 7.2 Hz, J = 0.7 Hz, 1 H, Ar), 6.98 
(dd, J = 7.4 Hz, J = 1.7 Hz, 1 H, Ar), 7.09 (ddd, J = 8.0 Hz, J = 7.6 Hz, J = 1.7 Hz, 1 H, Ar), 
10.96 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 14.1, 15.0, 15.2  (CH3), 20.3, 25.2, 36.4 
(CH2), 56.4 (OCH3), 61.6 (OCH2CH3), 110.9 (CH), 111.5 (C), 121.4, 125.0, 129.1, 130.5 
(CH), 130.6, 133.8, 138.4, 147.6, 157.4, 160.4, 172.6  (C). IR (Nujol, cm-1): 	~  = 3057 (w), 
2961 (s), 2932 (s), 2872 (m), 2835 (w), 1657 (s), 1608 (m), 1560 (w), 1494 (w), 1463 (m),  
1395 (m), 1373 (m), 1278 (s), 1245 (s), 1178 (s), 1111 (m), 1029 (m), 788 (m), 751 (m). GC-
MS (EI, 70 eV): m/z (%) = 342 (M+, 58), 296 (100), 281 (71),  265 (46),  253 (80),  225 (8),  
197 (5), 181 (10), 165 (11), 115 (5), 91 (3), 77 (3). HRMS (EI): Calcd. for C21H26O4 : 
342.18256; found: 342.18256. 
 
Ethyl 4-hexyl-3-hydroxy-2'-methoxy-5-propyl[1,1'-biphenyl]-2-carboxylate (20i).  
Starting with 19b (0.292 g, 1.0 mmol), 5h (0.400 g, 1.1 mmol) 
and TiCl4 (0.209 g, 1.1 mmol), 20i was isolated (0.123 g, 32%) 
by column chromatography (silica gel, n-hexane/EtOAc = 40:1  
20:1) as a colorless oil. 1H NMR (300 MHz, CDCl3):  = 0.68 (t, 
J = 7.0 Hz, 3 H, CH3), 0.82 (t(br), J = 7.2 Hz, 3 H, CH3), 0.89 (t, 
J = 7.2 Hz, 3 H, CH3), 1.25-1.52 (m, 10 H, CH2), 2.51 (t, J = 8.3 Hz, 2 H, CH2), 2.58 (t, J = 
7.0 Hz, 2 H, CH2), 3.60 (s, 3 H, CH3), 3.87 (q, J = 7.0 Hz, 2 H, OCH2CH3), 6.49 (s, 1 H, Ar), 
6.74 (dd, J = 8.1 Hz, J = 0.9 Hz, 1 H, Ar), 6.88 (ddd, J = 7.4 Hz, J = 7.4 Hz, J = 0.9 Hz, 1 H, 
Ar), 7.08 (dd, J = 7.4 Hz, J = 1.7 Hz, 1 H, Ar), 7.20 (ddd, J = 8.1 Hz, J = 8.0 Hz, J = 1.9 Hz, 1 
H, Ar), 11.04 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.4, 14.5, 14.6  (CH3), 23.1, 
24.4, 26.5, 29.7, 30.0, 32.0, 35.7 (CH2), 55.7 (OCH2CH3), 60.9 (OCH3), 110.2 (CH), 110.7 
(C), 120.7, 123.9, 128.4 (CH),  128.7 (C), 129.9 (CH), 133.1, 137.6, 147.6, 156.7, 159.7, 
171.9  (C). ). IR (Nujol, cm-1): 	~  = 2957 (s), 2929 (s), 2870 (m), 1658 (s), 1609 (m), 1560 












817 (w), 751 (s).  GC-MS (EI, 70 eV): m/z (%) = 398 (M+, 45), 352 (27), 335 (13),  309 (100), 
266 (24),  238 (2). HRMS (EI): Calcd. for C25H34O4 : 398.24440; found: 398.24516. 
 
General procedure for synthesis of benzo[c]chromen-6-ones 21 and 27: To a CH2Cl2 
solution of 20 was added BBr3 at 0 °C. The solution was allowed to warm to 20 °C during 18 
h. To the solution was added an aqueous solution of KOtBu (0.1 M) and the solution was stirred 
for 15 min. The organic and the aqueous layer were separated and the latter was extracted with 
CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and the filtrate was 
concentrated in vacuo. The product 21 was purified by chromatography (silica gel; n-hexane/ 
EtOAc = 20:1) as a colourless solid. 
 
7-Hydroxy-9-methyl-6H-benzo[c]chromen-6-one (21a).  
Starting with 20a (0.278 g, 0.971 mmol) in CH2Cl2 (15 mL), BBr3 
(0.973 g, 3.89 mmol) and KOtBu (20 mL, 0.1 M aqueous solution), 21a 
was isolated as a colourless solid (0.219 g, 92%), mp. = 150-151 °C. 1H 
NMR (250 MHz, CDCl3):  = 2.42 (s, 3 H, CH3), 6.77-6.78 (m, 1 H, 
Ar), 7.15 (s, 1 H, Ar), 7.21 (dd, J = 7.0 Hz, J = 1.5 Hz, 1 H, Ar), 7.25-
7.27 (m, 1H,Ar), 7.37 (ddd, J = 8.3 Hz, J = 7.0 Hz, J = 1.5 Hz, 1 H, Ar), 7.90 (dd, J = 7.9 Hz, 
J = 1.2 Hz, 1 H, Ar), 11.20 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 23.0 (CH3), 104.3 
(C), 113.5, 117.4, 118.1 (CH), 118.7 (C) 123.7, 125.4, 130.9 (CH), 135.3, 149.4, 151.1, 162.8, 
165.8 (C). IR (KBr, cm-1): 	~  = 3438 (m), 3068 (m), 2923 (w), 1680 (s), 1627 (s), 1568 (s), 
1512 (w), 1456 (m), 1421 (m), 1276 (s), 1235 (s), 1208 (s), 1148 (m), 1078 (s), 842 (m), 750 
(s), 511 (m). GC-MS (EI, 70 eV): m/z (%) = 226 (M+, 100), 197 (20), 169 (8), 141 (8), 115 
(11), 77 (3). HRMS (EI): Calcd. for C14H10O3 : 226.06245; found 226.061951. 
 
7-Hydroxy-8,9-dimethyl-6H-benzo[c]chromen-6-one (21b).  
Starting with 20b (0.100 g, 0.349 mmol) in CH2Cl2 (10 mL), BBr3 
(0.349 g, 1.39 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 21b 
was isolated as a colourless solid (0.058 g, 69%), mp. = 164-166 °C. 1H 
NMR (250 MHz, CDCl3):  = 2.20 (s, 3 H, CH3), 2.39 (s, 3 H, CH3), 
7.18 (s, 1 H, Ar), 7.28 (dd, J = 7.6 Hz, J = 1.2 Hz, 1 H, Ar), 7.34-7.35 
(m, 1 H, Ar), 7.39 (ddd, J = 8.5 Hz, J = 6.8 Hz, J = 1.2 Hz, 1 H, Ar), 7.95 (dd, J = 7.9 Hz, J = 
1.5 Hz, 1 H, Ar), 11.55 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 10.3, 20.3 (CH3), 28.6 






130.5, 146.6, 149.3, 158.9, 164.6 (C). IR (KBr, cm-1): 	~  = 2955 (m), 2923 (s), 2852 (m), 
1670 (s), 1608 (m), 1560 (m), 1520 (m), 1457 (m), 1410 (m), 1361 (m), 1319 (m),  1280 (s), 
1235  (s), 1246 (m), 1175 (m), 1136 (s), 1094 (m), 903 (w), 800 (w), 759 (s), 546 (w). GC-
MS (EI, 70 eV): m/z (%) = 240 (M+, 100), 225 (39), 211 (5), 197 (6), 181 (3), 165 (8), 152 
(7), 139 (4), 115 (6), 76 (3). HRMS (EI): Calcd. for C15H12O3 : 240.07810; found 240.07779. 
 
8-Ethyl-7-hydroxy-9-methyl-6H-benzo[c]chromen-6-one (21c).  
Starting with 20c (0.100 g, 0.333 mmol) in CH2Cl2 (10 mL), BBr3 
(0.334 g, 1.33 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
21c was isolated as a colourless solid (0.052 g, 62%), mp. = 109-111 
°C. 1H NMR (250 MHz, CDCl3):  = 1.16 (t,  J =  7.6 Hz, 3 H, CH3), 
2.41 (s, 3 H, CH3), 2.70 (q, J =  7.3 Hz, 2 H, CH2), 7.20 (s, 1 H, Ar), 
7.22-7.24 (m, 1 H, Ar), 7.25-7.26 (m, 1 H, Ar), 7.36 (ddd, J = 7.6 Hz, J = 7.6 Hz,  J = 1.5 Hz, 
1 H, Ar), 7.89 (dd, J = 7.9 Hz, J = 1.2 Hz, 1 H, Ar), 11.50 (s, 1 H, OH). 13C NMR (62 MHz, 
CDCl3):  = 12.8 (CH3), 19.2 (CH2), 20.4 (CH3), 103.6 (C), 113.5, 117.4 (CH), 118.3 (C), 
122.7, 124.8, 129.7 (CH), 130.5, 131.6, 146.5, 150.3, 159.8, 165.6 (C). IR (KBr, cm-1): 	~  = 
3437 (m), 2967 (m), 1671 (s), 1622 (m), 1610 (m), 1560 (m), 1453 (m), 1404 (m), 1227 (s), 
1177 (m),  1135 (m), 1110 (m), 903 (w), 807 (m), 769 (s). GC-MS (EI, 70 eV): m/z (%) = 254 
(M+, 46), 240 (22), 239 (100), 152 (8), 115 (4), 76 (3). HRMS (EI): Calcd. for C16H14O3 : 
254.09375; found 254.09304. 
 
8-Hexyl-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (21d).  
Starting with 20d (0.100 g, 0.270 mmol) in CH2Cl2 (10 mL), 
BBr3 (0.271 g, 1.079 mmol) and KOtBu (10 mL, 0.1 M aqueous 
solution), 21d was isolated as a colourless solid (0.061 g, 65%), 
mp. = 88-90 °C. 1H NMR (250 MHz, CDCl3):  = 1.33 (t(br),  J =  
7.0 Hz, 3 H, CH3), 1.19-1.29 (m, 8 H, CH2), 2.86 (s, 3 H, CH3), 
3.12 (t, J =  7.0 Hz, 2 H, CH2), 7.19 (s, 1 H, Ar), 7.26 (ddd, J = 8.5 Hz, J = 8.2 Hz,  J = 0.9 
Hz, 1 H, Ar), 7.29-7.30 (m, 1 H, Ar), 7.38 (ddd, J = 7.3 Hz, J = 7.0 Hz,  J = 1.5 Hz, 1 H, 
Ar),7.94 (dd, J = 8.2 Hz, J = 1.2 Hz, 1 H, Ar), 11.52 (s, 1 H, OH). 13C NMR (75 MHz, 
CDCl3):  = 13.1, 19.8 (CH3), 21.1, 25.1, 27.7, 28.7, 30.7 (CH2), 102.7 (C), 112.6, 116.6 
(CH), 117.6 (C), 121.9, 123.9 (CH), 128.6 (C), 128.7 (CH), 130.8, 145.8, 149.5, 159.2, 164.8 
(C). IR (KBr, cm-1): 	~  = 3057 (w), 2955 (m), 2922 (s), 2853 (m), 1673 (s), 1624 (m), 1609 








(w), 906 (w), 804 (m), 769 (m), 751 (m), 621 (w). GC-MS (EI, 70 eV): m/z (%) = 310 (M+, 
22), 292 (2), 263 (5), 240 (34), 239 (100), 165 (5), 115 (2). HRMS (EI): Calcd. for C20H22O3 : 
310.15635; found 310.15649. 
 
7-Hydroxy-9-methyl-8-octyl-6H-benzo[c]chromen-6-one (21e).  
Starting with 20e (0.250 g, 0.627 mmol) in CH2Cl2 (20 mL), BBr3 
(0.651 g, 2.509 mmol) and KOtBu (20 mL, 0.1 M aqueous 
solution), 21e was isolated as a colourless solid (0.128 g, 60%), 
mp. = 87-89 °C. 1H NMR (300 MHz, CDCl3):  = 0.81 (t(br),  J =  
7.5 Hz, 3 H, CH3), 1.18-1.21 (m, 12 H, CH2), 2.37 (s, 3 H, CH3), 
2.63 (t, J =  7.0 Hz, 2 H, CH2), 7.19 (s, 1 H, Ar), 7.22-7.24 (m, 1 H, Ar), 7.25-7.26 (m, 1 H, 
Ar), 7.35 (ddd, J = 8.1 Hz, J = 7.0 Hz,  J = 1.8 Hz, 1 H, Ar), 7.89 (dd, J = 7.9 Hz, J = 1.2 Hz, 
1 H, Ar), 11.46 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.9, 20.6 (CH3), 22.5, 25.6, 
28.5, 29.2, 29.3, 29.8, 31.3 (CH2), 102.8 (C), 113.4, 117.5, 122.6, 124.7, 129.3  (CH), 129.6, 
131.5, 146.6, 147.4, 150.2, 159.9, 165.6 (C). IR (KBr, cm-1): 	~  =  2950 (m), 2919 (s), 2850 
(s), 1680 (s), 1625 (m), 1610 (m), 1556 (m), 1458 (m), 1405 (m), 1334 (m), 1273 (s), 1178 
(m), 1135 (s), 1121 (m), 1045 (w), 906 (w), 757 (s), 625 (w), 550 (w), 471 (w). GC-MS (EI, 
70 eV): m/z (%) = 338 (M+, 22), 253 (4), 240 (36), 239 (100), 207 (9), 152 (5), 115 (2), 77(1). 
HRMS (EI): Calcd. for C22H26O3: 338.18765; found 338.18719. 
 
7-Hydroxy-9-propyl-6H-benzo[c]chromen-6-one (21f).  
Starting with 20e (0.100 g, 0.333 mmol) in CH2Cl2 (8 mL), BBr3 
(0.336 g, 1.341 mmol) and KOtBu (20 mL, 0.1 M aqueous solution), 
21f was isolated as a colourless solid (0.065 g, 77%), mp. = 97-99 
°C. 1H NMR (300 MHz, CDCl3):  = 0.92 (t , J = 7.2 Hz, 3 H, CH3), 
1.63-1.70 (m, 2 H, CH2), 2.64 (t, J = 7.4 Hz, 2 H, CH2), 6.84-6.85 
(m, 1 H, Ar), 7.19 (s. 1 H, Ar), 7.27 (dd, J = 8.3 Hz, J = 0.7 Hz, 1 H, Ar), 7.32 (dd, J = 8.4 
Hz, J = 0.9 Hz, 1 H, Ar). 7.41 (ddd, J = 8.4 Hz, J = 6.8 Hz, J = 1.7 Hz, 1 H, Ar),  7.97 (dd, J = 
8.3 Hz, J = 1.7 Hz, 1 H, Ar), 11.22 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 14.1, 
(CH3), 24.3, 39.2 (CH2), 104.5 (C), 112.9, 116.8, 118.1 (CH), 118.8 (C), 123.6, 125.3, 130.8 
(CH), 135.3, 151.1, 154.0,  162.8, 165.7 (C). IR (KBr, cm-1): 	~  = 3436 (m), 3139 (w), 2962 
(m), 2931 (m), 2872 (w), 1678 (s), 1625 (s), 1565 (s), 1511 (w), 1424 (s), 1319 (m), 1226 (s), 
1104 (w), 1071 (s), 835 (w), 767 (s), 715 (m). GC-MS (EI, 70 eV): m/z (%) = 254 (M+, 65), 








76 (3). HRMS (EI): Calcd. for C16H14O3 : 254.09375; found 254.09365.  
 
7-Hydroxy-8-methyl-9-propyl-6H-benzo[c]chromen-6-one (21g).  
Starting with 20g (0.076 g, 0.241 mmol) in CH2Cl2 (7 mL), BBr3 
(0.242 g, 0.964 mmol) and KOtBu (20 mL, 0.1 M aqueous solution), 
21g was isolated as a colourless solid (0.047 g, 73%), mp. = 113-
115 °C. 1H NMR (300 MHz, CDCl3):  = 0.96 (t , J = 7.2 Hz, 3 H, 
CH3), 1.57-1.65 (m, 2 H, CH2), 2.22 (s, 3 H, CH3), 2.67 (t, J = 7.6 
Hz, 2 H, CH2), 7.19 (s, 1 H, Ar), 7.28 (dd, J = 8.3 Hz, J = 0.9 Hz, 1 H, Ar), 7.33 (m(br), 1 H, 
Ar), 7.38 (ddd, J = 8.7 Hz, J = 8.1 Hz, J = 1.5 Hz, 1 H, Ar), 7.96 (dd, J = 8.0 Hz, J = 1.7 Hz, 1 
H, Ar), 11.57 (s, 1 H, OH). 13C NMR (125 MHz, CDCl3):  = 11.1, 14.1 (CH3), 23.3, 36.7 
(CH2), 103.5 (C), 112.6, 117.6 (CH), 118.6 (C), 122.9 (CH), 124.2 (C), 124.9, 129.8 (CH), 
131.7, 150.4, 151.5, 160.4, 165.8 (C). IR (KBr, cm-1): 	~  = 3065 (m), 2965 (s), 2924 (s), 2853 
(s), 1668 (s), 1624 (w), 1607 (m), 1516 (w), 1427 (m), 1326 (w), 1271 (s), 1157 (m), 1146 
(m), 801 (m), 767 (s). GC-MS (EI, 70 eV): m/z (%) = 268 (M+, 100), 253 (48), 240 (74), 225 
(37), 181 (5), 152 (12), 115 (7), 89 (3)  76 (3). HRMS (EI): Calcd. for C17H16O3 : 268.10940; 
found 268.10923. 
 
8-Ethyl-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (21h).  
Starting with 20h (0.084 g, 0.246 mmol) in CH2Cl2 (7 mL), BBr3 
(0.246 g, 0.981 mmol) and KOtBu (20 mL, 0.1 M aqueous solution), 
21h was isolated as a colourless solid (0.049 g, 71%), mp. = 96-98 
°C. 1H NMR (300 MHz, CDCl3):  = 0.98 (t , J = 7.4 Hz, 3 H, CH3), 
1.12 (t, J = 7.4 Hz, 3 H, CH3),  1.59-1.67 (m, 2 H, CH2, 2.67 (q, J = 
8.0 Hz, 2 H, CH2), 2.72 (t, J = 7.6 Hz, 2 H, CH2),  7.18 (s, 1 H, Ar), 7.26 (dd, J = 8.0 Hz, J = 
0.7 Hz, 1 H, Ar), 7.32-7.34 (m, 1 H, Ar), 7.37 (ddd, J = 8.7 Hz, J = 7.0 Hz, J = 1.5 Hz, 1 H, 
Ar), 7.95 (dd, J = 7.9 Hz, J = 1.7 Hz, 1 H, Ar), 11.54 (s, 1 H, OH). 13C NMR (75 MHz, 
CDCl3):  = 12.7, 13.1 (CH3),18.0,  23.3, 34.9 (CH2), 102.6 (C), 111.7, 116.5 (CH), 117.6 
(C), 121.8, 123.8, 128.8 (CH), 129.3, 130.8, 149.4, 149.9, 159.4, 164.8 (C). IR (KBr, cm-1): 
	~  = 2963 (s), 2930 (m), 2870 (m), 1669 (s), 1621 (m), 1609 (m), 1557 (m), 1468 (m), 1404 
(m), 1332 (m), 1249 (s), 1139 (s), 1005 (w), 806 (w), 750 (s). GC-MS (EI, 70 eV): m/z (%) = 
282 (M+, 72), 267 (100), 254 (6), 239 (36), 226 (21), 208 (5), 181 (7), 165 (11), 115 (4), 89 










8-Hexyl-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (21i).  
Starting with 20i (0.067 g, 0.168 mmol) in CH2Cl2 (6 mL), BBr3 
(0168 g, 0.672 mmol) and KOtBu (20 mL, 0.1 M aqueous 
solution), 21i was isolated as a colourless solid (0.035 g, 62%), 
mp. = 78-80 °C. 1H NMR (300 MHz, CDCl3):  = 0.83 (t(br), J = 
7.6 Hz, 3 H, CH3), 0.98 (t, J = 7.2 Hz, 3 H, CH3), 1.18-1.26 (m, 
10 H, CH2), 1.61 (t, J = 7.6 Hz, 2 H, CH2), 2.66 (t, J = 7.6, 2 H, CH2), 7.18 (s, 1 H, Ar), 7.27 
(dd, J = 7.6 Hz, J = 0.9 Hz, 1 H, Ar), 7.32 (m, 1 H, Ar), 7.37 (ddd, J = 8.5 Hz, J = 7.0 Hz, J = 
1.5 Hz, 1 H, Ar), 7.95 (dd, J = 8.2 Hz, J = 1.5 Hz, 1 H, Ar), 11.54 (s, 1 H, OH). 13C NMR (75 
MHz, CDCl3):  = 13.0, 13.2 (CH3), 21.6, 23.2, 24.8, 28.4, 28.6, 30.6, 35.0 (CH2), 102.5 (C), 
111.7, 116.5 (CH), 117.6 (C), 121.8, 123.8 (CH), 128.2 (C), 128.8 (CH), 130.7, 149.4, 150.1, 
159.4, 164.8 (C). IR (Nujol, cm-1): 	~  = 2961 (s), 2924 (s), 2852 (m), 1683 (w), 1622 (w), 
1611 (w), 1462 (w), 1409 (w), 1268 (s), 1122 (s), 1021 (m), 864 (w), 803 (m), 789 (m), 670 
(w). GC-MS (EI, 70 eV): m/z (%) =338 (M+, 34), 320 (5), 295 (12), 281 (10), 267 (100), 239 
(28), 207 (9), 165 (18), 149 (13), 125 (18), 111 (30), 83 (50), 69 (60), 57 (80). HRMS (EI): 
Calcd. for C22H26O3 : 338.18765; found 338.18733. 
 
4-(2-Chlorophenyl)-4-hydroxy-3-buten-2-one (23d).  
Starting with LDA (75 mmol),  acetone 6a (2.904 g, 50.0 mmol) and 2-
chlorobenzoyl chloride 22d (10.501 g, 60.0 mmol) in THF (62.5 mL), 
23d (2.514 g, 25 %) was isolated as a yellowish oil. 1H NMR (300 
MHz, CDCl3):  = 2.09 (s, 3 H, CH3), 5.95 (s, 1 H, CH), 7.23 (m, 1 H, 
CHClph), 7.27 (m, 1 H, CHClph), 7.32 (m, 1 H, CHClph), 7.48 (m, 1 H, CHClph), 15.64 (s(br), 1 H, 
OH). 13C NMR (75 MHz, CDCl3):  = 25.8 (CH3), 102.2 (CH), 127.4, 130.3 (CHClph), 130.6 
(CClph), 131.1, 132.1 (CHClph), 135.9 (CClph), 185.0 (COH), 193.1 (COCH3). (IR (neat, cm-1): 
	~  = 2964 (w), 1762 (m), 1602 (s), 1434 (s), 1291 (m), 1099 (m), 1046 (s), 952 (m), 766 (s), 
535 (w). MS (EI, 70 eV): m/z (%) = 196 ([M]+, [37Cl] 1), 181 (10), 161 (100), 139 (26), 111 
(11), 85 (9), 75 (10), 69 (15), 43 (13). HRMS (EI): Calcd. for C10H9ClO2  ([M]+, 35Cl): 














 Starting THF(62.5 mL), LDA (65.5 mmol), acetone 6a (2.904 g, 50.0 
mmol) and 1-naphthoyl chloride 22g (11.400 g, 60.0 mmol), 23g 
(4.563 g, 43 %) was isolated as a yellow viscous oil.1H NMR (300 
MHz, CDCl3):  = 2.23 (s, 3 H, COCH3), 6.14 (s, 1 H, CH), 7.45-7.62 
(m, 4 H, CHNapth), 7.888.07 (m, 2 H, CHNapth), 8.488.52 (m, 1 H, 
CHNapth), 16.14 (s(br), 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 25.8 (COCH3), 97.4 (CH), 
125.1, 125.2, 126.7, 126.8, 127.7, 128.9 (CHNapth), 130.5 (CNapth), 132.4 ( CHNapth), 134.2, 
134.6 (CNapth),  189.6 (COH), 197.3 (COCH3). IR (neat, cm-1): 	
~  = 2927 (w), 1745 (s), 1715 
(s), 1590 (s), 1472 (m), 1435 (s), 1360 (m), 1292 (s), 1254 (m), 1119 (m), 1053 (m), 964 (w), 
845 (w), 765 (m), 742 (m), 606 (w). MS (EI, 70 eV): m/z (%) = 212 ([M]+, 99), 197 (56), 179 
(43), 169 (72), 155 (85), 141 (26), 127 (100), 115 (14), 101 (9), 85 (18), 77 (14), 69 (31), 63 
(9), 51 (6), 43 (27).  
 
1-Hydroxy-1-(2-naphthyl)-1-hexen-3-one (23h).  
Starting with THF (62.5 mL), LDA (65.5 mmol), 2-
Pentanone 6c (4.306 g, 50.0 mmol) and 2-naphthoyl 
chloride 22f (11.400 g, 60.0 mmol),  23h was isolated as a 
yellowish oil (7.449 g, 62 %). 1H NMR (300 MHz, 
CDCl3):  = 0.87 (t,  3J = 7.4 Hz, 3 H, CH2CH2CH3), 1.561.64 (m, 2 H, CH2CH2CH3 ), 2.28 
(t, 3J = 7.6 Hz, 2 H, CH2CH2CH3), 6.18 (s, 1 H, CH), 7.357.39 (m, 2 H, CHNapth), 7.667.70 
(m, 2 H, CHNapth), 7.73 (m, 1 H, CHNapth), 7.74 (m, 1 H, CHNapth), 8.27 (s, 1 H, CHNapth), 16.21 
(s(br), 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 12.4 (CH2CH2CH3), 18.1 (CH2CH2CH3) , 
40.0 (CH2CH2CH3), 95.3 (CH), 121.1, 125.5 ( CHNapth), 126.5, 126.8 (CNapth), 126.9, 127.2, 
128.1 (CHNapth), 131.1 (CNapth), 131.6, 134.0 (CHNapth), 182.1 (COH), 195.5 
(COCH2CH2CH3). ( IR (KBr, cm-1): 	
~  = 2960 (m), 2873 (w), 1631 (s), 1465 (m), 1386 (m), 
1278 (w), 1152 (w), 953 (w), 781 (s), 746 (w). MS (EI, 70 eV): m/z (%) = 240 ([M]+, 82), 211 
(22), 197 (100), 170 (19), 155 (95), 127 (67), 101 (5), 77 (9), 69 (77), 43 (10). HRMS (EI): 
Calcd. for C16H16O2: 240.11448; found: 240.11470. 
 
General procedure for the synthesis of fluorinated 1,3-dicarbonyl compounds 24.  
A stirred solution of 23 (16 mmol) and selectfluor (16 mmol) in acetonitrile (2 mL/1 mmol of 
23) was refluxed for 4 h. After cooling, the precipitate was filtered off, and the filtrate was 




extracted with CH2Cl2. The combined organic extracts were dried (Na2SO4) and filtered. The 
filtrate was concentrated in vacuo and the residue was purified by chromatography (silica gel, 
n-heptane/dichloromethane) to give the fluorinated 1,3-dicarbonyl compunds 24. 
 
2-Fluoro-1-(2-methoxyphenyl)-1,3-butanedione (24a).  
Starting with 23a (3.088 g, 16.1 mmol) and selectfluor (5.695 g, 16.1 
mmol) in acetonitrile (32 mL), 24a (2.500 g, 73%) was isolated as a 
colourless oil.  1H NMR (300 MHz, CDCl3):  = 2.21 (s, 3 H, CH3), 
3.75 (s, 3 H, OCH3), 6.06 (d, 2JH,F = 48.0 Hz, 1 H, CH), 6.86-6.89 (m, 2 
H, CHAn), 7.43 (m, 1 H, CHAn), 7.55 (m, 1 H, CHAn).13C NMR (75 MHz, CDCl3):  = 24.1 
(COCH3), 55.8 (OCH3An), 97.9 (d, 1J = 194.9 Hz, COCFCOCH3), 112.1, 121.5 (CHAn), 125.0 
(COCH3An), 131.7 (CHAn), 135.5 (d, 4J = 3.5 Hz, CHAn), 170.1 (d, 3J = 26.9 Hz, CAn), 193.4 
(d, 2J = 21.0 Hz, COCFCOCH3), 199.6 (d, 2J = 22.5 Hz, COCFCOCH3). 19F NMR (235 
MHz, CDCl3):  = 191.1 (CF). IR (KBr, cm-1): 	
~  = 2960 (m), 2874 (w), 1726 (s), 1600 (s), 
1489 (s), 1301 (s), 1254 (s), 1163 (m), 1081 (s), 962 (w), 757 (s). MS(EI, 70 eV): m/z (%) = 
210 ([M+], 50), 135 (100), 120 (2), 108 (2), 92 (11), 77 (22), 63 (4), 43 (8). HRMS (EI): 
Calcd. for C16H11FO3: 210.06867; found: 286.06820. 
 
2-Fluoro-1-(2-methoxyphenyl)-1,3-hexanedione (24b).  
Starting with 23b (0.881 g, 4.0 mmol) and selectfluor (1.417 g, 
4.0 mmol) in acetonitrile (8 mL), 24b (0.808 g, 90%) was 
isolated as a colourless oil. 1H NMR (300 MHz, CDCl3):  = 
0.88 (t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 1.551.63 (m, 2 H, 
CH2CH2CH3), 2.58 (t(br), 3J = 7.2 Hz, 2 H, CH2CH2CH3), 3.82 
(s, 3 H, OCH3), 5.93 (d, 2JH,F = 45.9 Hz, 1 H, CH), 6.96 (d, 3J = 8.5 Hz, 1 H, CHAn), 7.01 (d, 
3J = 7.6 Hz, 1 H, CHAn), 7.467.52 (m, 1 H, CHAn), 7.62-7.66 (m, 1 H, CHAn). 13C NMR (75 
MHz, CDCl3):  = 14.0 (COCH2CH2CH3), 16.6 (d, 4J = 1.2 Hz, COCH2CH2CH3), 40.9 
(COCH2CH2CH3), 55.9 (OCH3An), 97.8 (d, 1J = 194.9 Hz, COCFCOCH2CH2CH3), 112.1, 
121.4 (CHAn), 125.1 (COCH3An), 131.0, 135.4 (CHAn), 169.7 (d, 3J = 27.0 Hz, CAn), 193.4 (d, 
2J = 20.6 Hz, COCFCOCH2CH2CH3), 201.8 (d, 2J = 21.5 Hz, COCFCOCH2CH2CH3). 19F 
NMR (235 MHz, CDCl3):  = 192.8 (CF). IR (neat, cm-1): 	
~  = 2966 (s), 2877 (m), 1731 (s), 
1686 (s), 1599 (s), 1486 (s), 1438 (s), 1290 (s), 1248 (s), 1163 (s), 1019 (s), 971 (m), 759 (s), 
651 (m). MS (EI, 70 eV): m/z (%) = 238 (M+, 3), 207 (10), 168 (5), 135 (100), 92 (8) 77 (16), 








2-Fluoro-1-(2-methylphenyl)-1,3-butanedione (24c).  
Starting with 23c (2.0618 g, 12.6 mmol) and selectfluor (4.4 g, 12.6 
mmol) in acetonitrile (25 mL), 24c (1.123 g, 46%) was isolated as a 
colourless oil. 1H NMR (300 MHz, CDCl3):  = 2.23 (s(br), 3 H, CH3), 
2.42 (s, 3 H, CH3An), 5.75 (d, 2JH,F = 50.1 Hz, 1 H, CH), 7.21 (m, 1 H, 
CHTol), 7.33 (m, 1 H, CHTol), 7.35 (m, 1 H, CHTol), 7.60 (m, 1 H, CHTol)..13C NMR (75 MHz, 
CDCl3):  = 21.2 (COCH3), 28.6 (CH3Tol), 95.8 (d, 1J = 196.5 Hz, COCFCOCH3), 124.6 (CH 
Tol), 127.1 (CCH3 Tol), 131.2, 131.6 (CH Tol), 139.7 (d, 4J = 3.6 Hz, CH Tol), 165.1 (C Tol), 172.0 
(d, 2J = 20.7 Hz, COCFCOCH3), 187.1 (d, 2J = 22.8 Hz, COCFCOCH3).  19F NMR (235 
MHz, CDCl3):  = 187.1 (CF). IR (KBr, cm-1): 	
~  = 3065 (w), 2929 (m), 1713 (s), 1692 (s), 
1602 (m), 1571 (m), 1457 (m), 1296 (s), 1101 (m), 958 (w), 765 (m). MS (EI, 70 eV): m/z (%) 
= 194 ([M+], 5), 179 (39), 159 (5), 131 (12), 119 (100), 103 (6), 91 (66), 77 (5), 65 (17), 51 
(5), 43 (19), 39 (6). HRMS (EI): Calcd. for C11H11FO2 : 194.07376; found: 194.07356. 
 
1-(2-Chlorophenyl)-2-fluoro-1,3-butanedione (24d).  
Starting with 23d (0.393 g, 2.0 mmol) and selectfluor (0.708 g, 2.0 
mmol) in acetonitrile (4 mL), 24d (0.180 g, 42%) was isolated as a 
colourless oil. 1H NMR (300 MHz, CDCl3):  = 2.23 (s, 3 H, CH3), 
5.79 (d, 2JH,F = 49.3 Hz, 1 H, CH), 7.29 (m, 1 H, CHClPh), 7.31 (m, 1 H, 
CHClPh), 7.39 (m, 1 H, CHClPh), 7.55 (m, 1 H, CHClPh). 13C NMR (75 MHz, CDCl3):  = 25.0 
(COCH3), 96.0 (d, 1J = 198.9 Hz, COCFCOCH3), 123.1, 124.5 (CHClPh), 125.7 (CClClPh), 
127.7, 133.6 (CHClPh), 168.7 (d, 3J = 24.6 Hz, CClPh), 191.8 (d, 2J = 20.3 Hz, COCFCOCH3), 
199.1 (d, 2J = 22.7 Hz, COCFCOCH3).19F NMR (235 MHz, CDCl3):  = 190.2 (CF). IR 
(neat, cm-1): 	~  = 3420 (w), 2925 (w), 1735 (s), 1683 (s), 1509 (s), 1358 (m), 1286 (s), 1122 
(m), 1063 (m), 970 (w), 780 (s).  
 
1-(4-Chlorophenyl)-2-fluoro-1,3-butanedione (24e).  
Starting with 23e (3.933 g, 20.0 mmol) and selectfluor (7.085 g, 
20.0 mmol) in acetonitrile (40 mL), 24e (2.5 g, 58%) was isolated 
as a colourless oil. 1H NMR (300 MHz, CDCl3):  = 2.27 (s, 3 H, 
CH3), 5.90 (d, 2JH,F = 49.9 Hz, 1 H, CH), 7.36 (m, 2 H, CHClPh), 
7.79 (m, 2 H, CHClPh). IR (KBr, cm-1): 	
~  = 3106 (w), 1924 (w)1740 (m), 1689 (s), 1590 (s), 
1488 (m), 1360 (s), 1179 (s), 1093 (s), 836 (s), 729 (m). MS (EI, 70 eV): m/z (%) = 216 










([M]+, [35Cl], 100), 113 ([M]+, [37Cl], 14), 111 ([M]+, [35Cl], 41), 87 (6), 75 (20), 50 (6), 43 
(23). HRMS (EI): Calcd. for C10H8ClFO2 ([M]+,35Cl): 214.01914; found: 214.01846. 
 
2-Fluoro-1-(4-fluorophenyl)-1,3-butanedione (24f).  
Starting with 23f (0.360 g, 2.0 mmol) and selectfluor (0.708 g, 2.0 
mmol) in acetonitrile (4 mL), 24f (0.185 g, 46%) was isolated as a 
colourless oil. 1H NMR (300 MHz, CDCl3):  = 2.25 (s, 3 H, CH3), 
5.90 (d, 2JH,F = 50.1 Hz, 1 H, CH), 7.07 (m, 2 H, CHFPh), 7.967.98 
(m, 2 H, CHFPh)..13C NMR (75 MHz, CDCl3):  = 24.7 (COCH3), 96.6 (d, 1J = 198.0 Hz, 
COCFCOCH3), 115.1 (d, 3J = 22.2 Hz, 2CHFPh), 128.9 (d, 3J = 4.4 Hz, CFPh), 131.6 (d, 4J = 
3.3 Hz, 2CHFPh), 165. 5 (d, 1J = 256.2 Hz, CFFPh), 187.7 (d, 2J = 19.2 Hz, COCFCOCH3), 
199.4 (d, 2J = 23.6 Hz, COCFCOCH3). IR (neat, cm-1): 	
~  = 3079 (m), 2929 (m), 1738 (s), 
1693 (s), 1599 (s), 1507 (s), 1414 (s), 1360 (s), 1240 (s), 1160 (s), 1013 (m), 851 (s), 610 (m). 
MS (EI, 70 eV): m/z (%) = 198 ([M+], 12), 183 (4), 123 (100), 107 (3), 95 (42), 75 (15), 43 
(17). HRMS (EI): Calcd. for C10H8F2O2: 198.04869; found: 198.139023. 
 
2-Fluoro-1-(1-naphthyl)-1,3-butanedione (24g).  
Starting with 23g (0.480 g, 2.0 mmol) and selectfluor (0.708 g, 2.0 
mmol) in acetonitrile (4 mL), 24g (0.193 g, 37%) was isolated as a 
colourless oil. 1H NMR (300 MHz, CDCl3):  = 2.20 (s, 3 H, CH3), 5.84 
(d, 2JH,F = 49.9 Hz, 1 H, CH), 7.377.39 (m, 4 H, CHNapth), 7.827.86 
(m, 2 H, CHNapth), 8.518.54 (m, 1 H, CHNapth). 13C NMR (75 MHz, 
CDCl3):  = 22.5 (COCH3), 97.5 (d, 1J = 200.4 Hz, COCFCOCH3), 127.1, 130.3, 130.5, 
130.9 (CHNapth), 131.8, 132.1 (CNapth), 132.2, 132.8, 133.4 (CHNapth), 167.7 (d, 3J = 26.8 Hz, 
CNapth), 188.8 (d, 2J = 28.4 Hz, COCFCOCH3), 199.5 (d, 2J = 23.1 Hz, COCFCOCH3). 19F 
NMR (235 MHz, CDCl3):  = 185.6 (CF). IR (neat, cm-1): 	
~  = 3400 (br(w)), 3072 (w), 
2927 (w), 1716 (s), 1590 (s), 1472 (m), 1435 (s), 1360 (m), 1291 (m), 1126 (m), 1053 (m), 
743 (s). MS (EI, 70 eV): m/z (%) = 230 ([M+], 25), 210 (5), 195 (5), 167 (12), 155 (100), 139 












2-Fluoro-1-(2-naphthyl)-1,3-hexanedione (24h).  
Starting with 23h (0.480 g, 2.0 mmol) and selectfluor 
(0.708 g, 2.0 mmol) in acetonitrile (4 mL), 24h (0.331 g, 
64%) was isolated as a colourless oil. 1H NMR (300 MHz, 
CDCl3):  = 0.80 (t, 3J = 7.6 Hz, 3 H, CH2CH2CH3), 
1.491.57 (m, 2 H, CH2CH2CH3), 2.58 (t(br), 3J = 8.0 Hz, 2 H, CH2CH2CH3), 5.84 (d, 2JH,F = 
48.4 Hz, 1 H, CH), 7.78-7.81 (m, 4 H, CHNapth), 8.41 (m, 1 H, CHNapth), 8.49 (m, 2 H, 
CHNapth).13C NMR (75 MHz, CDCl3):  = 13.8 (COCH2CH2CH3), 16.6 (d, 4J = 1.6 Hz, 
COCH2CH2CH3), 40.5 (COCH2CH2CH3), 97.1 (d, 1J = 197.7 Hz, COCFCOCH2CH2CH3), 
124.5 (d, 4J = 197.7 Hz, CHNapth), 127.4 , 128.2, 129.1, 129.8, 130.4 (CHNapth), 132.6 (CNapth), 
133.0 (CHNapth), 136.5 (CNapth), 165.7 (d, 3J = 19.7 Hz, CNapth), 190.6 (d, 2J = 18.9 Hz, 
COCFCOCH2CH2CH3), 203.2 (d, 2J = 22.6 Hz, COCFCOCH2CH2CH3). 19F NMR (235 MHz, 
CDCl3):  = 190.7 (CF). IR (KBr, cm-1): 	
~  = 3060 (w), 2965 (m), 2876 (w), 1732 (m), 1686 
(s), 1629 (s), 1596 (m), 1467 (m), 1281 (m), 1126 (m), 1098 (m), 864 (w), 755 (m). MS (EI, 
70 eV): m/z (%) = 258 ([M+], 27), 229 (12), 215 (5), 188 (19), 155 (100), 127 (54), 101 (3), 
71 (10), 43 (15), HRMS (EI): Calcd. for C16H15FO2: 258.10506; found: 258.10470. 
 
3-Fluoro-4-(2-methoxyphenyl)-4-(silyloxy)-3-buten-2-one (25a).  
Starting with benzene (30 mL), 24a (2.502 g, 11.9 mmol), triethylamine 
(1.926 g, 19.0 mmol) and trimethylchlorosilane (2.326 g, 21.4 mmol), 
25a was isolated as a yellowish oil (3.322 g, 99%). 1H NMR (300 MHz, 
CDCl3):  = 0.10-0.11 (m, 9 H, Si(CH3)3), 1.90 (s, 3 H, CH3), 3.73 (s, 3 
H, OCH3), 6.87 (m, 1 H, CHAn), 6.90 (m, 1 H, CHAn), 7.127.14 (m, 1 H, CHAn) 7.32 (m, 1 H, 
CHAn). 13C NMR (75 MHz, CDCl3):  = 0.1 (OSi(CH3)3), 25.8 (COCH3), 55.0 (COCH3An), 
110.6, 120.0 (CHAn), 123.4 (COCH3An), 130.3, 131.1 (CHAn), 143.3 (C), 145.8 (d, 1J = 240.4 
Hz, CF), 156.7 (CAn), 190. 3 (d, 2 J = 27.5 Hz, COCH3).   
 
2-Fluoro-1-(2-methoxyphenyl)-1-(silyloxy)-1-hexen-3-one (25b).  
Starting with benzene (39 mL), 24b (3.079 g, 12.9 mmol), 
triethylamine (2.090 g, 20.6 mmol) and trimethylchlorosilane 
(2.524 g, 23.2 mmol), 25b was isolated as a yellowish oil (3.163 
g, 79%). 1H NMR (300 MHz, CDCl3):  = 0.09 (m, 9 H, 
Si(CH3)3), 0.76 (t, 3J = 7.4 Hz, 3 H, CH2CH2CH3), 1.441.47 (m, 2 H, CH2CH2CH3), 2.30 










6.90 (d, 3J = 7.6 Hz, 1 H, CHAn), 7.11 (dd, 3J = 7.6 Hz, 4J = 1.7 Hz, 1 H, CHAn), 7.31 (dd, 3J = 
7.6 Hz, 4J = 0.9 Hz, 1 H, CHAn). 13C NMR (75 MHz, CDCl3):  = 0.1 (OSi(CH3)3), 13.1 
(COCH2CH2CH3), 16.6 (d, 4J = 1.2 Hz, COCH2CH2CH3), 40.7 (COCH2CH2CH3), 54.8 
(COCH3), 110.5, 119.8 (CHAn), 123.6 (COCH3An), 130.2, 130.7 (CHAn), 134.6 (C), 145.6 (d, 
1J = 243.2 Hz, CF), 156.6 (d, 3J = 9.9 Hz, CAn), 193.2 (d, 2J = 28.5 Hz, COCH2CH2CH3).  19F 
NMR (235 MHz, CDCl3):  = 145.9 (CF). 
 
2-Fluoro-3-methyl-1-(2-methylphenyl)-1,3-butadienyloxy(trimethyl)silane (25c).  
Starting with benzene (18 mL), 24c (1.123 g, 5.8 mmol), triethylamine 
(0.936 g, 9.2 mmol) and trimethylchlorosilane (1.131 g, 10.5 mmol), 
25c was isolated as a yellowish oil (1.001 g, 65%). 1H NMR (300 
MHz, CDCl3):  = 0.03 (m, 9 H, Si(CH3)3), 2.11 (s, 3 H, CH3Tol), 7.12 
(m, 2 H, CHTol), 7.18 (m, 2 H, CTol). 13C NMR (75 MHz, CDCl3):  = 0.1 (OSi(CH3)3), 18.5 
(COCH3), 27.1 (CH3Tol), 125.1, 127.6, 128.8, 129.8 (CHTol), 131.0 (CCH3Tol), 136.0 (d, 3 J = 
2.7 Hz, CTol), 143.5 (C), 145.6 (d, 1 J = 241.0 Hz, CFCOCH3), 189.2  (d, 2 J = 24.4 Hz, 
COCH3).   
 
4-(2-Chlorophenyl)-3-fluoro-4-(silyloxy)-3-buten-2-one (25d).  
Starting with benzene (26 mL), 24d (2.281 g, 10.6 mmol), triethylamine 
(1.719 g, 17.0 mmol) and trimethylchlorosilane (2.076 g, 19.1 mmol), 
25d was isolated as a yellowish oil (2.432 g, 80%). 1H NMR (300 MHz, 
CDCl3):  = 0.09 (m, 9 H, Si(CH3)3), 1.97 (s, 3 H, CH3), 7.38 (m, 1 H, 
CHClPh), 7.40 (m, 1 H, CHClPh), 7.50 (m, 1 H, CHClPh), 7.54 (m, 1 H, CHClPh). 13C NMR (75 
MHz, CDCl3):  = 0.1 (OSi(CH3)3), 27.6 (COCH3), 126.2, 129.1, 130.1, 131.8 (CHClPh), 
132.5, 133.4 (CClPh), 143.5 (d, 2J = 12.6 Hz, C), 145.2 (d, 1 J = 244.7 Hz, CFCOCH3), 190.1  
(d, 2 J = 29.7 Hz, COCH3).   
 
4-(4-Chlorophenyl)-3-fluoro-4-(silyloxy)-3-buten-2-one (25e).  
Starting with benzene (35 mL), 24e (2.511 g, 11.6 mmol), 
triethylamine (1.885 g, 18.6 mmol) and trimethylchlorosilane 
(2.277 g, 18.6 mmol), 25e was isolated as a yellowish oil (2.183 g, 
70%). 1H NMR (300 MHz, CDCl3):  = 0.13 (m, 9 H, Si(CH3)3), 
2.09 (s, 3 H, CH3), 7.19 (m, 2 H, CHClPh), 7.56 (m, 2 H, CHClPh). 13C NMR (75 MHz, CDCl3): 










(CClClPh), 144.7 (d, 1 J = 237.4 Hz, CFCOCH3), 149.9 (d, 3 J = 12.1 Hz, CClPh) 185.1  (d, 2 J = 
29.4 Hz, COCH3).  
 
3-Fluoro-4-(4-fluorophenyl)-4-(silyloxy)-3-buten-2-one (25f).  
Starting with benzene (26 mL), 24f (2.064 g, 10.4 mmol), 
triethylamine (1.684 g, 16.7 mmol) and trimethylchlorosilane 
(2.034 g, 18.7 mmol), 25f was isolated as a yellowish oil (2.306 g, 
82%). 1H NMR (300 MHz, CDCl3):  = 0.23 (m, 9 H, Si(CH3)3), 
2.20 (s, 3 H, CH3), 7.03 (m, 2 H, CHFPh), 7.76-7.78 (m, 2 H, CHFPh). 13C NMR (75 MHz, 
CDCl3):  = 0.4 (OSi(CH3)3), 19.0 (COCH3), 114.6 (d, 2 J = 21.5 Hz, 2CHFPh), 130.8 (d, 2 J = 
6.9 Hz, 2CHFPh), 144.8 (d, 1 J = 237.9 Hz, CFCOCH3), 146.4 (C), 149.7 (d, 3 J = 12.2 Hz, 
CFPh), 164.5 (d, 1 J = 252.5 Hz, CFFPh), 185.5  (d, 2 J = 29.1 Hz, COCFCOCH3). 19F NMR 
(235 MHz, CDCl3):  = 144.1 (CF).  
 
4-(1-Naphthyl)-4-[(trimethylsilyl)oxy]-3-buten-2-one (25g).  
Starting with benzene (24 mL), 24g (2.425 g, 9.4 mmol), triethylamine 
(1.520 g, 15.0 mmol) and trimethylchlorosilane (1.836 g, 16.9 mmol), 
25g was isolated as a yellowish oil (2.016 g, 71%). 1H NMR (300 MHz, 
CDCl3):  = 0.16 (m, 9 H, Si(CH3)3), 1.94 (s(br), 3 H, CH3), 7.56 (m, 4 
H, CHNapth), 7.92 (m, 3 H, CHNapth). 13C NMR (75 MHz, CDCl3):  = 
0.1 (OSi(CH3)3), 27.2 (COCH3), 124.1, 124.4, 125.6, 125.7 (CHNapth), 126.3 (d, 3J = 11.8 Hz, 
CNapth),  126.4 (CHNapth), 127.2, 127.8 (CNapth), 127.9, 129.7 (CHNapth), 144.3 (C), 145.9 (d, 1J 
= 242.6 Hz, CFCOCH3), 189.8 (d, 2J = 26.7 Hz, COCH3).  
 
2-Fluoro-1-(2-naphthyl)-1-(silyloxy)-1-hexen-3-one (25h).  
Starting with benzene (19 mL), 24h (1.9155 g, 7.4 mmol), 
triethylamine (1.200 g, 11.8 mmol) and 
trimethylchlorosilane (1.449 g, 13.3 mmol), 25h was 
isolated as a yellowish oil (1.813 g, 74%). 1H NMR (300 
MHz, CDCl3):  = 0.100.24 (m, 9 H, Si(CH3)3), 0.91 (t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 
1.541.62 (m, 2 H, CH2CH2CH3), 2.57 (t(br), 3J = 8.5 Hz, 2 H, CH2CH2CH3), 7.37 (m, 1 H, 
CHNapth), 7.39 (m, 1H, CHNapth), 7.697.78 (m, 4 H, CHNapth), 8.26 (m, 1H, CHNapth). 13C 
NMR (75 MHz, CDCl3):  = 0.1 (OSi(CH3)3), 13.1 (COCH2CH2CH3), 19.6 (d, 4J = 2.7 Hz, 









(CHNapth), 131.7, 134.4 (CNapth), 134.5 (C), 145.0 (d, 1J = 238.4 Hz, CFCOCH2CH2CH3), 
152.8 (d, 3J = 10.7 Hz, CNapth), 186.9 (d, 2J = 29.7 Hz, COCH2CH2CH3).  19F NMR (235 MHz, 
CDCl3):  = 142.9 (CF). 
 
Methyl 6-fluoro-3-hydroxy-2'-methoxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26a).   
Starting with 25a (0.847 g, 3.0 mmol), 5a (0.852 g, 3.3 mmol) and 
TiCl4 (0.620 g, 3.3 mmol),  26a was isolated  as a colorless solid 
(0.383 g, 44%), (mp = 105107 ºC). 1H NMR (300 MHz, CDCl3):  = 
2.22 (s(br), 3 H, CH3), 3.37 (s, 3 H, OCH3), 3.65 (s, 3 H, COOCH3), 
6.85 (d, 4JH,F = 8.1 Hz, 1 H, CHAr), 6.92 (dd, 3J = 7.4 Hz, 4J = 0.9 Hz, 
1 H, CHAn), 7.017.04 (m, 1H, CHAn), 7.197.23 (m, 1 H, CHAn), 
7.257.28 (m, 1 H, CHAn), 10.57 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3):  = 14.3 (d, 3J = 
3.6 Hz, CH3), 50.6 (OCH3An), 54.4 (COOCH3), 109.2 (d, 3J = 9.6 Hz, CHAr), 110.0 
(CCOOCH3Ar ), 117.8 (d, 4J = 4.2 Hz, CHAn), 119.0 (CHAn), 123.6 (COCH3An), 124.8 (d, 2J = 
19.5 Hz, CCFAr), 127.9, 129.2 (CHAn), 132.1 (d, 2J = 21.5 Hz, CCH3Ar), 150.6 (d, 1J = 233.0 
Hz, CFAr), 155.4 (CAn), 156.2 (d, 4J = 2.1 Hz, COHAr), 169.7 (d, 4J = 2.1 Hz, COOCH3). 19F 
NMR (235 MHz, CDCl3):  = 126.9 (CF). IR (KBr, cm-1): 	
~  = 3012 (w), 2844 (w), 1662 
(s), 1499 (m), 1459 (s), 1378 (s), 1239 (s), 1106 (m), 1074 (m), 1025 (m), 806 (m). MS (EI, 
70 eV): m/z (%) = 290 ([M+], 50), 258 (100), 241 (6), 229 (26), 187 (10), 159 (6), 133 (8). 
HRMS (EI): Calcd. for C16H15FO4 : 290.09489; found: 290.09473. 
 
Methyl 6-fluoro-3-hydroxy-2'-methoxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26b).  
Starting with 25a (0.847 g, 3.0 mmol), 5b (0.898 g, 3.3 mmol) and 
TiCl4 (0.620 g, 3.3 mmol),    26b was isolated  a colorless solid (0.494 
g, 54%), (mp = 98100 ºC). 1H NMR (300 MHz, CDCl3):  = 2.17 
(s(br), 6 H, CH3), 3.36 (s, 3 H, OCH3An), 3.64 (s, 3 H, COOCH3), 6.84 
(dd, 3J = 8.1 Hz, 4J = 0.9 Hz, 1 H, CHAn), 6.91 (dd, 3J = 7.4 Hz, 4J = 
1.1 Hz, 1 H, CHAn), 7.017.04 (m, 1H, CHAn), 7.23 (ddd, 3J = 8.1 Hz, 3J = 8.1 Hz, 4J = 1.8 
Hz, 1 H, CHAn), 10.91 (s, 1 H, OHAr) . 13C NMR (75 MHz, CDCl3):  = 10.7 (d, 4J = 2.3 Hz, 
CH3), 11.1 (d, 3J = 5.8 Hz, CCH3Ar), 50.6 (OCH3An), 54.6 (COOCH3), 108.6 (d, 3J = 2.9 Hz, 
CCOOCH3Ar), 109.1, 119.0 (CHAn), 121.6 (d, 2J = 20.4 Hz, CCFAr), 124.0 (COCH3An), 125.0 
(d, 3J = 3.4 Hz, CAn), 124.0 (CHAn), 129.4 (d, 4J = 1.7 Hz, CHAn), 130.4 (d, 2J = 19.8 Hz, 
FCCCH3Ar),  150.2 (d, 1J = 232.2 Hz, CFAr), 154.5 (d, 3J = 1.7 Hz, CCH3Ar), 155.5 (COHAr), 










cm-1): 	~  = 3016 (w), 2960 (m), 2841 (w), 1660 (s), 1621 (m), 1499 (m), 1437 (s), 1340 (s), 
1248 (s), 1228 (s), 1095 (s), 903 (m), 805 (s), 749 (s). MS (EI, 70 eV): m/z (%) = 304 (M+, 
39), 272 (71), 257 (100), 241 (60), 229 (22), 213 (9), 199 (10), 183 (14), 165 (12), 149 (40), 
112 (16), 97 (21), 83 (30), 69 (65), 57 (64). HRMS (EI): Calcd. for C17H17FO4: 304.11054; 




Starting with 25a (0.424 g, 1.5 mmol), 5a (0.357 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol),  26c was isolated as a colorless solid 
(0.220 g, 33%), (mp = 8183 ºC). 1H NMR (300 MHz, CDCl3):  = 
0.64 (t, 3J = 7.2 Hz, 3 H, CH2CH3), 1.09 (t, 3J = 7.4 Hz, 3 H, 
OCH2CH3 ), 2.19 (s(br), 3 H, CH3), 2.68 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.64 (s, 3 H, 
OCH3An), 3.86 (q, 3J = 7.2 Hz, 2 H, COOCH2CH3), 6.82 (d, 3J = 8.4 Hz, 1 H, CHAn), 
6.866.91 (m, 1 H, CHAn), 6.99 (d, 3J = 7.4 Hz, 1H, CHAn), 7.23 (ddd, 3J = 8.1 Hz, 3J = 7.4 
Hz, 4J = 1.7 Hz, 1 H, CHAn), 10.99 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3):  = 10.4 
(CH2CH3), 11.9 (COOCH2CH3), 12.0 (d, 3J = 11.2 Hz, CH3), 18.6 (d, 4J = 1.6 Hz, CH2CH3), 
54.5 (OCH3An), 59.7 (COOCH2CH3), 109.0 (d, 3J = 2.9 Hz, CCOOCH2CH3Ar), 109.3, 119.1 
(CHAn), 121.5 (d, 2J = 20.4 Hz, CCFAr), 124.0 (COCH3An), 127.5 (CHAn), 129.4 (d, 4J = 1.7 
Hz, CHAn), 129.6 (d, 2J = 19.2 Hz, CCH3Ar), 130.9 (d, 3J = 3.5 Hz, CAn), 150.4 (d, 1J = 232.1 
Hz, CFAr), 154.5 (d, 3J = 1.7 Hz, CCH2CH3Ar), 155.7(COHAr), 169.9 (d, 4J = 3.4 Hz, 
COOCH2CH3). 19F NMR (235 MHz, CDCl3):  = 125.5 (CF). IR (KBr, cm-1): 	
~  = 3420 
(w(br)), 3058 (w), 2970 (m), 2933 (m), 2873 (m), 1653 (s), 1615 (m), 1499 (m), 1466 (m), 
1398 (s), 1326 (s), 1276 (s), 1243 (s), 1225 (s), 1080 (m), 1029 (m), 752 (s). MS (EI, 70 eV): 
m/z (%) = 332 ([M+], 44), 286 (86), 271 (75), 255 (100), 228 (8), 213 (9), 199 (17), 183 (16), 
152 (9), 133 (6), 69 (12). HRMS (EI): Calcd. for C19H21FO4: 332.14184; found: 332.14174. 
Anal. calcd. for C19H21FO3:  C 68.66, H 6.36; found: C 68.83, 6.81. 
 
Methyl 6-fluoro-3-hydroxy-2'-methoxy-5-propyl[1,1'-biphenyl]-2-carboxylate (26d). 
Starting with 25b (0.621 g, 2.0 mmol), 5a (0.568 g, 2.2 mmol) and 
TiCl4 (0.414 g, 2.2 mmol), 26d was isolated as a colorless solid 
(0.229 g, 35%), (mp = 6770 ºC). 1H NMR (300 MHz, CDCl3):  = 
0.83 (t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 1.53 (m, 2 H, 












3 H, OCH3An), 3.58 (s, 3 H, COOCH3), 6.71 (d, 4JH,F = 6.4 Hz, 1 H, CHAr), 6.79 (dd, 3J = 8.1 
Hz, 4J = 0.7 Hz, 1 H, CHAn), 6.85 (ddd, 3J = 7.4 Hz, 3J = 7.4 Hz, 4J = 0.9 Hz, 1 H, CHAn), 6.97 
(m, 1H, CHAn), 7.18 (ddd, 3J = 8.1 Hz, 3J = 8.1 Hz, 4J = 1.7 Hz, 1 H, CHAn), 10.50 (s, 1 H, 
OH). 13C NMR (75 MHz, CDCl3):  = 12.7 (CH2CH2CH3), 21.6 (d, 4J = 1.1 Hz, 
CH2CH2CH3), 30.5 (d, 3J = 2.2 Hz, CH2CH2CH3), 50.6 (OCH3An), 54.5 (COOCH3), 109.3 
(CHAn), 109.8 (d, 3J = 2.3 Hz, CCOOCH2CH3Ar), 116.9 (d, 3J = 2.9 Hz, CHAr), 119.1 (CHAn), 
123.7 (COCH3An), 124.9 (d, 2J = 19.8 Hz, CCFAr), 127.8 (CHAn), 129.3 (d, 4J = 1.7 Hz, 
CHAn), 136.5 (d, 2J = 19.8 Hz, CCH2CH2CH3Ar), 150.4 (d, 1J = 233.8 Hz, CFAr), 155.5 
(COHAr), 156.3 (d, 3J = 2.9 Hz, CAn), 169.8 (d, 4J = 2.9 Hz, COOCH3). 19F NMR (235 MHz, 
CDCl3):  = 128.2 (CF). IR (KBr, cm-1): 	
~  = 3067 (w), 2959 (s), 2873 (m), 1669 (s), 1622 
(m), 1583 (w), 1499 (m), 1435 (s), 1332 (s), 1239 (s), 1110 (m), 1028 (m), 847 (m), 752 (s). 
GC-MS (EI, 70 eV): m/z (%) = 318 ([M+], 36), 286 (100), 258 (29), 243 (4), 229 (5), 215 (9), 




Starting with 25b (0.621 g, 2.0 mmol), 5b (0.598 g, 2.2 mmol) and 
TiCl4 (0.414 g, 2.2 mmol),  26e was isolated as a colorless solid 
(0.228 g, 34%) , (mp = 62-64 ºC). 1H NMR (300 MHz, CDCl3):  = 
0.84 (t, 3J = 7.4 Hz, 3 H, CH2CH2CH3), 1.44 (m, 2 H, 
CH2CH2CH3), 2.13 (s, 3 H, CH3), 2.54 (t(br), 3J = 7.6 Hz, 2 H, 
CH2CH2CH3), 3.30 (s, 3 H, OCH3An), 3.58 (s, 3 H, COOCH3), 6.78 (d, 4J = 7.6 Hz, 1 H, 
CHAn), 6.84 (ddd, 3J = 7.4 Hz, 3J = 7.4 Hz, 4J = 0.9 Hz, 1 H, CHAn), 6.98 (m, 1H, CHAn), 7.17 
(ddd, 3J = 8.1 Hz, 3J = 8.1 Hz, 4J = 1.7 Hz, 1 H, CHAn), 10.85 (s, 1 H, OHAr) . 13C NMR (75 
MHz, CDCl3):  = 13.5 (d, 4J = 2.3 Hz, CH3), 15.9 (CH2CH2CH3), 24.5 (CH2CH2CH3), 30.5 
(d, 3J = 3.6 Hz, CH2CH2CH3), 53.5 (OCH3An), 57.5 (COOCH3), 111.8 (d, 3J = 2.9 Hz, 
CCOOCH3), 112.2, 122.0 (CHAn), 124.6 (d, 2J = 21.0 Hz, CCFAr), 127.0 (COCH3An), 127.6 
(d, 3J = 4.0 Hz, CAn), 130.6 (CHAn), 132.4 (d, 4J = 1.7 Hz, CHAn), 137.8 (d, 2J = 19.2 Hz, 
CCH2CH2CH3Ar), 153.3 (d, 1J = 232.1 Hz, CFAr), 157.6 (COHAr), 158.1 (d, 3J = 2.3 Hz, 
CCH3Ar), 173.3 (d, 4J = 2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 127.1 (CF). 
IR (KBr, cm-1): 	~  = 3421 (m(br)), 3009 (w), 2956 (m),  1659 (s), 1616 (m), 1500 (w), 1411 
(s), 1338 (s), 1266 (s), 1220 (s), 1137 (m), 1025 (m),  750 (m). GC-MS (EI, 70 eV): m/z (%) = 
332 ([M+], 47), 300 (100), 285 (27), 269 (13), 257 (38), 241 (17), 199 (10), 133 (3). HRMS 








(26f).    
Starting with 25b (0.467 g, 1.5 mmol), 5c (0.499 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol 26f was isolated  as a colorless oil (0.286 g, 
55%). 1H NMR (300 MHz, CDCl3):  = 0.59 (t, 3J = 7.0 Hz, 3 H, 
CH2CH2CH3), 0.86 (t, 3J = 7.2 Hz, 3 H, CH2CH3), 1.07 (t, 3J = 7.4 
Hz, 3 H, OCH2CH3 ), 1.46 (m, 2 H, CH2CH2CH3), 2.53 (q, 3J = 7.8 
Hz, 2 H, CH2CH3),  2.62 (s(br), 3J = 7.6 Hz, 2 H, CH2CH2CH3), 3.58 (s, 3 H, OCH3An), 3.80 
(q, 3J = 7.0 Hz, 2 H, COOCH2CH3), 6.77 (dd, 3J = 8.1 Hz, 4J = 0.7 Hz, 1 H, CHAn), 6.83 (ddd, 
3J = 7.4 Hz, 3J = 7.4 Hz, 4J = 1.1 Hz, 1 H, CHAn), 6.96 (dd, 3J = 7.4 Hz, 4J = 1.1 Hz, 1 H, 
CHAn), 7.17 (ddd, 3J = 8.1 Hz, 3J = 8.1 Hz, 4J = 1.7 Hz, 1 H, CHAn), 10.91 (s, 1 H, OH) . 13C 
NMR (75 MHz, CDCl3):  = 14.8 (CH2CH3), 15.8 (CH2CH2CH3), 16.0 (COOCH2CH3), 21.5 
(d, 4J = 1.6 Hz, CH2CH3), 25.4 (d, 4J = 1.1 Hz, CH2CH2CH3), 30.2 (d, 3J = 3.3 Hz, 
CH2CH2CH3), 57.7 (OCH3An), 62.6 (COOCH2CH3), 112.1 (d, 3J = 2.9 Hz, CCOOCH2CH3Ar), 
112.3, 120.0 (CHAn), 124.8 (d, 2J = 20.9 Hz, CCFAr), 127.4 (COCH3An), 130.4 (CHAn), 132.4 
(d, 4J = 1.7 Hz, CHAn), 133.4 (d, 3J = 3.5 Hz, CAn), 137.1 (d, 3J = 18.6 Hz, CCH2CH2CH3Ar), 
153.4 (d, 1J = 232.7 Hz, CFAr), 157.7 (d, 3J = 1.7 Hz, CCH2CH3Ar ), 158.6 (COHAr), 172.8 (d, 
4J = 2.5 Hz, COOCH2CH3). 19F NMR (235 MHz, CDCl3):  = 126.8 (CF). IR (KBr, cm-1): 
	~  = 2958 (s), 2870 (m), 1655 (s), 1616 (m), 1503 (m), 1468 (m), 1415 (m), 1399 (m), 1246 
(s), 1233 (s), 1097 (m), 750 (s). GC-MS (EI, 70 eV): m/z (%) = 360 ([M+], 56), 314 (100), 299 
(50), 283 (67), 271 (31), 199 (8). HRMS (EI): Calcd. for C21H25FO4: 360.17314; found: 
360.17255.  
 
Methyl 6-fluoro-3-hydroxy-2',5-dimethyl[1,1'-biphenyl]-2-carboxylate (26g).  
Starting with 25c (0.360 g, 1.5 mmol), 5a (0.426 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol),  26g was isolated as a colorless viscous oil 
(0.180 g, 44%). 1H NMR (300 MHz, CDCl3):  = 2.07 (s(br), 3 H, 
CH3Tol), 2.30 (s(br), 3 H, CH3),  3.41 (s, 3 H, COOCH3), 6.84 (d, 4JH,F 
= 6.4 Hz, 1 H, CHAr), 6.97 (d, 3J = 7.4 Hz, 1 H, CHTol), 7.21 (m, 1 H, 
CHTol), 7.227.24 (m, 2 H, CHTol), 10.79 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 15.8 
(d, 3J = 3.6 Hz, CH3Tol), 20.1 (CH3), 50.3 (COOCH3), 110.3 (d, 3J = 2.7 Hz, CCOOCH3Ar), 
118.9 (d, 3J = 4.3 Hz, CHAr), 125.5, 127.8, 128.9 (CHTol), 129.4 (CCH3Tol), 129.6 (d, 4J = 3.5 
Hz, CHTol), 133.9 (d, 2J = 21.5 Hz, CCFAr), 136.0 (d, 2J = 13.9 Hz, CCH3Ar), 139.6 (CTol), 











COOCH3). 19F NMR (235 MHz, CDCl3):  = 126.8 (CFAr). IR (neat, cm-1): 	
~  = 2925 (m), 
2875 (w), 1669 (s), 1624 (w), 1437 (m), 1334 (m), 1240 (s), 1221 (s), 1077 (m), 846 (m), 755 
(m), 644 (w). GC-MS (EI, 70 eV): m/z (%) = 274 ([M+], 29), 242 (100), 214 (10), 199 (11), 
183 (6), 171 (16), 136 (3). HRMS (EI): Calcd. for C16H15FO3: 274.09997; found: 274.10009.  
 
Ethyl 4-ethyl-6-fluoro-3-hydroxy-2',5-dimethyl[1,1'-biphenyl]-2-carboxylate (26h). 
Starting with 25c (0.360 g, 1.5 mmol), 5c (0.495 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol) CH2Cl2 (3 mL),  26h was isolated  as a 
colorless viscous oil (0.185 g, 40%). 1H NMR (300 MHz, CDCl3):  = 
0.72 (t, 3J = 7.0 Hz, 3 H, CH2CH3), 1.23 (t, 3J = 7.4 Hz, 3 H, 
COOCH2CH3), 2.12 (s, 3 H, CH3Tol), 2.32 (s(br), 3 H, CH3Ar), 2.82 (q, 
3J = 7.4 Hz, 2 H, CH2CH3), 3.95 (q, 3J = 7.0 Hz, 2 H, COOCH2CH3), 7.03 (d, 3J = 7.4 Hz, 1 
H, CHTol), 7.177.23 (m, 1 H, CHTol), 7.267.28 (m, 2 H, CHTol), 11.29 (s, 1 H, OH) . 13C 
NMR (75 MHz, CDCl3):  = 11.8 (d, 3J = 6.1 Hz, CH3Tol), 13.2 (CH2CH3), 13.5 
(COOCH2CH3), 20.0 (d, 4J = 2.2 Hz, CH2CH3), 20.2 (CH3Tol), 61.3 (COOCH2CH3), 109.7 (d, 
3J = 2.9 Hz, CCOOCH2CH3Ar), 125.5 (CHTol), 126.3 (CCH3Tol), 126.6 (CTol), 127.6 (CHTol), 
129.1 (d, 4J = 1.1 Hz, CHTol), 129.5 (CHTol), 131.3 (d, 2J = 19.8 Hz, CCFAr), 132.3 (d, 3J = 3.5 
Hz, CCH2CH3Ar), 136.5 (d, 2J = 19.5 Hz, CCH3Ar), 151.6 (d, 1J = 231.0 Hz, CFAr), 156.5 (d, 4J 
= 1.7 Hz, COHAr), 171.1 (d, 4J = 3.2 Hz, COOCH2CH3). 19F NMR (235 MHz, CDCl3):  = 
125.5 (CFAr). IR (KBr, cm-1): 	
~  = 2926 (s), 2855 (w), 1661 (s), 1616 (w), 1456 (m), 1374 
(m), 1328 (m), 1272 (m), 1226 (s), 1214 (s), 1170 (w), 1038 (w), 759 (m), 734 (m), 450 (w). 
GC-MS (EI, 70 eV): m/z (%) = 316 ([M+], 39), 270 (43), 255 (100), 237 (11), 213 (4), 183 
(12), 165 (6). HRMS (EI): Calcd. for C19H21FO3: 316.14692; found: 316.14730.  
 
Methyl 2'-chloro-6-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26i). 
Starting with 25d (0.429 g, 1.5 mmol), 5a (0.426 g, 1.6 mmol), TiCl4 
(0.310 g, 1.6 mmol), 26i was isolated as a reddish oil (0.118 g, 26%). 
1H NMR (300 MHz, CDCl3):  = 2.22 (s(br), 3 H, CH3), 3.38 (s, 3 H, 
COOCH3), 6.81 (d, 4JH, F = 6.6 Hz, 1 H, CHAr), 7.067.08 (m, 1 H, 
CHClPh), 7.197.22 (m, 2 H, CHClPh),  7.347.37 (m, 1 H, CHClPh), 
10.82 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 14.4 (d, 3J = 3.9 Hz, CH3), 51.0 
(COOCH3), 108.7 (d, 3J = 1.7 Hz, CCOOCH3Ar), 118.7 (d, 3J = 3.4 Hz, CHAr), 125.2 (d, 2J = 
19.8 Hz, CCFAr), 127.7 (3CHPh), 129.4 (d, 4J = 1.1 Hz, CHPh), 132.1 (d, 3J = 1.1 Hz, CPh), 










= 2.3 Hz, COHAr), 169.3 (d, 4J = 2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 
126.4 (CF). IR (Nujol, cm-1): 	~  = 1674 (s), 1632 (w), 1376 (s), 1331 (s), 1215 (s), 1074 (m), 
858 (m), 760 (s). GC-MS (EI, 70 eV): m/z (%) = GC-MS (EI, 70 eV): m/z (%) = 296 ([M+], 
[37Cl], 3), 294 ([M+], [35Cl], 9), 259 (100), 234 (15), 199 (21),  170 (24), 151 (4), 129 (4), 85 
(9), 75 (4). HRMS (EI): Calcd. for C15H12ClFO3 ([M]+, 35Cl): 294.04535; found: 294.04604.  
 
Methyl 2'-chloro-6-fluoro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26j).  
Starting with 25d (0.429 g, 1.5 mmol), 5b (0.448 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol), 26j was isolated by column 
chromatography as a colorless solid (0.177 g, 38%), (mp = 76-78 ºC). 
1H NMR (300 MHz, CDCl3):  = 2.19 (s(br), 6 H, CH3), 3.38 (s, 3 H, 
COOCH3), 7.067.09 (m, 2 H, CHClPh), 7.187.21 (m, 2 H, CHClPh), 
11.19 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 12.3 (d, 4J = 2.9 Hz, CH3), 12.6 (d, 3J = 
5.2 Hz, CH3), 52.4 (COOCH3), 109.0 (d, 3J = 2.6 Hz, CCOOCH3Ar), 123.8 (d, 2J = 21.0 Hz, 
CCFAr), 126.5 (d, 4J = 1.1 Hz, CHClPh), 127.5 (d, 3J = 3.5 Hz, CCH3Ar), 128.9, 129.1, 131.0 
(CHClPh), 132.3 (d, 2J = 19.8 Hz, CCH3Ar), 133.7 (d, 3J = 1.1 Hz, CClPh), 135.7 (CClClPh), 151.5 
(d, 1J = 232.1 Hz, CFAr), 156.7 (d, 4J = 1.7 Hz, COHAr), 171.4 (d, 4J = 3.4 Hz, COOCH3). 19F 
NMR (235 MHz, CDCl3):  = 125.4 (CF). GC-MS (EI, 70 eV): m/z (%) = 310 ([M+], [37Cl], 
5), 308 ([M+], [35Cl], 15), 273 (38), 241 (100), 213 (7), 183 (15), 170 (9), 136 (5), 82 (3). 
HRMS (EI): Calcd. for C16H16ClFO3 ([M]+, 35Cl): 308.06100; found: 308.06159.  
 
Ethyl 2'-chloro-4-ethyl-6-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26k). 
Starting with 25d (0.405 g, 1.5 mmol), 5c (0.494 g, 1.6 mmol), TiCl4 
(0.310 g, 1.6 mmol), 26k was isolated as a reddish viscous oil (0.192 
g, 38%). 1H NMR (300 MHz, CDCl3):  = 0.49 (t, 3J = 7.2 Hz, 3 H, 
CH2CH3), 0.93 (t, 3J = 7.6 Hz, 3 H, COOCH2CH3), 2.20 (s(br), 3 H, 
CH3), 2.52 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.72 (q, 3J = 7.0 Hz, 2 H, 
COOCH2CH3), 6.906.93 (m, 1 H, CHClPh), 6.997.06 (m, 2 H, CHClPh), 7.167.19 (m, 1 H, 
CHClPh),  11.12 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3):  =  11.8 (d, 3J  5.8 Hz, CCH3), 
13.2 (CH2CH3), 13.4 (COOCH2CH3), 20.1 (d, 4J = 2.3 Hz, CH2CH3), 61.4 (COOCH2CH3Ar), 
109.4 (d, 3J = 2.3 Hz, CCOOCH2CH3Ar), 123.9 (d, 2J = 21.0 Hz, CCFAr), 126.4, 128.8, 129.1 
(CHClPh), 131.0 (d, 4J = 1.7 Hz, CHClPh), 131.6 (d, 2J = 19.2 Hz, CCH3Ar), 133.3 (d, 3J = 2.9 
Hz, CCH2CH3Ar), 133.9 (d, 3J = 1.1 Hz, CClPh), 136.1 (CClClPh), 151.6 (d, 1J = 232.7 Hz, 











MHz, CDCl3):  = 125.1 (CF). GC-MS (EI, 70 eV): m/z (%) = 338 ([M+], [37Cl], 4), 336 
([M+], [35Cl], 14), 301 (27), 292 ([37Cl], 5), 290 ([35Cl], 16), 275 ([37Cl], 4), 273 ([35Cl], 11), 
255 (100), 247 (4), 207 (4), 183 (15), 170 (4). HRMS (EI): Calcd. for C18H18ClFO3 ([M]+, 
35Cl): 336.09230; found: 336.09156. 
 
Methyl 4'-chloro-6-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26l).  
Starting with 25e (0.574 g, 2.0 mmol), 5a (0.568 g, 2.2 mmol) and 
TiCl4 (0.414 g, 2.2 mmol), 26l was isolated as a colorless solid 
(0.171 g, 30%). 1H NMR (300 MHz, CDCl3):  = 2.21 (s(br), 3 H, 
CH3), 3.39 (s, 3 H, COOCH3), 6.78 (d, 4JH,F = 6.4 Hz, 1 H, CHAr), 
7.037.06 (m, 2 H, CHClPh), 7.277.30 (m, 2 H, CHClPh), 11.59 (s, 
1 H, OH). 13C NMR (75 MHz, CDCl3):  = 14.5 (d, 3J = 3.7 Hz, CH3), 50.8 (COOCH3), 108.8 
(d, 3J = 1.7 Hz, CCOOCH3Ar), 118.3 (d, 3J = 3.5 Hz, CHAr), 126.8 (d, 4J = 1.1 Hz, 2 CHClPh), 
127.3 (d, 2J = 19.2 Hz, CCFAr), 129.2 (2CHClPh), 132.3 (d, 2J = 14.5 Hz, CCH3Ar), 132.6 
(CClPh), 133.1 (CClClPh), 150.5 (d, 1J = 234.3 Hz, CFAr), 156.6 (d, 4J = 1.8 Hz, COHAr), 169.5 
(d, 4J = 2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 127.4 (CF). GC-MS (EI, 70 
eV): m/z (%) = 296 ([M+], [37Cl], 11), 294 ([M+], [35Cl], 31), 264 ([37Cl], 32), 262 ([35Cl], 
100), 236 ([37Cl], 8), 234 ([35Cl], 24), 199 (11), 170 (24), 151 (3), 85 (9). HRMS (EI): Calcd. 
for C15H12ClFO3 ([M]+, 35Cl): 294.04535; found: 294.04581. 
 
Methyl 4'-chloro-6-fluoro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26m). 
Starting with 25e (0.574 g, 2.0 mmol), 5b (0.598 g, 2.2 mmol) and 
TiCl4 (0.414 g, 2.2 mmol),  26m was isolated as a yellowish solid 
(0.198 g, 32%), (mp = 8792 ºC). 1H NMR (300 MHz, CDCl3):  
= 2.14 (s(br), 6 H, CH3), 3.35 (s, 3 H, COOCH3), 6.997.02 (m, 2 
H, CHClPh), 7.227.25 (m, 2 H, CHClPh), 10.89 (s, 1 H, OH) . 13C 
NMR (75 MHz, CDCl3):  = 12.2 (d, 4J = 2.9 Hz, CH3), 12.5 (d, 3J = 5.8 Hz, CCH3Ar), 52.2 
(COOCH3), 109.2 (d, 3J = 2.9 Hz, CCOOCH3Ar), 125.4 (d, 2J = 19.8 Hz, CCFAr), 127.0 (d, 3J 
= 3.4 Hz, CCH3Ar), 128.2 (2CHClPh),  130.8 (2CHClPh), 132.1 (d, 2J = 19.8 Hz, CCH3Ar), 133.3 
(CClPh), 135.0 (CClClPh), 151.6 (d, 1J = 232.7 Hz, CFAr), 156.3 (d, 4J = 1.7 Hz, COHAr), 171.5 
(d, 4J = 2.9 Hz, COOCH3).   19F NMR (235 MHz, CDCl3):  = 126.4 (CF). GC-MS (EI, 70 
eV): m/z (%) = 310 ([M+], [37Cl], 10), 308 ([M+], [35Cl], 30), 278 ([37Cl], 19), 276 ([35Cl], 54), 
261 (7), 241 (100), 233 (6), 213 (8), 183 (15), 170 (12), 136 (5). HRMS (EI): Calcd. for 










35Cl): 308.06100; found: 308.06178. 
 
Ethyl 4'-chloro-4-ethyl-6-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26n). 
Starting with 25e (0.574 g, 2.0 mmol),5c (0.660 g, 2.2 mmol) 
and TiCl4 (0.414 g, 2.2 mmol), 26n was isolated as a yellowish 
solid (0.297 g, 44%), (mp = 7375 ºC). 1H NMR (300 MHz, 
CDCl3):  = 0.69 (t, 3J = 7.0 Hz, 3 H, CH2CH3), 1.09 (t, 3J = 7.4 
Hz, 3 H, COOCH2CH3), 2.20 (s(br), 3 H, CH3), 2.69 (q, 3J = 7.4 
Hz, 2 H, CH2CH3), 3.89 (q, 3J = 7.2 Hz, 2 H, COOCH2CH3), 7.037.07 (m, 2 H, CHClPh), 
7.257.30 (m, 2 H, CHClPh), 11.01 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 11.7 
(CH2CH3), 13.3 (d, 3J = 9.0 Hz, CH3), 14.3 (COOCH2CH3), 20.0 (d, 3J = 2.3 Hz, CH2CH3), 
61.5 (COOCH2CH3), 109.6 (d, 3J = 2.4 Hz, CCOOCH2CH3Ar), 125.7 (d, 2J = 20.4 Hz, 
CCFAr), 128.1 (2CHClPh), 130.0 (2CHClPh), 131.3 (d, 2J = 19.2 Hz, CCH3Ar), 133.0 (d, 3J = 2.9 
Hz, CCH2CH3Ar), 133.3 (CClPh), 135.3 (CClClPh), 151.7 (d, 1J = 232.7 Hz, CFAr), 156.3 (d, 4J = 
1.7 Hz, COHAr), 171.1 (d, 4J = 2.9 Hz, COOCH2CH3).  19F NMR (235 MHz, CDCl3):  = 
126.0 (CF). IR (KBr, cm-1): 	~  = 2973 (m), 2875 (w), 1660 (s), 1616 (w), 1797 (m), 1395 
(s), 1375 (s), 1331 (s), 1226 (s), 1106 (m), 1086 (s), 1017 (m), 823 (s), 810 (m), 514 (m). GC-
MS (EI, 70 eV): m/z (%) = 338 ([M+], [37Cl], 10), 336 ([M+], [35Cl], 29), 292 ([37Cl], 14), 290 
([35Cl], 40), 275 (12), 255 (100), 237 (8), 212 (3), 183 (17), 170 (4). HRMS (EI): Calcd. for 
C18H18ClFO3 ([M]+,35Cl): 336.09230; found: 336.09218.  
 
Methyl 4',6-difluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26o).  
Starting with 25f (0.405 g, 1.5 mmol), 5a (0.426 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol), 26o was isolated as a colorless viscous 
oil (0.135 g, 32%). 1H NMR (300 MHz, CDCl3):  = 2.20 (s(br), 3 
H, CH3), 3.38 (s, 3 H, COOCH3), 6.77 (d, 4JH,F = 6.4 Hz, 1 H, 
CHAr), 6.967.01 (m, 2 H, CHFPh), 7.047.09 (m, 2 H, CHFPh), 
10.57 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 14.3 (d, 3J = 3.9 Hz, CH3), 50.8 
(COOCH3), 109.0 (d, 3J = 1.7 Hz, CCOOCH3Ar), 113.6 (d, 2J = 21.9 Hz, 2CHFPh), 118.1 (d, 3J 
= 4.4 Hz, CHAr), 127.5 (d, 2J = 19.2 Hz, CCFAr), 129.4 (d, 4J = 1.7 Hz, CHFPh), 129.6 (d, 4J = 
1.1 Hz, CHFPh), 130.5 (d, 3J = 3.4 Hz, CFPh), 132.4 (d, 2J = 21.5 Hz, CCH3Ar), 150.7 (d, 1J = 
233.8 Hz, CFAr), 156.6 (d, 4J = 1.7 Hz, COHAr), 161.1 (d, 1J = 244.3 Hz, CFFPh), 169.6 (d, 4J 
= 2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 127.5 (CFAr), 115.5 (CFFPh). GC-











151 (3), 133 (2), 85 (4). HRMS (EI): Calcd. for C15H12F2O3: 278.07490; found: 278.07532.  
 
Methyl 4',6-difluoro-3-hydroxy-4,5-dimethyl[1,1'-biphenyl]-2-carboxylate (26p).  
Starting with 25f  (0.405 g, 1.5 mmol), 5b (0.448 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol),   26p was isolated  as a colorless viscous 
oil (0.177 g, 40%). 1H NMR (300 MHz, CDCl3):  = 2.11 (s(br), 6 
H, CH3), 3.32 (s, 3 H, COOCH3), 6.926.96 (m, 2 H, CHFPh), 
6.997.03 (m, 2 H, CHFPh), 10.86 (s, 1 H, OH). 13C NMR (75 MHz, 
CDCl3):  = 12.2 (d, 4J = 2.3 Hz, CH3), 12.5 (d, 3J = 5.7 Hz, CCH3), 52.1 (COOCH3), 109.5 
(d, 3J = 2.5 Hz, CCOOCH3Ar), 114.9 (d, 2J = 21.4 Hz, 2CHFPh), 125.7 (d, 2J = 20.4 Hz, 
CCFAr), 126.9 (d, 3J = 3.6 Hz, CFPh), 131.0 (d, 4J = 1.8 Hz, CHFPh), 131.1 (d, 4J = 1.2 Hz, 
CHFPh), 132.0 (d, 2J = 19.5 Hz, CCH3Ar), 132.4 (d, 3J = 3.5 Hz, CCH3Ar), 151.8 (d, 1J = 231.9 
Hz, CFAr), 155.8 (d, 4J = 1.8 Hz, COHAr), 162.5 (d, 1J = 244.1 Hz, CFFPh), 171.6 (d, 4J = 3.1 
Hz, COOCH3).19F NMR (235 MHz, CDCl3):  = 126.5 (CFAr), 115.5 (CFFPh). IR (KBr, 
cm-1): 	~  = 2926 (m), 2875 (w), 1665 (s), 1616 (w), 1515 (s), 1440 (s), 1334 (s), 1259 (m), 
1219 (s), 1174 (m), 1096 (m), 1015 (m), 833 (m), 805 (m), 586 (m). GC-MS (EI, 70 eV): m/z 
(%) = 292 ([M+], 64), 260 (100), 245 (81), 231 (9), 217 (43), 183 (17), 170 (5), 151 (3). 
HRMS (EI): Calcd. for C16H14F2O3: 292.09055; found: 292.09034.  
 
Ethyl 4-ethyl-4',6-difluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (26q). 
Starting with 25f (0.405 g, 1.5 mmol), 5c (0.495 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol), 26q was isolated as a colorless viscous 
oil (0.170 g, 35%). 1H NMR (300 MHz, CDCl3):  = 0.69 (t, 3J = 
7.2 Hz, 3 H, CH2CH3), 1.09 (t, 3J = 7.4 Hz, 3 H, COOCH2CH3), 
2.19 (s(br), 3 H, CH3), 2.69 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.88 
(q, 3J = 7.0 Hz, 2 H, COOCH2CH3), 6.957.02 (m, 2 H, CHFPh), 7.047.11 (m, 2 H, CHFPh), 
11.00 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 11.8 (d, 3J = 2.3 Hz, CH3), 13.4 
(CH2CH3), 13.5 (COOCH2CH3), 20.0 (d, 4J = 2.3 Hz, CH2CH3), 61.4 (COOCH2CH3), 109.8 
(d, 3J = 1.7 Hz, CCOOCH2CH3Ar), 114.7, 115.7 (CHFPh), 125.9 (d, 2J = 20.4 Hz, CCFAr), 
131.0 (d, 2J = 1.1 Hz, CHFPh), 131.1 (d, 2J = 2.3 Hz, CHFPh), 131.3 (d, 2J = 20.4 Hz, CCFAr), 
132.7 (d, 3J = 3.5 Hz, CFPh), 132.8 (d, 3J = 2.9 Hz, CCH2CHAr), 151.9 (d, 1J = 232.7 Hz, 
CFAr), 156.2 (d, 4J = 1.7 Hz, COHAr), 162.5 (d, 1J = 243.7 Hz, CFFPh), 171.2 (d, 4J = 3.5 Hz, 
COOCH3). 19F NMR (235 MHz, CDCl3):  = 126.1 (CFAr), 115.9 (CFFPh). GC-MS (EI, 70 











(4), 133 (3). HRMS (EI): Calcd. for C18H18F2O3: 320.17071; found: 320.12229.  
 
Methyl 3-fluoro-6-hydroxy-4-methyl-2-(1-naphthyl)benzoate (26r).  
Starting with 25g (0.454 g, 1.5 mmol), 5a (0.426 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol),  26r was as a reddish solid(0.135 g, 31%), 
(mp = 119121 ºC). 1H NMR (300 MHz, CDCl3):  = 2.25 (s(br), 3 H, 
CH3), 3.01 (s, 3 H, COOCH3), 6.88 (dd, 3J = 6.6 Hz, 4J = 0.7 Hz, 1 H, 
CHNapth), 7.17 (dd, 3J = 7.0 Hz, 4J = 1.3 Hz, 1 H, CHNapth), 7.297.32 
(m, 1 H, CHNapth), 7.35 (m, 1 H, CHAr), 7.377.39 (m, 1 H, CHNapth), 
7.417.44 (m, 1 H, CHNapth), 7.767.81 (m, 2 H, CHNapth), 10.82 (s, 1 H, OH). 13C NMR (75 
MHz, CDCl3):  = 14.5 (d, 3J = 3.5 Hz, CH3), 50.6 (COOCH3), 109.7 (d, 3J = 2.3 Hz, 
CCOOCH3Ar), 118.4 (d, 3J = 3.5 Hz, CHAr), 123.9, 124.1, 124.5, 125.0, 125.1, 126.6 
(CHNapth), 126.7 (d, 2J = 15.7 Hz, CCFAr),  127.1 (CHNapth), 131.1, 132.1, 132.5 (CNapth), 132.7 
(d, 2J = 12.2 Hz, FCCCH3Ar), 151.1 (d, 1J = 233.8 Hz, CFAr), 156.9 (d, 4J = 2.3 Hz, COHAr), 
169.6 (d, 4J = 2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 125.6 (CFAr). IR (Nujol, 
cm-1): 	~  = 1665 (m), 1463 (s), 1376 (s), 1335 (m), 1225 (m), 1080 (w), 953 (w), 789 (m), 551 
(w). GC-MS (EI, 70 eV): m/z (%) = 310 ([M+], 38), 278 (100), 249 (18), 233 (8), 220 (15), 
155 (3), 110 (10). HRMS (EI): Calcd. for C19H15FO3: 310.09997; found: 310.10006.  
 
Methyl 3-fluoro-6-hydroxy-4,5-dimethyl-2-(1-naphthyl)benzoate (26s).  
Starting with 25g (0.454 g, 1.5 mmol), 5b (0.448 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol), 26s was isolated  as a reddish solid (0.180 
g, 37%), (mp = 8891 ºC). 1H NMR (300 MHz, CDCl3):  = 2.12 
(s(br), 3 H, CH3), 2.17 (s(br), 3 H, CH3), 2.92 (s, 3 H, COOCH3), 7.10 
(dd, 3J = 7.0 Hz, 4J = 1.1 Hz, 1 H, CHNapth), 7.197.19 (m, 1 H, 
CHNapth), 7.307.32 (m, 2 H, CHNapth), 7.667.72 (m, 3 H, CHNapth), 
11.15 (s, 1 H, OHAr) . 13C NMR (75 MHz, CDCl3):  = 13.1 (d, 4J = 2.3 Hz, CH3), 13.4 (d, 3J 
= 5.8 Hz, CCH3), 52.8 (COOCH3), 111.0 (d, 3J = 2.9 Hz, CCOOCH3Ar), 125.7 (d, 2J = 21.5 
Hz, CCFAr), 126.2, 126.4, 126.7, 127.1 (CHNapth), 127.5 (d, 4J = 1.1 Hz, CHNapth), 127.9 (d, 3J 
= 3.4 Hz, CCH3Ar), 128.6, 129.3 (CHNapth), 133.1 (d, 2J = 19.8 Hz, CCH3Ar), 133.5, 134.4, 
135.3 (CHNapth), 152.9 (d, 1J = 231.5 Hz, CFAr), 155.5 (d, 4J = 1.7 Hz, COHAr), 172.4 (d, 4J = 
2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 124.0 (CF). IR (Nujol, cm-1): 	
~  = 
1664 (s), 1457 (s), 1377 (s), 1339 (s), 1260 (s), 1226 (s), 1098 (m), 924 (w), 779 (s), 432 








220 (17), 162 (4), 110 (8). HRMS (EI): Calcd. for C20H17FO3: 324.11562; found: 324.11546.  
 
Ethyl 3-ethyl-5-fluoro-2-hydroxy-4-methyl-6-(1-naphthyl)benzoate (26t).  
Starting with 25g (0.454 g, 1.5 mmol), 5c (0.495 g, 1.6 mmol) and 
TiCl4 (0.310 g, 1.6 mmol), 26t was isolated as a reddish solid (0.223 
g, 42%), (mp = 6872 ºC). 1H NMR (300 MHz, CDCl3):  = 0.80 (t, 
3J = 7.4 Hz,  3 H, CH2CH3), 1.16 (t, 3J = 7.5 Hz,  3 H, COOCH2CH3),  
2.56 (s(br), 3 H, CH3Ar), 2.68 (q, 3J = 7.6 Hz,  2 H, CH2CH3), 3.58 (q, 
3J = 7.3 Hz,  2 H, COOCH2CH3), 7.11 (m, 1 H, CHNapth), 7.217.26 
(m, 4 H, CHNapth), 7.687.76 (m, 2 H, CHNapth), 11.10 (s, 1 H, OHAr). 13C NMR (75 MHz, 
CDCl3):  = 11.9 (d, 3J = 5.6 Hz, CH3Ar), 12.6 (CH2CH3Ar), 13.5 (COOCH2CH3Ar), 20.1 (d, 4J 
= 1.6 Hz, CH2CH3Ar), 61.1 (COOCH2CH3Ar), 110.4 (d, 3J = 2.3 Hz, CCOOCH2CH3Ar), 125.0 
(d, 2J = 21.5 Hz, CCFAr), 125.4 (d, 4J = 1.1 Hz, CHNapth), 125.8, 125.9, 126.2, 126.6, 127.7,  
128.4 (CHNapth), 131.5 (d, 2J = 19.2 Hz, CCH3Ar), 132.9 (d, 3J = 2.9 Hz, CCH2CH3Ar), 133.1, 
133.6 (CNapth), 134.8 (d, 4J = 1.1 Hz, CCH3Ar), 152.3 (d, 1J = 231.5 Hz, CFAr), 156.6 (d, 4J = 
1.7 Hz, COHAr), 171.1 (d, 4J = 3.5 Hz, COOCH3Ar).  19F NMR (235 MHz, CDCl3):  = 124.0 
(CF). IR (Nujol, cm-1): 	~  = 1663 (s), 1460 (s), 1357 (s), 1327 (m), 1206 (m), 1109 (w), 1041 
(w), 790 (m), 641 (w). GC-MS (EI, 70 eV): m/z (%) = 352 ([M+], 36), 306 (34), 291 (100), 
273 (5), 220 (13), 162 (2), 110 (2). HRMS (EI): Calcd. for C22H21FO3: 352.14692; found: 
352.14689. 
 
Methyl 3-fluoro-6-hydroxy-2-(2-naphthyl)-4-propylbenzoate (26u).  
Starting with 25h (0.495 g, 1.5 mmol), 5a (0.424 g, 1.6 
mmol) and TiCl4 (0.310 g, 1.6 mmol),  26u was isolated  as a 
colorless viscous oil (0.143 g, 30%). 1H NMR (300 MHz, 
CDCl3):  = 0.88 (t, 3J = 7.4 Hz, 3 H, CH2CH2CH3), 
1.541.62 (m, 2 H, CH2CH2CH3), 2.53 (t, 3J = 7.4 Hz, 2 H, 
CH2CH2CH3), 3.21 (s, 3 H, COOCH3), 6.80 (d, 4JH,F = 6.3 Hz, 1 H, CHAr), 7.22 (dd, , 3J = 8.4 
Hz, 4J = 1.7 Hz, 1 H, CHNapth), 7.377.40 (m, 2 H, CHNapth),  7.58 (m, 1 H, CHNapth), 
7.717.77 (m, 3 H, CHNapth), 10.58 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 14.2 
(CH2CH2CH3), 23.1 (d, 4J = 1.1 Hz, CH2CH2CH3), 32.0 (d, 3J = 1.7 Hz, CH2CH2CH3), 52.1 
(COOCH3), 110.7 (d, 3J = 1.7 Hz, CCOOCH3Ar), 118.7 (d, 4J = 2.8 Hz, CHNapth), 125.6 
(CHNapth), 126.4 (d, 3J = 5.2 Hz, CHAr), 127.3, 128.1, 128.4, 129.7 (CHNapth), 129.9, 130.2 










(d, 3J = 19.8 Hz, CCH2CH2CH3Ar), 152.0 (d, 1J = 234.4 Hz, CFAr), 158.0 (d, 4J = 2.0 Hz, 
COHAr), 171.2 (d, 4J = 2.9 Hz, COOCH3). 19F NMR (235 MHz, CDCl3):  = 128.8 (CF). IR 
(neat, cm-1): 	~  = 2960 (s), 2872 (w), 1668 (s), 1619 (w), 1437 (s), 1332 (s), 1234 (s), 1092 
(m), 819 (m), 787 (m), 746 (m), 478 (m). GC-MS (EI, 70 eV): m/z (%) = 338 ([M+], 50), 306 
(100), 278 (44), 249 (31), 220 (32), 207 (5), 169 (6), 125 (5), 110 (9). HRMS (EI): Calcd. for 
C21H19FO3: 338.13127; found: 338.13136.  
 
Methyl 3-fluoro-6-hydroxy-5-methyl-2-(2-naphthyl)-4-propylbenzoate (26v).  
Starting with 25h (0.495 g, 1.5 mmol), 5b (0.448 g, 1.6 
mmol), TiCl4 (0.310 g, 1.6 mmol)  26v was isolated as a 
colorless solid (0.180 g, 34%), (mp = 8790 ºC). 1H NMR 
(300 MHz, CDCl3):  = 0.85 (t, 3J = 7.4 Hz, 3 H, 
CH2CH2CH3), 1.391.52 (m, 2 H, CH2CH2CH3), 2.16 (s, 3 H, 
CH3), 2.55 (t(br), 3J = 7.4 Hz, 2 H, CH2CH2CH3), 3.16 (s, 3 H, COOCH3), 7.18 (dd, 3J = 8.3 
Hz, 4J = 1.5 Hz, 1 H, CHNapth), 7.317.34 (m, 2 H, CHNapth), 7.54 (m, 1 H, CHNapth), 7.657.72 
(m, 3 H, CHNapth), 10.89 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 10.2 (d, 4J = 2.3 Hz, 
CH3), 12.6 (CH2CH2CH3), 21.8 (d, 4J = 1.1 Hz, CH2CH2CH3), 27.8 (d, 3J = 3.9 Hz, 
CH2CH2CH3), 50.9 (COOCH3), 107.9 (d, 3J = 2.9 Hz, CCOOCH3Ar), 124.4, 124.5 (CHNapth), 
124.7 (d, 2J = 19.8 Hz, CCFAr), 125.1 (CCH3Ar), 125.4, 126.2, 126.3, 126.3, 126.5 (CHNapth), 
130.9, 131.6, 132.1 (CNapth), 134.6 (d, 2J = 19.2 Hz, CCH2CH2CH3Ar), 150.4 (d, 1J = 232.7 Hz, 
CFAr), 154.7 (d, 4J = 1.7 Hz, COHAr), 169.9 (d, 4J = 3.5 Hz, COOCH3).  19F NMR (235 MHz, 
CDCl3):  = 127.7 (CF). IR (KBr, cm-1): 	
~  = 2959 (m), 2871 (w), 1664 (s), 1617 (w), 1440 
(s), 1414 (s), 1331 (s), 1264 (s), 1224 (s), 1115 (w), 1017 (m), 895 (w), 819 (m), 744 (m), 475 
(m). GC-MS (EI, 70 eV): m/z (%) = 352 ([M+], 47), 320 (100), 305 (37), 292 (15), 277 (20), 
249 (4), 220 (17), 176 (7), 146 (6), 116 (5). HRMS (EI): Calcd. for C22H21FO3: 352.14692; 
found: 352.14732.  
 
Ethyl 3-ethyl-5-fluoro-2-hydroxy-6-(2-naphthyl)-4-propylbenzoate (26w).  
Starting with 25h (0.495 g, 1.5 mmol), 5c (0.484 g, 1.6 
mmol) and TiCl4 (0.310 g, 1.6 mmol),  26w was isolated 
(0.204 g, 35%) by column chromatography (silica gel, n-
heptane/EtOAc = 30:1  20:1) as a colorless viscous oil. 1H 
NMR (300 MHz, CDCl3):  = 0.31 (t, 3J = 7.2 Hz, 3 H, 











1.451.58 (m, 2 H, CH2CH2CH3), 2.59 (t(br), 3J = 8.0 Hz, 2 H, CH2CH2CH3), 2.67 (t, 3J = 8.0 
Hz, 2 H, CH2CH3), 3.74 (q, 3J = 7.2 Hz, 2 H, COOCH2CH3), 7.25 (dd, 3J = 8.3 Hz, 4J = 1.5 
Hz, 1 H, CHNapth), 7.357.40 (m, 2 H, CHNapth), 7.57 (m, 1 H, CHNapth), 7.687.79 (m, 3 H, 
CHNapth), 11.00 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 13.1 (CH2CH2CH3), 14.4 
(CH2CH3), 14.7 (COOCH2CH3), 20.0 (d, 4J = 1.6 Hz, CH2CH2CH3), 23.9 (d, 4J = 1.1 Hz, 
CH2CH3), 28.8 (d, 3J = 3.3 Hz, CH2CH2CH3), 61.3 (COOCH2CH3), 110.2 (d, 3J = 2.9 Hz, 
CCOOCH2CH3Ar), 126.1, 126.3 (CHNapth), 127.0 (d, 2J = 20.4 Hz, CCFAr), 127.3, 128.0 
(CHNapth), 128.1 (d, 4J = 1.6 Hz, CHNapth), 128.2 (d, 4J = 1.1 Hz, CHNapth), 128.2 (CHNapth), 
132.3 (d, 3J = 3.5 Hz, CCH2CH3Ar), 132.8, 133.4 (CNapth), 134.3 (d, 4J = 1.1 Hz, CNapth), 135.9 
(d, 2J = 18.6 Hz, FCCCH2CH2CH3Ar), 152.1 (d, 1J = 232.7 Hz, CFAr), 156.5 (d, 4J = 1.7 Hz, 
COHAr), 171.3 (d, 4J = 3.5 Hz, COOCH2CH3).  19F NMR (235 MHz, CDCl3):  = 127.4 
(CF). IR (neat, cm-1): 	~  = 2964 (s), 2873 (m), 1660 (s), 1613 (m), 1507 (m), 1416 (s), 1373 
(s), 1328 (s), 1257 (s), 1243 (s), 1210 (s), 1164 (m), 1030 (m), 819 (m), 749 (s), 477 (m). GC-
MS (EI, 70 eV): m/z (%) = 380 ([M+], 65), 334 (100), 305 (10), 291 (39), 273 (37), 246 (5), 
176 (5), 152 (3), 131 (3), 116 (3). HRMS (EI): Calcd. for C24H25FO3: 380.17822; found: 
380.17793. 
 
10-Fluoro-7-hydroxy-9-methyl-6H-benzo[c]chromen-6-one (27a).  
Starting with 26a (0.060 g, 0.21 mmol) in CH2Cl2 (5 mL), BBr3 (0.207 
g, 0.83 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 27a was 
isolated as a colourless solid (0.046 g, 91%). 1H NMR (300 MHz, 
CDCl3):  = 2.33 (s(br), 3 H, CH3), 6.81 (d, 4JH,F = 5.9 Hz, 1 H, CHAr), 
7.247.26 (m, 1 H, CHAn), 7.28 (m, 1H, CHAn), 7.387.43 (m, 1 H, 
CHAn), 8.358.39 (m, 1 H, CHAn), 11.21 (s, 1 H, OH) . 13C NMR (62 MHz, CDCl3):  = 15.7 
(d, 3J = 6.2 Hz, CH3), 103.4 (d, 3J = 3.7 Hz, CCOAr), 115.4 (d, 3J = 5.2 Hz, CHAn), 117.2 
(CHAn), 118.3 (d, 3J = 4.9 Hz, CHAn), 120.5 (d, 3J = 11.2 Hz, CAn), 125.2 (d, 4J = 2.5 Hz, 
CHAr), 127.4 (d, 2J = 22.9 Hz, CAr), 130.3 (d, 4J = 2.5 Hz, CHAn), 136.8 (d, 2J = 20.5 Hz, 
CCH3Ar), 149.9 (COAn), 150.5 (d, 1J = 241.1 Hz, CFAr), 158.1  (d, 4J = 2.5 Hz, COHAr), 164.5 
(d, 4J = 3.1 Hz, CO).  19F NMR (235 MHz, CDCl3):  = 126.7 (CFAr). IR (KBr, cm-1): 	
~  = 
2954 (w), 2853 (w), 1672 (s), 1607 (m), 1455 (w), 1432 (w), 1278 (m), 1206 (s), 1104 (m), 
1065 (m), 758 (s). MS (EI, 70 eV): m/z (%) = 244 ([M+], 100), 229 (17), 216 (11), 196 (9), 







10-Fluoro-7-hydroxy-8,9-dimethyl-6H-benzo[c]chromen-6-one (27b).  
Starting with 26b (0.060 g, 0.20 mmol) in CH2Cl2 (5 mL), BBr3 (0.197 
g, 0.78 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 27b was 
isolated as a colourless solid (0.043 g, 84%), mp. = 151154 °C. 1H 
NMR (250 MHz, CDCl3):  = 2.21 (s, 3 H, CH3), 2.28 (s(br), 3 H, 
CH3), 7.257.28 (m, 2H, CHAn), 7.367.42 (m, 1H, CHAn), 8.358.40 
(m, 1H, CHAn), 11.60 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3):  = 11.7 (d, 4J = 2.2 Hz, 
CH3), 12.3 (d, 3J = 7.8 Hz, CH3), 102.5 (d, 3J = 5.2 Hz, CCOAr), 116.3 (d, 3J = 5.2 Hz, CAn), 
117.2 (CHAn), 117.7 (d, 2J = 12.8 Hz, CCFAr), 125.2 (CHAn), 126.3 (d, 3J = 4.0 Hz, CCH3Ar), 
127.4 (CHAn), 129.8 (d, 4J = 2.3 Hz, CHAn), 135.3 (d, 2J = 19.2 Hz, CCH3Ar), 149.8 (COAn), 
150.3 (d, 1J = 241.1 Hz, CFAr), 156.4  (d, 4J = 1.7 Hz, COHAr), 165.1 (d, 4J = 3.4 Hz, CO). 19F 
NMR (235 MHz, CDCl3):  = 125.4 (CFAr). IR (KBr, cm-1): 	
~  = 2962 (m), 2925 (m), 2854 
(w), 1677 (s), 1622 (w), 1606 (m), 1440 (s), 1335 (m), 1270 (s), 1179 (s), 1095 (s), 1228 (s), 
1022 (m), 799 (s), 757 (s). GC-MS (EI, 70 eV): m/z (%) = 258 ([M+], 100), 243 (25), 229 (4), 
215 (3), 199 (3), 183 (4), 170 (4), 152 (3). HRMS (EI): Calcd. for C15H11FO3: 258.06867; 
found: 258.06807.  
 
8-Ethyl-10-fluoro-7-hydroxy-9-methyl-6H-benzo[c]chromen-6-one (27c).  
Starting with 26c (0.060 g, 0.18 mmol) in CH2Cl2 (5 mL), BBr3 
(0.180 g, 0.72 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
27c  was isolated as a colourless solid (0.037 g, 75%), mp. = 
119121 °C. 1H NMR (300 MHz, CDCl3):  = 1.10 (t, 3J = 7.4 Hz, 3 
H, CH2CH3), 2.34 (s(br), 3 H, CH3), 2.74 (q, 3J = 7.2 Hz, 2 H, 
CH2CH3), 7.19 (m, 1 H, CHAn), 7.297.30 (m, 1 H, CHAn), 7.377.43 (m, 1 H, CHAn), 
8.398.43 (m, 1 H, CHAn), 11.60 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 10.7 (d, 3J = 
8.7 Hz, CH3), 11.9 (CH2CH3), 18.5 (d, 4J = 2.3 Hz, CH2CH3), 103.4 (d, 3J = 4.4 Hz, CCOAr), 
115.5 (d, 3J = 5.2 Hz, CAn), 116.3 (CHAn), 117.1 (d, 2J = 12.8 Hz, CCFAr), 124.2, 126.5 
(CHAn), 128.9 (d, 4J = 2.3 Hz,   CHAn), 131.3 (d, 3J = 3.5 Hz, CCH2CH3Ar), 133.8 (d, 2J = 14.9 
Hz, CCH3Ar), 148.0 (COAn), 148.3 (d, 1J = 241.0 Hz, CFAr), 155.4 (d, 4J = 1.7 Hz, COHAr), 
164.4 (d, 4J = 3.4 Hz, CO). 19F NMR (235 MHz, CDCl3):  = 124.7 (CFAr). IR (KBr, cm-1): 
	~  = 2967 (m), 2876 (w), 1672 (s), 1608 (m), 1563 (w), 1413 (s), 1339 (s), 1287 (s), 1268 (s), 
1178 (s), 1164 (s), 872 (m), 768 (s), 738 (m). MS (EI, 70 eV): m/z (%) = 272 ([M+], 42), 257 










10-Fluoro-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (27d).  
Starting with 26d (0.148 g, 0.46 mmol) in CH2Cl2 (8 mL), BBr3 
(0.465 g, 1.85 mmol) and KOtBu (20 mL, 0.1 M aqueous solution), 
27d was isolated as a colourless solid (0.060 g, 47%), mp. = 
8890°C. 1H NMR (300 MHz, CDCl3):  = 0.93 (t, 3J = 7.2 Hz, 3 H, 
CH2CH2CH3), 1.571.70 (m, 2 H, CH2CH2CH3), 2.65 (t(br), 3J = 
7.2 Hz, 2 H, CH2CH2CH3), 6.82 (d, 4JH,F = 5.7 Hz, 1 H, CHAr), 7.247.26 (m, 1 H, CHAn), 
7.27 (m, 1 H, CHAn), 7.377.43 (m, 1H, CHAn), 8.378.41 (m, 1 H, CHAn), 11.22 (s, 1 H, OH) 
.13C NMR (75 MHz, CDCl3):  = 12.7 (CH2CH2CH3), 21.7 (d, 4J = 1.1 Hz, CH2CH2CH3), 
30.8 (d, 3J = 3.9 Hz, CH2CH2CH3), 102.7 (d, 3J = 4.0 Hz, CCOAr), 115.3 (d, 3J = 5.2 Hz, CAn), 
116.7 (d, 3J = 3.4 Hz, CHAr), 120.0 (d, 2J = 12.2 Hz, CCFAr), 124.3, 126.5, 126.8 (CHAn), 
129.4 (d, 4J = 1.1 Hz, CHAn), 140.3 (d, 2J = 19.2 Hz, CCH2CH2CH3Ar), 148.5 (d, 1J = 243.2 
Hz, CFAr), 149.1 (COAn), 157.4 (d, 4J = 2.0 Hz, COHAr), 163.8 (d, 4J = 2.9 Hz, CO). 19F NMR 
(235 MHz, CDCl3):  = 125.7 (CF). IR (KBr, cm-1): 	
~  = 3054 (w), 2965 (m), 2870 (m), 
1700 (s), 1629 (m), 1569 (m), 1447 (m), 1435 (s), 1276 (s), 1203 (s), 1106 (s), 952 (w), 756 
(s), 735 (m). GC-MS (EI, 70 eV): m/z (%) = 272 ([M+], 100), 257 (10), 244 (96), 215 (21), 
199 (10), 183 (3), 170 (11), 157 (7), 133 (9). HRMS (EI): Calcd. for C18H19FO4: 272.08432; 
found: 272.08412.  
 
10-Fluoro-7-hydroxy-8-methyl-9-propyl-6H-benzo[c]chromen-6-one (27e).  
Starting with 26e (0.100 g, 0.30 mmol) in CH2Cl2 (8 mL), BBr3 
(0.30 g, 1.20 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
27e was isolated as a colourless solid (0.052 g, 60%). 1H NMR (300 
MHz, CDCl3):  = 0.95 (t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 
1.441.60 (m, 2 H, CH2CH2CH3), 2.14 (s, 3 H, CH3), 2.70 (t(br), 3J 
= 7.6 Hz, 2 H, CH2CH2CH3), 7.23 (m, 1H, CHAn), 7.25 (m, 1H, CHAn), 7.337.39 (m, 1H, 
CHAn), 8.468.78 (m, 1H, CHAn), 11.60 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3):  = 10.4 
(d, 4J = 2.2 Hz, CH3 ), 13.1 (CH2CH2CH3), 21.5 (d, 4J = 1.9 Hz, CH2CH2CH3), 27.7 (d, 3J = 
5.4 Hz, CH2CH2CH3), 101.7 (d, 3J = 5.2 Hz, CCOAr), 115.4 (d, 3J = 5.2 Hz, CAn), 116.2 
(CHAn), 116.9 (d, 2J = 12.8 Hz, CCFAr), 124.2 (CHAn), 125.4 (d, 3J = 4.0 Hz, CCH3Ar), 126.5  
(CHAn), 128.8 (d, 4J = 2.3 Hz, CHAn), 138.7 (d, 2J = 18.0 Hz, CCH2CH2CH3Ar), 148.9 (COAn), 
149.4 (d, 1J = 241.4 Hz, CFAr), 155.8 (d, 4J = 1.7 Hz, COHAr), 164.2 (d, 4J = 3.4 Hz, CO). 19F 
NMR (235 MHz, CDCl3):  = 126.9 (CF). IR (KBr, cm-1): 	
~  = 2968 (s), 2926 (s), 2853 (m), 










(s), 729 (m). GC-MS (EI, 70 eV): m/z (%) = 286 ([M+], 100), 271 (47), 258 (47), 243 (12), 
229 (6), 215 (2), 199 (7), 183 (6), 170 (7), 152 (5), 133 (4). HRMS (EI): Calcd. for 
C17H15FO3: 286.09997; found: 286.09965. 
 
8-Ethyl-10-fluoro-7-hydroxy-9-propyl-6H-benzo[c]chromen-6-one (27f).  
Starting with 26f (0.124 g, 0.35 mmol) in CH2Cl2 (6 mL), BBr3 
(0.124 g, 0.35 mmol) and KOtBu (10 mL, 0.1 M aqueous solution), 
27f was isolated as a colourless solid (0.069 g, 67%). 1H NMR (300 
MHz, CDCl3):  = 0.99 (t, 3J = 7.2 Hz, 3 H, CH2CH2CH3), 1.13 (t, 
3J = 7.2 Hz, 3 H, CH2CH3), 1.511.64 (m, 2 H, CH2CH2CH3), 2.70 
(q, 3J = 8.2 Hz, 2 H, CH2CH3),  2.75 (t(br), 3J = 8.3 Hz, 2 H, CH2CH2CH3), 7.247.29 (m, 2 
H, CHAn), 7.367.42 (m, 1 H, CHAn), 8.398.43 (m, 1 H, CHAn), 11.62 (s, 1 H, OH) . 13C 
NMR (75 MHz, CDCl3):  = 12.7 (CH2CH3), 13.2 (CH2CH2CH3), 18.5 (d, 4J = 1.6 Hz, 
CH2CH3), 22.5 (d, 4J = 1.1 Hz, CH2CH2CH3), 27.7 (d, 3J = 5.8 Hz, CH2CH2CH3), 102.0 (d, 3J 
= 4.6 Hz, CCOAr), 115.5 (d, 3J = 5.2 Hz, CAn), 116.3 (CHAn), 117.1 (d, 2J = 12.8 Hz, CCFAr), 
124.2, 126.5 (CHAn), 128.9 (d, 4J = 1.7 Hz, CHAn), 131.1 (d, 3J = 3.5 Hz, CCH2CH3Ar), 138.3 
(d, 2J = 18.0 Hz, CCH2CH2CH3Ar), 149.0 (COAn), 149.7 (d, 1J = 242.0 Hz, CFAr), 155.8 (d, 4J 
= 1.1 Hz, COHAr), 164.4 (d, 4J = 3.5 Hz, CO).19F NMR (235 MHz, CDCl3):  = 126.3 (CF). 
IR (KBr, cm-1): 	~  = 2961 (s), 2929 (m), 2870 (m), 1686 (s), 1608 (m), 1410 (s), 1336 (m), 
1278 (m), 1171 (s), 1114 (s), 1092 (m), 891 (w), 752 (s). GC-MS (EI, 70 eV): m/z (%) = 300 
([M+], 100), 285 (74), 272 (7), 257 (70), 244 (18), 229 (5), 199 (7), 183 (8), 170 (6), 152 (3), 
133 (3). HRMS (EI): Calcd. for C18H17FO3: 300.11562; found: 300.11481.  
 
Methyl 4'-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (29a).  
Starting with 28a (0.378 g, 1.5 mmol), 5a(0.429 g, 1.6 mmol) and 
TiCl4 (0.312 g, 1.6 mmol, 29a was isolated  as a colorless oil (0.114 
g, 44%). 1H NMR (300 MHz, CDCl3):  = 2.25 (s, 3 H, CH3), 3.41 
(s, 3 H, OCH3), 6.49 (s, 1 H, CHAr), 6.74 (s, 1 H, CHAr), 6.92-9.98 
(m, 2 H, CH), 6.83 (s, 2 H, CH), 10.74 (s, 1 H, OH) . 13C NMR (75 
MHz, CDCl3):  = 20.5 (CH3), 50.5 (OCH3), 108.2  (CAr), 113.4 (d, 2J = 21.5 Hz, 2CHAr), 
116.1, 123.0 (CHAr), 128.5 (d, 3J = 8.0 Hz, 2CHAr), 137.8 (d, 4J = 3.5 Hz, CAr), 142.5, 143.9 
(CAr), 160.9 (d, 1J = 219.5 Hz, CFAr), 162.5 (COHAr), 170.2 (CO). IR (KBr, cm-1): 	
~  = 2948 
(s), 2895 (m), 1675 (s), 1616 (m), 1493 (m), 1458 (m), 1405 (m), 1399 (m), 1254 (s), 1219 










171 (21), 157 (6), 146 (4). HRMS (EI): Calcd. for C15H13FO3 : 260.08432; found: 260.08383.  
 
Ethyl 4-ethyl-4'-fluoro-3-hydroxy-5-methyl[1,1'-biphenyl]-2-carboxylate (29b) .  
Starting with 28a (0.378 g, 1.5 mmol), 5c (0.484 g, 1.6 mmol) 
and TiCl4 (0.312 g, 1.6 mmol, 29b was isolated  as a colorless oil 
(0.132 g, 44%).1H NMR (300 MHz, CDCl3):  = 0.73 (t, 3J = 7.2 
Hz, 3 H, CH2CH3), 1.09 (t, 3J = 7.4 Hz, 3 H, OCH2CH3), 2.25 (s, 
3 H, CH3), 2.66 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.91 (q, 3J = 7.3 
Hz, 2 H,OCH2CH3), 6.49 (s, 1 H, CHAr), 6.91-6.97 (m, 2 H, CHAr), 7.08-7.11 (m, 2 H, CHAr), 
7.24-7.27 (m, 1 H, CHAr), 11.14 (s, 1 H, OH) . 13C NMR (75 MHz, CDCl3):  = 12.0 
(CH2CH3), 18.4 (OCH2CH3), 18.5 (CH3), 28.6 (CH2CH3), 59.8 (OCH2CH3), 108.3  (CAr), 
113.2  (d, 2J = 21.1 Hz, 2CHAr), 123.2 (CHAr), 128.7 (CAr), 129.0 (d, 3J = 8.0 Hz, 2CHAr), 
136.6 (CAr), 138.4 (d, 4J = 3.3 Hz, CAr), 141.1 (CAr), 158.7 (COHAr), 160.8 (d, 1J = 244.0 Hz, 
CFAr), 170.3 (CO). IR (KBr, cm-1): 	
~  = 2958 (s), 2870 (m), 1655 (s), 1616 (m), 1503 (m), 
1468 (m), 1415 (m), 1399 (m), 1246 (s), 1233 (s), 1097 (m), 750 (s). GC-MS (EI, 70 eV): m/z 
(%) = 302 ([M+], 53), 256 (73), 241 (100), 223 (10), 213 (57), 199 (8), 183 (29). HRMS (EI): 
Calcd. for C18H19FO3 : 302.13127; found: 302.13190. 
 
General procedure for synthesis of fluorenones 30 and 31:  
A solution of 29 (1 mmol) in concentrated sulfuric acid (12 mL) was stirred at room 
temperature for one hour. To the solution was added water and it was stirred for further 15 
minutes. The organic and the aqueous layer were separated and the latter was extracted with 
CH2Cl2. The combined organic layers were dried (Na2SO4), filtered and the filtrate was 
concentrated in vacuo. The product was purified by chromatography (silica gel; n-heptane/ 
EtOAc = 20:1) to give 30.  
 
7-fluoro-1-hydroxy-3-methyl-9H-fluoren-9-one (30a).  
Starting with 29a (0.114 g, 0.438 mmol) and conc. sulfuric acid 
(2.307 mL), 30a was isolated  as a yellow oil (0.156 g, 68%). 1H 
NMR (300 MHz, CDCl3):  = 2.27 (s, 3 H, CH3), 6.45 (s, 1 H, 
CHAr), 6.74 (s, 1 H, CHAr), 7.01-7.09 (m, 1 H, CHAr), 7.21 (dd, 3J 
= 7.4 Hz, 4J = 3.0 Hz, 1 H, CHAr), 7.34 (dd, 3J = 7.5 Hz, 4J = 4.5 Hz, 1 H, CHAr), 8.15 (s, 1 H, 
OH) . 13C NMR (62 MHz, CDCl3):  = 22.5 (CH3), 111.4  (d, 2J = 23.9 Hz, CHAr), 114.1, 








(d, 3J = 8.5 Hz, CAr), 139.6 (d, 4J = 2.4 Hz, CAr), 143.4, 149.9 (CAr), 157.5 (COHAr), 163.4 (d, 
1J = 247.4 Hz, CFAr), 194.0 (CO). GC-MS (EI, 70 eV): m/z (%) = 228 ([M+], 100), 199 (36), 
170 (26), 151 (3), 100 (5), 85  (9). HRMS (EI): Calcd. for C14H9FO2 : 228.05811; found: 
228.057995. 
 
2-Ethyl-7-fluoro-1-hydroxy-3-methyl-9H-fluoren-9-one (30b).  
Starting with 29b (0.132 g, 0.437 mmol) and conc. sulfuric acid 
(2.340 mL), 30b was isolated  as a yellow viscous oil (0.194 g, 
76%). 1H NMR (300 MHz, CDCl3):  = 1.06 (t, 3J = 7.6 Hz, 3 
H, CH2CH3), 2.26 (s, 3 H, CH3), 2.56 (q, 3J = 7.4 Hz, 2 H, 
CH2CH3), 6.57 (s, 1 H, CHAr), 7.03 (ddd, 3J = 8.2 Hz, 3J = 6.3 Hz, 4J = 0.5 Hz,1 H, CHAr), 
7.19 (m, 1 H, CHAr), 7.29 (m, 1 H, CHAr), 8.42 (s, 1 H, OH). 13C NMR (75 MHz, CDCl3):  = 
11.2 (CH2CH3), 18.3 (CH3), 28.2 (CH2CH3), 109.6  (d, 2J = 23.1 Hz, CHAr), 111.9 (CAr), 
113.1 (CHAr), 118.4 (d, 2J = 22.9, CHAr), 119.7 (d, 3J = 8.6 Hz, CHAr), 126.4, 129.7 (CAr),  
135.0 (d, 3J = 6.8 Hz, CAr), 138.0 (d, 4J = 3.7 Hz, CAr), 144.7 (CAr), 154.0 (COHAr), 161.2 (d, 
1J = 245.5 Hz, CFAr), 192.7 (d, 4J = 1.8 Hz, CO). GC-MS (EI, 70 eV): m/z (%) = 256 ([M+], 
42), 241 (100), 213 (8), 183 (12), 170 (7). HRMS (EI): Calcd. for C16H13FO2 : 256.08941; 
found: 256.08976. 
 
7-Chloro-4-fluoro-1-hydroxy-3-methyl-9H-fluoren-9-one (31a).  
Starting with 26l (0.031 g, 0.105 mmol) and conc. Sulfuric acid 
(1.2 mL), 31a was isolated as a yellow solid (0.021 g, 77 %). 1H 
NMR (300 MHz, CDCl3):  = 2.22 (d, 4JH,F = 1.3 Hz, 3 H, CH3),  
6.52 (d, 3J  = 5.9 Hz, 1 H, CHAr), 7.18 (m, 1 H, CHClPh), 7.38 (d, 
3J = 8.0 Hz, 1 H, CHClPh), 7.52 (m, 1 H, CHClPh), 8.02 (s, 1 H, 
OH). 13C NMR (75.5 MHz, CDCl3):  = 16.0 (d, 3J = 4.0 Hz, CH3), 112.3 (d, 2J  = 24.0 Hz, 
CCH3Ar), 116.4 (d, 3J  = 4.6 Hz, CClPh), 121.1 (CHClPhr), 124.9 (d, 4J = 1.7 Hz, CHClPh), 125.2 
(d, 3J = 3.5 Hz, CHAr), 134.6 (CHClPh), 136.3 (CClPh), 138.4 (d, 2J = 19.0 Hz, CAr), 145.0 (CAr), 
152.4 (CClPh), 153.8 (COHAr), 163.6 (d, 1J = 250.5 Hz, CFAr), 193.7 (CO). 19F NMR (235 
MHz, CDCl3):  = 131.7 (CFAr). IR (KBr, cm–1): 	
 = 3423 (br, m), 2973 (m), 2851 (w), 1698 
(s), 1636 (w), 1605 (m), 1456 (m), 1310 (m), 1270 (m), 1180 (s), 1088 (m), 793 (m), 580 (w). 
GC-MS (EI, 70 eV): m/z (%) = 264 ([M+], [37Cl], 34), 262 ([M+], [35Cl], 100), 235 ([37Cl], 3), 
233 ([35Cl], 8), 199 (13), 170 (23), 151 (3), 131 (3), 99 (6), 85 (9). HRMS (EI): Calcd. for 








7-Chloro-4-fluoro-1-hydroxy-2,3-dimethyl-9H-fluoren-9-one (31b).  
Starting with 26m (0.036 g, 0.12 mmol) and conc. Sulfuric acid 
(1.390 mL), 31b was isolated as a yellow solid (0.024 g, 75%). 
1H NMR (300 MHz, CDCl3):  = 2.06 (s, 3 H, CH3), 2.12 (s(br), 
3 H, CH3), 7.33 (dd, 3J  = 8.0 Hz, 4J = 1.9 Hz, 1 H, CHClPh), 7.42 
(m, 1 H, CHClPh), 7.46 (d, 3J = 1.8 Hz, 1 H, CHClPh), 8.32 (s, 1 H, OH). 13C NMR (75.5 MHz, 
CDCl3):  = 11.5 (d, 4J = 1.7 Hz, CH3), 12.5 (d, 3J = 5.2 Hz, CH3), 115.4 (d, 3J  = 5.2 Hz, 
CCH3Ar), 123.5 (d, 2J  = 17.4 Hz, CCH3Ar), 124.7, 125.2 (CHClPh), 129.3 (d, 4J = 2.3 Hz, 
CClPh),  134.7 (d, 2J = 28.5 Hz, CAr), 134.9 (CHClPh), 136.0 (CClPh), 136.2 (d, 3J = 5.8 Hz, 
CClPh), 140.1 (CAr), 150.5 (d, 1J = 244.9 Hz, CFAr), 152.5 (COHAr), 194.3 (CO). 19F NMR 
(235 MHz, CDCl3):  = 129.5 (CFAr). IR (KBr, cm–1): 	
 = 3414 (br, s), 2923 (m), 2852 (m), 
1696 (s), 1636 (w), 1604 (m), 1453 (s), 1382 (w), 1288 (s), 1274 (s), 1170 (s), 1078 (m), 1021 
(m), 878 (w), 793 (m), 743 (m), 629 (m). GC-MS (EI, 70 eV): m/z (%) = 278 ([M+], [37Cl], 
37), 276 ([M+], [35Cl], 100), 263 ([37Cl], 12), 261 ([35Cl], 40), 235 ([37Cl], 3), 233 ([35Cl], 10), 
213 (5), 207 (23), 183 (17), 170 (11), 138 (6), 91 (11). HRMS (EI): Calcd. for C15H10ClFO2 
([M]+, 35Cl): 276.03479; found: 276.03481. 
 
4,7-Difluoro-1-hydroxy-2,3-dimethyl-9H-fluoren-9-one (31c).  
Starting with 26p (0.078g, 0.27 mmol) and conc. sulfuric acid (3.2 
mL), 31c was isolated as a yellow solid (0.069 g, 74 %). 1H NMR 
(300 MHz, CDCl3):  = 2.00 (s, 3 H, CH3), 2.01 (d, 4JH,F = 2.1 Hz, 
3 H, CH3), 7.00 (ddd, 3J = 8.5 Hz, 3J  = 8.7 Hz, 4J  = 2.5 Hz, 1 H, 
CHFPh), 7.14 (dd, 3J = 7.2 Hz, 4J  = 2.4 Hz, 1 H, CHFPh), 7.38 (dd, 3J = 8.1 Hz, 4J  = 2.5 Hz, 1 
H, CHFPh), 8.24 (s, 1 H, OH). 13C NMR (75.5 MHz, CDCl3):  = 11.4 (d, 4J  = 1.7 Hz, CH3), 
12.4 (d, 3J  = 5.8 Hz, CH3), 112.0 (d, 2J  = 22.7 Hz, CHFPh), 115.8 (d, 3J = 5.2 Hz, CCH3Ar), 
121.1 (d, 2J = 22.7 Hz, CCH3Ar),  123.5 (d, 3J = 18.6 Hz, CHFPh), 125.3 (CHFPh), 128.5 (d, 3J = 
1.1 Hz, CFPh), 136.0 (d, 2J = 16.3 Hz, CAr), 136.7 (d, 3J = 8.1 Hz, CFPh), 137.6 (d, 3J = 1.7 Hz, 
CAr), 150.2 (d, 1J = 244.3 Hz, CFFPh),  152.4 (COHAr), 163.3 (d, 1J = 248.4 Hz, CFAr), 194.0 
(d, 4J = 2.3 Hz, CO). 19F NMR (235 MHz, CDCl3):  = 131.1 (CFAr), 111.9 (CFFPh). GC-
MS (EI, 70 eV): m/z (%) = 260 ([M+], 100), 245 (51), 231 (7), 217 (13), 201 (9), 183 (14), 











2-Ethyl-4,7-difluoro-1-hydroxy-3-methyl-9H-fluoren-9-one (31d).  
Starting with 26q (0.037 mg, 0.12 mmol) and conc. sulfuric acid 
(1.38 mL), 31d was isolated as a yellow solid (0.022 g, 69 %). 
1H NMR (300 MHz, CDCl3):  = 1.05 (t, 3J = 7.4 Hz,  3 H, 
CH2CH3), 2.16 (s, 3 H, CH3), 2.57 (q, 3J  = 7.4 Hz, 2 H, 
CH2CH3), 7.06 (ddd, 3J = 8.5 Hz, 3J  = 8.5 Hz, 4J  = 2.4 Hz, 1 H, CHFPh), 7.20 (dd, 
3J = 5.1 Hz, 4J  = 0.3 Hz, 1 H, CHFPh), 7.48 (dd, 3J = 8.1 Hz, 4J  = 3.6 Hz, 1 H, CHFPh), 8.31 
(s, 1 H, OH). 13C NMR (75.5 MHz, CDCl3):  = 9.5 (CH2CH3), 11.2 (CH3), 17.0 (d, 4J 
 = 2.3 Hz, CH2CH3), 109.6 (d, 2J  = 23.3 Hz, CHFPh), 113.8 (CCH2CH3Ar), 118.8 (d, 2J = 22.7 
Hz, CHFPh), 121.4 (d, 4J = 16.3 Hz, CCH3FPh), 123.2 (CHFPh), 126.3 (CAr), 133.1 (d, 2J = 17.4 
Hz, CAr), 134.6 (CFPh), 135.4 (CFPh), 148.1 (d, 1J = 244.3 Hz, CFPh), 150.1 (COHAr), 161.0 (d, 
1J = 248.4 Hz, CFAr), 191.9 (CO). 19F NMR (235 MHz, CDCl3):  = 129.8 (CFAr),  111.8 
(CFFPh). IR (KBr, cm–1): 	
 = 3445 (br, m), 2975 (w), 2939 (m), 2852 (w), 1684 (s), 1603 (w), 
1485 (m), 1265 (m), 1095 (m), 837 (w), 598 (w). GC-MS (EI, 70 eV): m/z (%) = 274 ([M+], 
43), 259 (100), 231 (6), 201 (8), 183 (7), 122 (2). HRMS (EI): Calcd. for C16H12FO2: 
274.07999; found: 274.07954. 
 
General procedure for the synthesis of homophthalates 33.  
To neat allene 32 (1.0 mmol) was added neat diene 5 (1.25 mmol)1 at 0 °C under argon 
atmosphere. The reaction mixture was stirred at 0 °C for 30 minutes and then the solution was 
stirred at 2040 °C for several hours. To the mixture was added an ethanolic solution (96%, 2 
mL) of triethylammonium fluoride (1.5 mmol). The solution was diluted with water and 
repeatedly extracted with diethyl ether or dicholoromethane. The combined organic layers 
were dried (Na2SO4), filtered and the filtrate was concentrated in vacuo. The residue was 
purified by column chromatography (silica gel, heptanes / EtOAc or petroleum ether / diethyl 
ether = 1:1) to give product 33. 
 
Methyl 3-ethyl-2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)-benzoate (33b).  
Starting with 5f (0.361 g, 1.25 mmol), 32 (0.156 g, 1.0 mmol), 
triethylammonium fluoride (0.242 g, 1.5 mmol) was added, 33b 
was isolated as a yellow viscous oil (0.139 g, 52%). Reaction 
time: 14 h (40 °C). 1H NMR (250 MHz, CD3OD):  = 0.98 (t, 3J 
= 7.4 Hz, 3 H, CH2CH3), 2.53 (q, 3J = 7.4 Hz, 2 H, CH2CH3), 3.58 (s, 3 H, COOCH3), 3.67 (s, 











CD3OD):  = 13.4 (CH2CH3), 16.8 (CH2CH3), 43.2 (CH2COOCH3), 52.6 (COOCH3), 52.7 
(CH2COOCH3), 104.6(CAr), 113.1 (CHAr), 117.8, 136.0 (CAr), 161.1, 163.9 (COHAr), 172.6 
(COOCH3), 174.2 (CH2COOCH3). IR (neat, cm-1): 	
~  = 3285 (w), 2961 (w), 1699 (s), 1646 
(m), 1604 (m), 1439 (m), 1275 (s), 1193 (s), 1156 (s), 1051 (m), 984 (m), 839 (m), 746 (m). 
GC-MS (EI, 70 eV): m/z (%) = 268 ([M+], 33), 250 (5), 236 (30), 222 (10), 208 (19), 189 
(22), 176 (100), 148 (8), 91 (6), 77 (6). 
 
Methyl 3-chloro-2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)-benzoate (33c).  
Starting with 5d (0.386 g, 1.25 mmol), 32 (0.156 g, 1.0 mmol), 
and triethylammonium fluoride (0.242 g, 1.5 mmol) was added, 
33c was isolated as a yellow viscous oil (0.177 g, 64%). 
Reaction time: 14 h (40 °C). 1H NMR (250 MHz, CD3OD):  = 
3.67 (s, 3 H, COOCH3), 3.82 (s, 2 H, CH2COOCH3), 3.85 (s, 3 H, CH2COOCH3), 6.38 (s, 1 
H, CHAr). 13C NMR (62 MHz, CD3OD):  = 43.0 (CH2COOCH3), 52.4 (COOCH3), 52.4 
(CH2COOCH3), 106.2 (CAr), 113.5 (CHAr), 137.6 (2CAr), 159.6, 161.6 (COHAr), 172.3 
(COOCH3), 173.8 (CH2COOCH3). IR (neat, cm-1): 	
~  = 3226 (w), 2958 (w), 1698 (m), 1654 
(m), 1435 (m), 1319 (m), 1235 (s), 1189 (s), 1076 (m), 959 (m), 800 (m), 687 (m). GC-MS 
(EI, 70 eV): m/z (%) = 276 ([M+], 37Cl, 16), 274 ([M+], 35Cl, 48), 244 (37Cl, 20), 242 (35Cl, 
42), 216 (37Cl, 37), 214 (35Cl, 100), 201 (37Cl, 24), 199 (35Cl, 76), 185 (13), 171 (8), 155 (33). 
HRMS (EI): Calcd. for C11H11O6Cl ([M+], 35Cl): 274.02387; found: 274.02379. 
 
Methyl 3-fluoro-2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)-benzoate (33d).  
Starting with 5e (0.920 g, 2.5 mmol), 32 (0.312 g, 2.0 mmol), 
and triethylammonium fluoride (0.483 g, 3.0 mmol) was added, 
33d was isolated as a red solid (0.361 g, 70%), mp. = 148156 
°C. Reaction time: 14 h (40 °C). 1H NMR (250 MHz, CD3OD):  
= 2.36 (s, 3 H, COOCH3), 2.47 (s, 2 H, CH2COOCH3), 2.54 (s, 3 H, CH2COOCH3), 5.04 (d, 
4J = 7.6 Hz, 1 H, CHAr). 13C NMR (62 MHz, CD3OD):  = 42.6 (CH2COOCH3), 52.4 
(COOCH3), 52.5 (CH2COOCH3), 106.7 (CAr), 114.2 (d, 3J = 1.3 Hz, CHAr), 126.3 (CAr), 
133.8 (d, 3J = 4.1 Hz, CAr), 140.6 (d, 1J = 234.3 Hz, CFAr), 150.8 (d, 2J = 9.6 Hz, COHAr), 
153.6 (d, 2J = 10.3 Hz, COHAr), 171.9 (COOCH3), 174.0 (CH2COOCH3). IR (neat, cm-1): 	
~  
= 3231 (w), 2956 (w), 1706 (s), 1657 (m), 1597 (m), 1437 (s), 1324 (m), 1249 (s), 1199 (s), 
1105 (m), 1059 (m), 979 (s), 844 (m), 743 (s). GC-MS (EI, 70 eV): m/z (%) = 258 ([M+], 49), 












Calcd. for C11H11FO6: 258.05342; found: 258.05382. 
 
Methyl 3-chloro-2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)-5-methylbenzoate (33g). 
Starting with 5g (0.386 g, 1.25 mmol), 32 (0.156 g, 1.0 mmol), 
and triethylammonium fluoride (0.242 g, 1.5 mmol), 33g was 
isolated as a yellow solid (0.135 g, 47%). Reaction time: 14 h 
(40 °C). 1H NMR (250 MHz, CDCl3):  = 2.13 (s, 3 H, CH3), 
3.64 (s, 3 H, COOCH3), 3.83 (s, 3 H, CH2COOCH3), 3.88 (s, 2 
H, CH2COOCH3), 6.21 (br, 1 H, OH), 11.88 (br, 1 H, OH). 13C NMR (62 MHz, CDCl3):  = 
12.2 (CH3), 37.2 (CH2COOCH3), 52.0 (COOCH3), 52.4 (CH2COOCH3), 106.4, 107.1, 117.1, 
134.4, 154.7, 157.4 (CAr), 171.1 (COOCH3), 171.2 (CH2COOCH3). IR (neat, cm-1): 	
~  = 3256 
(w), 2956 (w), 1716 (s), 1648 (m), 1577 (m), 1436 (m), 1326 (s), 1216 (s), 1165 (s), 1001 (m), 
962 (m), 808 (m). GC-MS (EI, 70 eV): m/z (%) = 290 ([M+], 37Cl, 16), 288 ([M+], 35Cl, 49), 
258 (37Cl, 18), 256 (35Cl, 48), 230 (37Cl, 37), 228 (35Cl, 100), 215 (37Cl, 29), 213 (35Cl, 90), 
196 (17), 105 (6), 77 (20). HRMS (EI): Calcd. for C12H13O6Cl ([M+], 35Cl): 288.03952; found: 
288.03964. 
 
Methyl 3-hexyl-4,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-benzoate (33k).  
Starting with 5h (0.557 g, 1.5 mmol), 32 (0.187 g, 1.2 mmol), 
and triethylammonium fluoride (0.290 g, 1.8 mmol), 33k was 
isolated as a colourless solid (0.170 g, 52%). Reaction time: 14 
h (40 °C). 1H NMR (250 MHz, CDCl3):  = 0.80 (t, 3J = 6.8 Hz, 
3 H, CH2(CH2)4CH3), 1.201.26 (m, 8 H, CH2(CH2)4CH3), 2.43 
(t, 3J = 6.8 Hz, 2 H, CH2(CH2)4CH3), 3.69 (s, 3 H, COOCH3), 3.80 (s, 3 H, CH2COOCH3), 
3.87 (s, 2 H, CH2COOCH3), 6.10 (s, 1 H, CHAr), 6.56 (s, 1 H, OHAr), 11.16 (s(br), 1 H, 
OHAr). 13C NMR (75 MHz, CDCl3):  = 14.1 ((CH2)5CH3), 22.6, 26.1, 29.5, 29.8, 31.7 
((CH2)5CH3), 36.8 (CH2COOCH3), 51.8 (COOCH3), 52.2 (CH2COOCH3), 102.9 (CHAr), 
105.5, 128.3, 134.8 (CAr), 159.9, 162.4 (COHAr), 171.1 (COOCH3), 173.4 (CH2COOCH3). 
GC-MS (EI, 70 eV): m/z (%) = 324 ([M+], 33), 292 (24), 253 (25), 221 (100), 189 (80), 163 
















Methyl 4,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-3-octylbenzoate (33l).  
Starting with 5i (0.465 g, 1.25 mmol), 32 (0.156 g, 1.0 mmol), 
and triethylammonium fluoride (0.242 g, 1.5 mmol), 33l was as a 
colourless viscous oil (0.197 g, 56%). Reaction time: 14 h (40 
°C). 1H NMR (250 MHz, CDCl3):  = 0.82 (t, 3J = 6.3 Hz, 3 H, 
CH2(CH2)6CH3), 1.18 (m, 12 H, CH2(CH2)6CH3), 3.63 (t, 3J = 
5.8 Hz, 2 H, CH2(CH2)6CH3), 3.69 (s, 3 H, COOCH3), 3.79 (s, 3 H, CH2COOCH3), 3.86 (s, 2 
H, CH2COOCH3), 6.08 (s, 1 H, CHAr), 6.92 (s, 1 H, OHAr), 11.16 (s, 1 H, OHAr). 13C NMR 
(75 MHz, CDCl3):  = 14.0 ((CH2)7CH3), 22.5, 26.0, 29.2, 29.4, 29.7, 29.8, 31.8 ((CH2)5CH3), 
36.7 (CH2COOCH3), 51.7 (COOCH3), 52.1 (CH2COOCH3), 102.8 (CHAr), 105.2, 123.3, 
134.6 (CAr), 160.1, 162.3 (COHAr), 171.0 (COOCH3), 173.5 (CH2COOCH3). IR (neat, cm-1): 
	~  = 3281 (w), 2923 (w), 2847 (w), 1701 (m), 1651 (m), 1592 (m), 1438 (w), 1329 (m), 1253 
(s), 1194 (s), 1152 (s), 1096 (w), 971 (m), 841 (m), 673 (m). GC-MS (EI, 70 eV): m/z (%) = 
352 ([M+], 43), 321 (15), 279 (5), 253 (98), 221 (100), 189 (14), 163 (13). HRMS (EI): Calcd. 
for C19H28O6: 352.18804; found: 352.18813. 
 
Methyl 4,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-3-phenoxy-benzoate (33o).  
Starting with 5j (0.630 g, 1.8 mmol), 32 (0.225 g, 1.4 mmol), 
and triethylammonium fluoride (0.348 g, 2.2 mmol), 33o was 
isolated as a yellow viscous oil (0.278 g, 58%). Reaction time: 
18 h (40 °C). 1H NMR (250 MHz, CDCl3):  = 3.48 (s, 3 H, 
COOCH3), 3.78 (s, 2 H, CH2COOCH3), 3.79 (s, 3 H, 
CH2COOCH3), 6.54 (s(br), 1 H, CHAr), 6.786.82 (m, 3 H, 
CHPh), 6.977.00 (m, 1 H, CHPh), 7.177.20 (m, 1 H, CHPh), 
7.24 (s(br), 1 H, OHAr), 11.45 (s(br), 1 H, OHAr). 13C NMR (62 MHz, CDCl3):  = 34.2 
(CH2COOCH3), 51.8 (COOCH3), 51.9 (CH2COOCH3), 103.9 (CHAr), 105.4 (CAr), 114.9 
(2CHPh), 123.1 (CHPh), 129.9 (2CHPh), 130.4, 133.9 (CAr), 154.8 (CPh), 157.1, 162.4 (COHAr), 
170.7 (COOCH3), 171.2 (CH2COOCH3). IR (neat, cm-1): 	
~  = 3350 (w), 2952 (w), 1734 (m), 
1658 (m), 1589 (m), 1489 (m), 1436 (m), 1329 (m), 1154 (s), 1022 (m), 978 (m), 750 (s), 688 
(s), 540 (m). MS (EI, 70 eV): m/z (%) = 332 ([M+], 100), 300 (70), 268 (43), 240 (84), 212 
(32), 191 (16), 171 (13), 109 (12), 77 (17), 69 (33). HRMS (EI): calcd. for C17H16O7: 













Methyl 4,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-3-(2-methyl-phenoxy)benzoate (33p). 
Starting with 5l (0.657 g, 1.8 mmol), 32 (0.225 g, 1.4 mmol), and 
triethylammonium fluoride (0.348 g, 2.2 mmol), 33p was 
isolated as a yellow viscous oil (0.249 g, 50%). Reaction time: 
17 h (40 °C). 1H NMR (250 MHz, CDCl3):  = 2.28 (s, 3 H, 
CH3Tol), 3.42 (s, 3 H, COOCH3), 3.71 (s, 2 H, CH2COOCH3), 
3.72 (s, 2 H, CH2COOCH3), 6.02 (s(br), 1 H, OHAr), 6.32 (d, 3J 
= 6.8 Hz, 1 H, CHTol), 6.49 (s, 1 H, CHAr), 6.806.86 (m, 1 H, 
CHTol), 7.067.09 (m, 2 H, CHTol), 11.38 (s(br), 1 H, OHAr). 13C NMR (62 MHz, CDCl3):  = 
16.1 (CH3Tol), 34.1 (CH2COOCH3), 51.7 (COOCH3), 51.9 (CH2COOCH3), 103.8 (CHAr), 
105.3 (CAr), 112.4, 122.6 (CHTol), 126.0 (CAr), 127.1 (CTol), 130.1, 131.4 (CHTol), 134.2 
(CTol), 154.8 (CAr), 155.2, 162.2 (COHAr), 170.7 (COOCH3), 171.2 (CH2COOCH3). IR (neat, 
cm-1): 	~  = 3368 (w), 2952 (w), 1735 (s), 1658 (m), 1592 (m), 1489 (m), 1435 (m), 1329 (m), 
1222 (s), 1187 (s), 1018 (m), 983 (m), 844 (m), 750 (s). MS (EI, 70 eV): m/z (%) = 346 ([M+], 
100), 314 (56), 282 (22), 271 (44), 254 (42), 226 (13), 193 (29), 105 (8), 91 (21). HRMS (EI): 
calcd. for C18H18O7: 346.10470; found: 346.10437. 
 
Methyl 4,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-3-(3-methyl-phenoxy)benzoate (33q). 
Starting with 5k (0.951 g, 2.5 mmol), 32 (0.312 g, 2.0 mmol), and 
triethylammonium fluoride (0.242 g, 3.0 mmol), 33q was isolated 
as a slightly yellow solid  0.336 g, 48%), m.p = 130133 °C. 
Reaction time: 14 h (40 °C). 1H NMR (250 MHz, CDCl3):  = 
2.15 (s, 3 H, CH3Tol), 3.43 (s, 3 H, COOCH3), 3.71 (s, 3 H, 
CH3COOCH), 3.73 (s, 2 H, CH2COOCH3), 6.14 (s(br), 1 H, 
OHAr), 6.47 (s, 1 H, CHAr), 6.506.54 (m, 2 H, CHTol), 6.72 (d, 3J 
= 7.6 Hz, 1 H, CHTol), 7.01 (d, 3J = 8.4 Hz, 1 H, CHTol), 11.39 (s(br), 1 H, OHAr). 13C NMR 
(62 MHz, CDCl3):  = 21.3 (CH3Tol), 34.1 (CH2COOCH3), 51.7 (COOCH3), 51.8 
(CH2COOCH3), 103.8 (CHAr), 105.1 (CAr), 111.8, 115.4, 123.7, 129.5 (CHTol), 130.3 
(CCH3Tol), 134.1, 140.1 (CAr), 154.9 (CTol), 157.1, 162.2 (COHAr), 170.7 (COOCH3), 171.4 
(CH2COOCH3). IR (neat, cm-1): 	
~  = 3239 (w), 2948 (w), 1700 (s), 1655 (m), 1595 (m), 1438 
(m), 1328 (m), 1228 (s), 1180 (s), 1105 (m), 983 (m), 844 (m), 770 (s). GC-MS (EI, 70 eV): 
m/z (%) = 346 ([M+], 100), 314 (51), 282 (35), 271 (51), 254 (39), 226 (19), 191 (18), 157 (4), 













Methyl 4,6-dihydroxy-2-(2-methoxy-2-oxoethyl)-3-(4-methylphenoxy)benzoate (33r). 
Starting with 5m (0.951 g, 2.5 mmol), 32 (0.312 g, 2.0 mmol), 
and triethylammonium fluoride (0.483 g, 3.0 mmol), 33r was as 
a brown solid (0.380 g, 54 %), m.p. = 116124 °C. Reaction 
time: 14 h (40 °C). 1H NMR (250 MHz, CD3OD):  = 2.15 (s, 3 
H, CH3Tol), 3.46 (s, 3 H, COOCH3), 3.73 (s, 3 H, CH2COOCH3), 
3.78 (s, 2 H, CH2COOCH3), 4.77 (s(br), 1 H, OHAr), 6.37 (s, 1 H, 
CHAr), 6.59 (d, 3J = 8.5 Hz, 2 H, CHTol), 6.93 (d, 3J = 8.4 Hz, 2 
H, CHTol). 13C NMR (62 MHz, CD3OD):  = 20.5 (CH3Tol), 34.6 
(CH2COOCH3), 52.3 (COOCH3), 52.5 (CH2COOCH3), 104.4 (CHAr), 105.1 (CAr), 115.7 
(2CHTol), 130.7 (2CHTol), 132.0 (CAr), 132.2 (CCH3Tol), 136.4 (CAr), 157.3 (COHAr), 157.8 
(CTol), 162.8 (COHAr), 172.1 (COOCH3), 173.5 (CH2COOCH3). IR (neat, cm-1): 	
~  = 3268 
(w), 2434 (w), 1702 (m), 1645 (m), 1610 (m), 1507 (m), 1440 (m), 1341 (m), 1217 (s), 1102 
(m), 990 (m), 821 (s), 773 (m). GC-MS (EI, 70 eV): m/z (%) = 346 ([M+], 100), 314 (30), 282 
(32), 271 (49), 254 (43), 239 (35), 239 (35), 191 (15), 157 (5), 129 (9), 91 (16), 69 (21). 
HRMS (EI): Calcd. for C18H18O7: 346.10470; found: 346.10523. 
 
Methyl 3-chloro-4-hydroxy-6-(2-methoxy-2-oxoethyl)-2-methylbenzoate (33y).  
Starting with 5p (0.349 g, 1.25 mmol), 32 (0.156 g, 1.0 mmol), 
and triethylammonium fluoride (0.242 g, 1.5 mmol), 33y was 
isolated as a reddish viscous oil (0.114 g, 42%). Reaction time: 
14 h (40 °C). 1H NMR (250 MHz, CDCl3):  = 2.31 (s, 3 H, 
CH3), 3.59 (s, 2 H, CH2COOCH3), 3.61 (s, 3 H, COOCH3), 3.62 (s, 1 H, OHAr), 3.66 (s, 3 H, 
CH2COOCH3), 6.32 (s, 1 H, CHAr). 13C NMR (62 MHz, CDCl3):  = 26.3 (CH3), 35.6 
(CH2COOCH3), 51.7 (COOCH3), 51.8 (CH2COOCH3), 82.7(CAr), 124.3 (CHAr), 144.4, 165.2, 
165.2 (CAr), 170.1 (COHAr), 198.9 (2CO). IR (neat, cm-1): 	
~  = 3002 (w), 2954 (w), 1731 (s), 
1649 (w), 1435 (m), 1356 (m), 1327 (m), 1252 (m), 1166 (s), 1012 (m), 859 (w). GC-MS (EI, 
70 eV): m/z (%) = 274 ([M+], 37Cl, 9), 272 ([M+], 35Cl, 25), 242 (37Cl, 40), 240 (35Cl, 100), 
211 (37Cl, 15), 209 (35Cl, 46), 197 (5), 180 (6), 154 (4), 125 (5), 89 (11), 77 (6). HRMS (EI): 














Methyl 4-hydroxy-6-(2-methoxy-2-oxoethyl)-2-methyl-3-phenoxybenzoate (33z). Starting 
with 5t (0.761 g, 2.0 mmol), 32 (0.251 g, 1.6 mmol), and 
triethylammonium fluoride (0.241 g, 1.5 mmol), 33z was 
isolated as a red viscous oil (0.359 g, 48%). Reaction 
time: 14 h (40 °C). 1H NMR (250 MHz, CDCl3):  = 1.27 
(t, 3J = 6.9 Hz, 3 H, OCH2CH3), 2.07 (s, 3 H, CH3Ar), 3.57 (s, 3 H, COOCH3), 3.61 (s, 3 H, 
CH2COOCH3), 3.71 (s, 2 H, CH2COOCH3), 3.86 (q, 3J = 6.9 Hz, 2 H, OCH2CH3), 6.38 (s, 1 
H, CHAr), 6.68 (m, 2 H, CHPh), 6.70 (m, 2 H, CHPh), 6.78 (s, 1 H, OHAr). 13C NMR (62 MHz, 
CDCl3):  = 14.7 (CH3Ar), 25.9 (OCH2CH3), 34.2 (CH2COOCH3), 51.5 (COOCH3), 51.9 
(CH2COOCH3), 63.7 (OCH2CH3), 95.2 (CAr), 115.3 (2CHPh), 115.8 (CAr), 117.3 (2CHPh), 
127.5 (CHAr), 145.1, 147.8 (CAr), 150.3, 154.5 (CPh), 165.5 (COHAr), 170.4 (COOCH3), 201.5 
(CH2COOCH3). IR (neat, cm-1): 	
~  = 3434 (w), 2953 (w), 1735 (s), 1502 (s), 1435 (m), 1194 
(s), 1140 (m), 1044 (m), 825 (m), 774 (w). GC-MS (EI, 70 eV): m/z (%) = 374 ([M+], 46), 342 
(81), 313 (100), 299 (3), 271 (7), 253 (6). HRMS (EI): Calcd. for C20H22O7: 374.13600; 
found: 374.13532. 
 
General Procedure for the synthesis of 2-(Arylsulfonyl)-4-hydroxypyridines 35:  
To the arylsulfonyl cyanide 34 (1.0 eq) was added dropwise the 1,3-bis-silyl enol ether 5 (2.0-
2.5 eq) at -78 °C. The mixture was warmed up to 4560 °C during 4896 h with stirring. To 
the mixture was added the solution of ammonium chloride (1M, 20 mL) and the organic and 
the aqueous layer were separated. The latter was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were dried (Na2SO4), filtered and the filtrate was concentrated in 
vacuo. The residue was purifed by chromatography (silica gel, n-heptane / EtOAc) to give 35. 
 
3-Chloro-2-ethoxy-6-(phenylsulfonyl)pyridin-4-ol (35a). 
Starting with  34a  (0.167 g, 1.0 mmol) and 5d 1 (0.617 g, 2.0 
mmol), 35a was isolated as yellow viscous oil (0.175 g, 56%); 
Reaction conditions: 48 h, 45 °C. 1H NMR (250 MHz, CDCl3):  
= 1.22 (t, 3J = 7.1 Hz, 3 H, OCH2CH3), 4.27  (q, 3J = 7.1 Hz, 2 H, 
OCH2CH3), 7.19 (s(br), 1 H, OHHeter), 7.447.49 (m, 2 H, CHPh), 7.52 (m, 1 H, CHPh), 7.55 (s, 
1 H, CHHeter), 7.96 (dd, 3J = 8.4 Hz, 4J = 1.5 Hz, 2 H, CHPh). 13C NMR (75 MHz, CDCl3):  = 
14.2 (OCH2CH3Heter),  64.1 (OCH2CH3), 105.6 (CHHeter), 106.9 (CHeter), 128.9 (2CHPh), 129.0 
(2CHPh), 133.8 (CHPh), 138.4 (CPh), 153.6 (COHHeter), 159.9, 160.4 (CHeter). IR (Neat, cm-1): 












1159 (m), 1093 (s), 1076 (s), 840 (s), 725 (s), 592 (s). HRMS (ESI): Calcd. for C13H12ClNO4S 




Starting with 34a (0.167 g, 1.0 mmol) and 5e 1 (0.589 g, 2.0 
mmol), 35b was isolated as red solid (0.179 g, 59%); Reaction 
conditions: 48 h, 45 °C. 1H NMR (250 MHz, CDCl3):  = 1.22 (t, 
3J = 7.1 Hz, 3 H, OCH2CH3), 4.26  (q, 3J = 7.0 Hz, 2 H, 
OCH2CH3), 7.19 (s(br), 1 H, OHHeter), 7.43 (m, 1 H, CHHeter), 7.467.50 (m, 2 H, CHPh), 
7.537.56 (m, 1 H, CHPh),  7.95 (dd, 3J = 8.4 Hz, 4J = 1.5 Hz, 2 H, CHPh). 13C NMR (75 MHz, 
CDCl3):  = 14.1 (OCH2CH3), 63.6 (OCH2CH3), 107.8 (CHHeter), 128.9 (2CHPh), 129.0 
(2CHPh), 133.8 (CHPh), 136.8 (d, 1J = 252.4 Hz, CFHeter), 138.4 (CPh), 149.4 (d, 4J = 6.7 Hz, 
CHeter), 151.3 (d, 2J = 10.2 Hz, COHHeter), 153.8 (d, 2J = 9.9 Hz, CHeter). 19F NMR (235 MHz, 
CDCl3): 162.05 (CFHeter). IR (Neat, cm-1): 	
~  = 3354 (w), 1576 (m), 1440 (m), 1353 (m), 
1317 (m), 1149 (s), 1076 (m), 1022 (m), 740 (s), 724 (s), 682 (s), 585 (s). HRMS (ESI): 
Calcd. for C13H12FNO4S ([M+H]+) : 298.05438; found: 298.05413, ([M+Na) : 320.03652; 
found: 320.03633. 
 
3-Ethyl-2-methoxy-6-(phenylsulfonyl)pyridin-4-ol  (35c). 
Starting with  34a (0.188 g, 1.0 mmol) and 5f 1 (0.576 g, 2.0 
mmol), 35c was isolated as yellow viscous oil (0.176 g, 60%); 
Reaction conditions: 48 h, 45 °C. 1H NMR (250 MHz, CD3OD): 
 = 0.97 (t, 3J = 7.9 Hz, 3 H, CH2CH3), 2.46 (q, 3J = 7.7 Hz, 2 H, 
CH2CH3), 3.24 (s, 3 H, OCH3Heter), 6.97 (s, 1 H, CHHeter), 7.327.35 (m, 3 H, CHPh), 7.78 (d, 
3J = 9.8 Hz, 2 H, CHPh). 13C NMR (75 MHz, CD3OD):  = 12.7 (CH2CH3), 17.3 (CH2CH3), 
50.0 (OCH3Heter), 104.9 (CHHeter), 118.1 (CHeter), 129.5 (2CHPh), 130.9 (2CHPh), 137.7 (CHPh), 
146.5 (CPh), 151.5 (COHHeter), 164.7, 165.3 (CHeter). IR (Neat, cm-1): 	
~  = 3417 (w), 2933 (w), 
1726 (m), 1613 (m), 1413 (m), 1319 (s), 1267 (s), 1146 (s), 1083 (s), 904 (w), 812 (m), 674 
(s), 592 (s).  MS (EI, 70 eV): m/z (%) = 293 ([M]+, 100), 229 (96), 186 (8), 160 (14), 139 
(64), 91 (37), 69 (26). HRMS (ESI): Calcd. for C14H15NO4S ([M+H]+) : 294.07946; found: 

















 Starting with 34a (0.167 g, 1.0 mmol) and 5n 1 (0.756 
g, 2.0 mmol), 35d was isolated as yellow viscous oil 
(0.243 g, 61%); Reaction conditions: 48 h, 45 °C. 1H 
NMR (250 MHz, CDCl3):  = 0.99 (t, 3J = 7.0 Hz, 3 H, 
OCH2CH3), 2.14 (s, 6 H, CH3Xyl), 4.16  (q, 3J = 7.0 Hz, 2 H, OCH2CH3), 6.37 (s, 2 H, CH Xyl), 
6.59 (s, 1 H, CHXyl), 6.77 (s(br), 1 H, OHHeterl), 7.457.48 (m, 2 H, CHPh), 7.48 (s, 1 H, 
CHHeter), 7.51 (m, 1 H, CHPh), 7.98 (dd, 3J = 8.5 Hz, 4J = 1.5 Hz, 2 H, CHPh).13C NMR (75 
MHz, CDCl3):  = 12.1 (OCH2CH3),  19.3 (2CH3Xyl), 61.2 (OCH2CH3), 104.8 (CHHeter), 111.1 
(2CHPh), 122.9 (CHXyl), 125.9 (CHeter), 126.9 (2CHPh), 127.1 (2CHXyl), 131.7 (CHPh), 136.7 
(CXyl), 137.5 (CPh), 148.8 (2CXyl), 154.5 (COHHeter), 155.1, 155.6 (CHeter). IR (Neat, cm-1): 	
~  
= 3324 (w), 1592 (s), 1468 (m), 1429 (m), 1305 (m), 1132 (s), 1095 (m), 997 (m), 831 (m), 
724 (s), 679 (s), 594 (s). HRMS (ESI): Calcd. for C21H21NO5S ([M+H]+) : 400.12132; found: 
400.12108, ([M+Na]+) : 422.10299; found: 422.10326. 
 
2-Methoxy-6-(phenylsulfonyl)-3-(phenylthio)pyridin-4-ol (35e). 
 Starting with  34a  (0.167 g, 1.0 mmol) and 5o 1 (0.746 g, 
2.0 mmol), 35e was isolated as yellow solid (0.210 g, 
56%); Reaction conditions: 96 h, 60 °C. 1H NMR (250 
MHz, CDCl3):  = 3.73 (s, 3 H, OCH3Heter), 7.02 (m, 1 H, 
CHPh), 7.05 (m, 1 H, CHPh), 7.15 (m, 2 H, CHPh), 7.18 (m, 2 H, CHPh), 7.45 (s, 1 H, CHHeter), 
7.47 (m, 1 H, CHHeter), 7.50 (s(br), 1 H, OHHeter), 7.547.57 (m, 1 H, CHPh), 8.01 (d, 3J = 6.9 
Hz, 2 H, CHPh ).. 13C NMR (75 MHz, CDCl3):  = 55.1 (OCH3Heter), 104.7 (CHHeter), 125.2 
(CHeter), 127.1 (CHPh), 128.1 (2CHPh), 125.9 (2CHPh), 129.2 (2CHPh), 129.3 (2CHPh), 132.6, 
137.3 (CPh), 133.8 (CHPh), 138.3 (CPh), 157.4 (COHHeter), 164.9, 166.5 (CHeter). IR (Neat, cm-
1): 	~  = 3246 (w), 1625 (m), 1559 (w), 1503 (m), 1445 (m), 1385 (m), 1301 (s), 1142 (s), 
1076 (s), 906 (m), 724 (s), 600 (s). HRMS (ESI): Calcd. for C18H15NO4S2 ([M+H]+) : 





















 Starting with  34b  (0.094 g, 1.0 mmol) and BISY (0.617 g, 
2.0 mmol), 35f was isolated as red viscous oil (0.156 g, 48%); 
Reaction conditions: 48 h, 45 °C. 1H NMR (250 MHz, CDCl3): 
 = 1.25 (t, 3J = 7.8 Hz, 3 H, OCH2CH3), 2.35 (s, 3 H, CH3Tol), 
4.28  (q, 3J = 6.8 Hz, 2 H, OCH2CH3), 7.19 (s, 1 H, CHHeter), 7.24 (d, 3J = 8.1 Hz, 2 H, CHTol), 
7.42 (s(br), 1 H, OHHeterl), 7.84 (d, 3J = 8.2 Hz, 2 H, CHTol).13C NMR (75 MHz, CDCl3):  = 
14.2 (OCH2CH3Heter),  21.6 (CH3Tol), 64.0 (OCH2CH3), 105.4 (CHHeter), 106.7 (CHeter), 129.1 
(2CHTol), 129.6 (2CHTol), 135.5, 144.8 (CTol), 153.9 (COHHeter), 159.8, 160.3 (CHeter). IR 
(Neat, cm-1): 	~  = 2952 (w), 1594 (m), 1415 (m), 1338 (m), 1252 (m), 1115 (s), 1078 (s), 840 
(s), 676 (s), 589 (s). MS (CI, Positive, 70 eV): m/z (%) = 330 ([M+1]+, 37Cl, 35), 328 ([M+1]+, 
35Cl, 100), 299 (4), 279 (2), 257 (5), 233 (3), 219 (3), 193 (3), 177 (4), 141 (5), 125 (5), 81 
(37Cl, 11), 79 (35Cl, 97), 71 (17). HRMS (ESI): Calcd. for C14H14ClNO4S ([M+H]+, 35Cl) : 
328.04048; found: 328.04058, ([M+Na]+, 35Cl) : 350.02243; found: 350.0039. 
 
2-ethoxy-3-fluoro-6-tosylpyridin-4-ol (35g). 
 Starting with 34b (0.188 g, 1.0 mmol) and 5e (0.589 g, 2.0 
mmol), 35g was isolated as red viscous oil  (0.178 g, 54%); 
Reaction conditions: 48 h, 45 °C. 1H NMR (250 MHz, CDCl3): 
 = 1.24 (t, 3J = 6.8 Hz, 3 H, OCH2CH3), 2.35 (s, 3 H, CH3Tol), 
4.27  (q, 3J = 6.8 Hz, 2 H, OCH2CH3), 7.23 (s(br), 1 H, OHHeter), 7.27 (d, 3 J = 8.1 Hz, 2 H, 
CHTol), 7.46 (dH, F, 4J = 5.0 Hz, 1 H, CHHeter), 7.82 (d, 3J = 8.5 Hz, 2 H, CHTol). 13C NMR (75 
MHz, CDCl3):  = 14.2 (OCH2CH3), 21.6 (CH3Tol), 63.5 (OCH2CH3), 107.6 (CHHeter), 128.9 
(2CHTol), 129.6 (2CHTol), 135.5 (CTol), 137.8 (d, 1J = 251.9 Hz, CFHeter), 144.8 (CTol), 149.7 
(d, 4J = 6.2 Hz, CHeter), 151.3 (d, 2J = 9.9 Hz, COHHeter), 153.7 (d, 2J = 9.9 Hz, CHeter). 19F 
NMR (235 MHz, CDCl3): 162.63 (CFHeter). IR (Neat, cm-1): 	
~  = 3255 (w), 1624 (m), 1505 
(m), 1425 (m), 1383 (m), 1261 (s), 1140 (m), 1084 (m), 811 (m), 686 (m), 600 (m). MS (CI, 
Positive, 70 eV): m/z (%) = 312 ([M+1]+, 100), 247 (8), 219 (6), 177 (3), 119 (11), 69 (7). 
HRMS (ESI): Calcd. for C14H14FNO4S ([M+H]+) : 312.07003; found: 312.06950, ([M+Na]+) : 



















 Starting with 34b (0.188 g, 1.0 mmol) and 5n (0.757 
g, 2.0 mmol), 35h was isolated as red viscous oil  
(0.253 g, 62%); Reaction conditions: 48 h, 45 °C. 1H 
NMR (250 MHz, CD3OD):  = 0.97 (t, 3J = 7.3 Hz, 
3 H, OCH2CH3), 2.29 (s, 6 H, CH3Xyl), 2.52 (s, 3 H, CH3Tol), 4.28  (q, 3J = 7.4 Hz, 2 H, 
OCH2CH3), 6.54 (s, 2 H, CHXyl), 6.72 (s, 1 H, CHXyl), 7.26 (s, 1 H, CHHeterl), 7.51 (d, 3J = 8.0 
Hz, 2 H, CHTol), 8.01 (d, 3J = 8.3 Hz, 2 H, CHTol).13C NMR (75 MHz, CD3OD):  = 14.2 
(OCH2CH3Heter), 21.3 (2CH3Xyl), 21.4 (CH3Tol), 62.7 (OCH2CH3Heter), 106.7 (CHHeter), 113.8 
(2CHXyl), 124.9 (CHXyl), 129.6 (2CHTol), 131.0 (2CHTol),  140.3 (CTol), 143.3 (2CXyl), 149.6 
(CTol), 158.4 (CHeter), 159.7 (CXyl), 159.9, 160.4 (CHeter), 170.8 (COHHeter). IR (Neat, cm-1): 	
~  
= 3248 (w), 2952 (w), 1632 (s), 1436 (m), 1309 (m), 1178 (s), 1092 (m), 1035 (m), 952 (w), 
805 (s), 696 (s). HRMS (ESI): Calcd. for C20H19NO4S ([M+1]+) : 414.13784; found: 
414.13769, ([M+Na]+) : 436.47982; found: 436.47842. 
 
2-Methy-6-(phenylsulfonyl)-3-(phenylthio)pyridin-4-ol (35i). 
 Starting with 34a (0.167 g, 1.0 mmol) and 5q 1 (0.704 g, 
2.0 mmol), 35i was isolated as yellow viscous oil (0.189 g, 
53%); Reaction conditions: 96 h, 60 °C. 1H NMR (250 
MHz, CDCl3):  = 2.46 (s, 3 H, CH3Heter), 6.89 (dd, 3J = 8.2 
Hz, 4J = 1.9 Hz, 2 H, CHTol), 7.10(m, 3 H, CHTol), 7.38 (s(br), 1 H, OHHeter), 7.47 (m, 3 H, 
CHTol), 7.59 (s, 1 H, CHHeter), 7.95 (dd, 3J = 8.4 Hz, 4J = 1.5 Hz, 2 H, CHTol). 13C NMR (62 
MHz, CDCl3):  = 20.4 (CH3Heter), 108.17 (CHHeter), 117.7 (CPh), 126.1 (CHeter), 127.1 
(2CHPh), 129.1 (2CHPh), 129.6 (2CHPh), 129.9 (2CHPh), 133.9 (2CHPh),  138.5 (CPh), 159.1, 
165.5 (CHeter), 165.6 (COHHeter). IR (Neat, cm-1): 	
~  = 3249 (w), 1562 (m), 1446 (m), 1397 
(m), 1307 (m), 1156 (s), 1082 (m), 905 (s), 721 (s), 684 (m), 601 (s). GC-MS (EI, 70 eV): m/z 
(%) = 357 ([M]+, 4), 292 (100), 252 (4), 216 (6), 147 (6), 109 (24), 77 (19), 65 (7), 51 (10). 



















 Starting with  34a (0.167 g, 1.0 mmol) and 5r 1 (0.733 g, 
2.0 mmol), 35j was isolated as yellow viscous oil  
(0.296 g, 79%); Reaction conditions: 96 h, 60 °C. 1H NMR 
(250 MHz, CDCl3):  = 2.20 (s, 3 H, CH3Tol), 2.48 (s, 3 H, 
CH3, CH3Heter), 6.82 (d, 3J = 8.2 Hz, 2 H, CHTol), 6.98 (d, 3J = 8.1 Hz, 1 H, CHPh), 7.45 (m, 1 
H, CHTol), 7.48 (m, 1 H, CHPh), 7.55 (s(br), 1 H, OHHeter), 7.63 (m, 1 H, CHHeter), 7.52 (m, 1 
H, CHTol), 8.00 (dd, 3J = 8.1 Hz, 4J = 1.5 Hz, 1 H, CHPh).13C NMR (75 MHz, CDCl3):  = 
18.9 (CH3Tol), 21.9 (CH3Heter), 105.9 (CHHeter), 113.2, 116.3 (CHeter), 126.0 (2CHPh), 126.7 
(CHTol), 127.1 (2CHTol), 127.2 (CHTol), 127.9 (CPh), 128.4 (2CHPh), 131.8 (CHPh), 135.5 
(CTol), 136.6 (CTol), 157.0 (COHHeter), 163.4 (CHeter). IR (Neat, cm-1): 	
~  = 3377 (w), 2921 (w), 
1561 (m), 1491 (m), 1446 (m), 1396 (m), 1306 (m), 1155 (s), 1081 (m), 1015 (w), 905 (s), 
803 (m), 722 (s), 684 (m), 600 (s). GC-MS (CI, Positive, 70 eV): m/z (%) = 371 ([M]+, 14), 
306 (100), 292 (5), 274 (4), 216 (5), 186 (3), 135 (6), 123 (27), 91 (8), 77 (24), 65 (4), 45 (7). 
HRMS (EI): Calcd. for C19H17NO3S2 ([M]+) : 371.06444; found: 371. 06407. 
 
2-methyl-3-(m-tolyloxy)-6-tosylpyridin-4-ol  (35k). 
Starting with  34b  (0.141 g, 0.750 mmol) and 5u (0.525 
g, 1.5 mmol), 35k was isolated as colourless solid  
(0.240 g, 58%); Reaction conditions: 48 h, 45 °C. 1H 
NMR (250 MHz, CDCl3):  = 2.16 (s, 3 H, CH3Tol), 
2.18 (s, 3 H, CH3Tol), 2.32 (s, 3 H, CH3Heter), 6.47 (m, 1 
H, CHTol), 6.53 (s, 1 H, CHHeter), 6.75 (d, 3J = 7.3 Hz, 1 H, CHTol), 7.007.06 (m, 2 H, CHTol), 
7.21 (d, 3J = 8.2 Hz, 2 H, CHTol), 7.62 (s(br), 1 H, OHHeter), 7.82 (d, 3J = 8.2 Hz, 2 H, 
CHTol).13C NMR (75 MHz, CDCl3):  = 17.1 (CH3Heter),  19.4, 19.7 (CH3Tol), 108.9 (CHHeter), 
109.9, 113.6, 121.9 (CHTol), 126.9 (2CHTol), 127.5 (CHTol), 127.8 (2CHTol), 133.9, 137.8 
(CTol), 138.2 (CHeter), 142.9 (CTol), 152.2 (CHeter), 152.6 (CTol), 154.3 (COHHeter), 179.3 (CHeter). 
GC-MS (CI, Positive, 70 eV): m/z (%) = 370 ([M+1]+, 100), 305 (58), 291 (4), 232 (8), 69 
(24). HRMS (ESI): Calcd. for C20H19NO4S ([M+H]+) : 370.11076; found: 370.11067, 

















Starting with  34b  (0.141 g, 0.75 mmol) and 5v 
(0.525 g, 1.75 mmol), 35l was isolated as yellow 
solid  (0.210 g, 57%); Reaction conditions: 48 h, 45 
°C. 1H NMR (250 MHz, CDCl3):  = 2.17 (s, 3 H, 
CH3Tol), 2.21 (s, 3 H, CH3Tol), 2.34 (s, 3 H, CH3Heter), 6.61 (d, 3J = 8.5 Hz, 2 H, CHTol), 6.98 
(d, 3J = 8.3 Hz, 2 H, CHTol), 7.19 (s, 1 H, CHHeter), 7.24 (d, 3J = 8.1 Hz, 2 H, CHTol), 7.64 
(s(br), 1 H, OHHeter), 7.86 (d, 3J = 8.2 Hz, 2 H, CHTol). 13C NMR (75 MHz, CDCl3):  = 19.1, 
21.6 (CH3Tol), 30.9 (CH3Heter), 110.3 (CHHeter), 113.8 (CTol), 114.7 (2CHTol), 128.9 (2CHTol), 
129.7 (2CHTol), 129.9 (CTol), 130.4 (2CHTol), 130.7 (CTol), 132.7, 136.0, 139.6 (CHeter), 144.7 
(CTol), 154.7 (COHHeter). MS (EI, 70 eV): m/z (%) = 369 ([M]+, 1), 320 (1), 305 (100), 288 
(10), 214 (13), 186 (9), 139 (8), 107 (9), 91 (45), 65 (16). HRMS (ESI): Calcd. for 




 Starting with 34b (0.188 g, 1.0 mmol) and 5q (0.705 g, 
2.0 mmol), 35m was isolated as colorless oil (0.240 g, 
64%); Reaction conditions: 96 h, 60 °C. 1H NMR (250 
MHz, CDCl3):  = 2.27 (s, 3 H, CH3Tol), 2.41 (s, 3 H, 
CH3Heter), 6.80 (d, 3J = 8.2 Hz, 2 H, CHTol), 7.027.06 
(m, 3 H, CHPh), 7.09 (s(br), 1 H, OHHeter), 7.18 (d, 3J = 8.0 Hz, 2 H, CHPh), 7.55 (s, 1 H, 
CHHeter), 7.82 (d, 3J = 8.3 Hz, 2 H, CHTol). 13C NMR (62 MHz, CDCl3):  =  21.6 (CH3Tol), 
23.7 (CH3Heter), 108.1 (CHHeter), 117.7 (CPh), 126.9 (CHPh), 127.3 (2CHTol), 129.1 (2CHPh), 
129.5 (2CHPh), 129.8 (2CHTol), 132.7 (CTol), 135.5 (CHeter), 145.1 (CTol), 159.2 (COHHeter), 
165.3, 165.8 (CHeter). IR (Neat, cm-1): 	
~  = 3057 (w), 1552 (w), 1396 (m), 1316 (m), 1152 (s), 
1081 (s), 905 (m), 728 (s), 678 (s), 590 (s). GC-MS (EI, 70 eV): m/z (%) = 371 ([M]+, 1), 306 
(100), 292 (3), 266 (6), 230 (4), 214 (3), 190 (4), 147 (5), 109 (22), 91 (17), 77 (6), 65 (14). 


















 Starting with  34b  (0.188 g, 1.0 mmol) and 5s 
(0.733 g, 2.0 mmol), 35n was isolated as colorless 
oil (0.200 g, 51%); Reaction conditions: 96 h, 60 °C. 
1H NMR (250 MHz, CDCl3):  = 2.17 (s, 3 H, 
CH3Tol), 2.31 (s, 3 H, CH3Tol), 2.45 (s, 3 H, CH3Heter), 6.85 (d, 3J = 8.2 Hz, 2 H, CHTol), 6.94 
(d, 3J = 8.1 Hz, 2 H, CHTol), 7.22 (d, 3J = 8.0 Hz, 2 H, CHTol), 7.60 (s, 1 H, CHHeter), 7.76 
(s(br), 1 H, OHHeter), 7.85 (d, 3J = 8.2 Hz, 2 H, CHTol). 13C NMR (62 MHz, CDCl3):  = 20.9, 
21.6 (CH3Tol), 23.9 (CH3Heter), 107.7 (CHHeter), 118.0 (CTol), 127.9 (2CHTol), 128.8 (2CHTol), 
129.1 (2CHTol), 129.7 (2CHTol), 135.6, 137.3 (CTol), 130.7 (CTol), 144.8, 159.5, 165.1 (CHeter), 
165.4 (COHHeter). IR (Neat, cm-1): 	
~  = 3279 (w), 1583 (m), 1546 (m), 1490 (m), 1393 (m), 
1306 (m), 1154 (s), 1124 (s), 1076 (s), 964 (w), 799 (s), 680 (s). MS (EI, 70 eV): m/z (%) = 
385 ([M]+, 13), 320 (100), 306 (7), 280 (11), 228 (11), 160 (6), 135 (10), 123 (45), 91 (38), 79 
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Data for X-Ray Crystal Structures 
 
Data for compound 16b (chapter 1): 
 
Table 1.  Crystal data and structure refinement for ah216. 
Identification code  ah216 
Empirical formula  C16 H13 F3 O3 
Formula weight  310.26 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Orthorhombic 
Space group (H.-M.)  Pbca  
Space group (Hall)  -P 2ac 2ab 
Unit cell dimensions a = 8.1866(6) Å = 90°. 
 b = 7.9746(6) Å = 90°. 
 c = 42.350(3) Å 
 = 90°. 
Volume 2764.8(3) Å3 
Z 8 
Density (calculated) 1.491 Mg/m3 
Absorption coefficient 0.129 mm-1 
F(000) 1280 
Crystal size 0.68 x 0.61 x 0.31 mm3 
 range for data collection 2.67 to 30.00°. 
Index ranges -9h11, -11k9, -27l59 
Reflections collected 17499 
Independent reflections 4026 [R(int) = 0.0285] 
Completeness to  = 30.00° 99.8 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9612 and 0.9177 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4026 / 0 / 206 
Goodness-of-fit on F2 1.134 
Final R indices [I>2(I)] R1 = 0.0616, wR2 = 0.1402 
R indices (all data) R1 = 0.0682, wR2 = 0.1437 
Extinction coefficient 0.0010(7) 
Largest diff. peak and hole 0.411 and -0.403 e.Å-3 
 
Data for compound 16f (chapter 1): 
 







_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum 
 'C13 H9 F3 O3 S' 
_chemical_formula_weight          302.26 
  
# CRYSTAL DATA 
  
_symmetry_cell_setting            orthorhombic 
_symmetry_space_group_name_H-M    'P n a 2 1' 
_symmetry_space_group_name_Hall   'P 2c -2n' 




 'x, y, z' 
 '-x, -y, z+1/2' 
 'x+1/2, -y+1/2, z' 
 '-x+1/2, y+1/2, z+1/2' 
  
_cell_length_a                    13.840(3) 
_cell_length_b                    4.9310(10) 
_cell_length_c                    35.860(7) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  90.00 
_cell_angle_gamma                 90.00 
_cell_volume                      2447.3(9) 
_cell_formula_units_Z             8 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     2049 
_cell_measurement_theta_min       5.978 
_cell_measurement_theta_max       44.283 
  
_exptl_crystal_description        needle 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.90 
_exptl_crystal_size_mid           0.09 
_exptl_crystal_size_min           0.06 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.641 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              1232 
_exptl_absorpt_coefficient_mu     0.307 
_exptl_absorpt_correction_type    'multi-scan' 
_exptl_absorpt_correction_T_min   0.7696 
_exptl_absorpt_correction_T_max   0.9818 
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_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 
 
Data for compound 16k (chapter 1): 
 






_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum 
 'C13 H9 F3 O4' 








 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'F'  'F'   0.0171   0.0103 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
  
# CRYSTAL DATA  
 
_symmetry_cell_setting            orthorhombic 
_symmetry_space_group_name_H-M    'P n a 2 1' 
_symmetry_space_group_name_Hall   'P 2c -2n' 




 'x, y, z' 
 '-x, -y, z+1/2' 
 'x+1/2, -y+1/2, z' 
 '-x+1/2, y+1/2, z+1/2' 
  
_cell_length_a                    13.851(3) 
_cell_length_b                    4.8284(10) 
_cell_length_c                    35.183(7) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  90.00 
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_cell_angle_gamma                 90.00 
_cell_volume                      2353.0(8) 
_cell_formula_units_Z             8 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     1347 
_cell_measurement_theta_min       6.001 
_cell_measurement_theta_max       45.365 
  
_exptl_crystal_description        needle 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.81 
_exptl_crystal_size_mid           0.09 
_exptl_crystal_size_min           0.05 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.616 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              1168 
_exptl_absorpt_coefficient_mu     0.149 
_exptl_absorpt_correction_type    'multi-scan' 
_exptl_absorpt_correction_T_min   0.8885 
_exptl_absorpt_correction_T_max   0.9926 
_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 
 
Data for compound 21c (chapter 2): 
 
Table 1.  Crystal data and structure refinement for ah54. 
Identification code  ah54 
Empirical formula  C16 H14 O3 
Formula weight  254.27 
Temperature  173(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group (H.-M.)  P21/c   
Space group (Hall)  -P 2ybc  
Unit cell dimensions a = 12.3408(2) Å = 90°. 
 b = 12.8642(2) Å = 98.0890(10)°. 
 c = 7.74600(10) Å 
 = 90°. 
Volume 1217.48(3) Å3 
Z 4 
Density (calculated) 1.387 Mg/m3 
Absorption coefficient 0.095 mm-1 
F(000) 536 
Crystal size 0.43 x 0.25 x 0.21 mm3 
 range for data collection 3.09 to 29.00°. 
Index ranges -16h16, -17k17, -10l10 
 144
Reflections collected 16584 
Independent reflections 3176 [R(int) = 0.0264] 
Completeness to  = 29.00° 97.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9803 and 0.9601 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3176 / 0 / 178 
Goodness-of-fit on F2 1.030 
Final R indices [I>2(I)] R1 = 0.0400, wR2 = 0.1088 
R indices (all data) R1 = 0.0508, wR2 = 0.1219 
Largest diff. peak and hole 0.286 and -0.169 e.Å-3 
 
 Data for compound 26m (chapter 3):  
 
Table 1.  Crystal data and structure refinement for FO3175. 
Identification code  FO3175 
Empirical formula  C16 H14 Cl F O3 
Formula weight  308.72 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P2(1)/n 
Unit cell dimensions a = 9.2577(3) Å = 90°. 
 b = 11.9231(5) Å = 107.529(3)°. 
 c = 13.5991(6) Å 
 = 90°. 
Volume 1431.37(10) Å3 
Z 4 
Density (calculated) 1.433 Mg/m3 
Absorption coefficient 0.285 mm-1 
F(000) 640 
Crystal size 0.05 x 0.04 x 0.04 mm3 
Theta range for data collection 2.92 to 27.49°. 
Index ranges -12<=h<=11, -15<=k<=15, -15<=l<=17 
Reflections collected 9370 
Independent reflections 3267 [R(int) = 0.0401] 
Completeness to theta = 27.49° 99.4 %  
Absorption correction NONE 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3267 / 0 / 197 
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Goodness-of-fit on F2 1.016 
Final R indices [I>2sigma(I)] R1 = 0.0422, wR2 = 0.1017 
R indices (all data) R1 = 0.0717, wR2 = 0.1160 
Largest diff. peak and hole 0.224 and -0.279 e.Å-3 
 
Data for compound 26n (chapter 3): 
 
Table 1.  Crystal data and structure refinement for fo3171. 
Identification code  FO3171 
Empirical formula  C18 H18 Cl F O3 
Formula weight  336.77 
Temperature  183(2) K 
Wavelength  0.71073 Å 
Crystal system  Triclinic 
Space group  P-1 
Unit cell dimensions a = 7.5963(6) Å = 81.374(4)°. 
 b = 9.5216(10) Å = 89.582(5)°. 
 c = 12.1083(11) Å 
 = 70.703(5)°. 
Volume 816.39(13) Å3 
Z 2 
Density (calculated) 1.370 Mg/m3 
Absorption coefficient 0.256 mm-1 
F(000) 352 
Crystal size 0.05 x 0.05 x 0.05 mm3 
Theta range for data collection 2.64 to 27.44°. 
Index ranges -9<=h<=9, -12<=k<=11, -15<=l<=15 
Reflections collected 5631 
Independent reflections 3672 [R(int) = 0.0337] 
Completeness to theta = 27.44° 98.5 %  
Absorption correction NONE 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3672 / 0 / 215 
Goodness-of-fit on F2 0.973 
Final R indices [I>2sigma(I)] R1 = 0.0521, wR2 = 0.1208 
R indices (all data) R1 = 0.0954, wR2 = 0.1470 
Largest diff. peak and hole 0.203 and -0.268 e.Å-3 
 
Data for compound 33b (chapter 4): 
 






_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum
 'C13 H16 O6' 







 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
_symmetry_cell_setting            orthorhombic 
_symmetry_space_group_name_H-M    'P b c n' 
_symmetry_space_group_name_Hall   '-P 2n 2ab' 
_symmetry_Int_Tables_number       60 
# CRYSTAL DATA 
loop_
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x+1/2, -y+1/2, z+1/2' 
 '-x, y, -z+1/2' 
 'x+1/2, -y+1/2, -z' 
 '-x, -y, -z' 
 'x-1/2, y-1/2, -z-1/2' 
 'x, -y, z-1/2' 
 '-x-1/2, y-1/2, z' 
_cell_length_a                    15.714(3) 
_cell_length_b                    8.2090(16) 
_cell_length_c                    20.299(4) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  90.00 
_cell_angle_gamma                 90.00 
_cell_volume                      2618.5(9) 
_cell_formula_units_Z             8 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     5726
_cell_measurement_theta_min       4.775 
_cell_measurement_theta_max       67.845 
_exptl_crystal_description        plate 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.58 
_exptl_crystal_size_mid           0.53 
_exptl_crystal_size_min           0.15 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.361 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              1136 
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_exptl_absorpt_coefficient_mu     0.109 
_exptl_absorpt_correction_type    'multi-scan' 
_exptl_absorpt_correction_T_min   0.9396 
_exptl_absorpt_correction_T_max   0.9839 
_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 





_diffrn_ambient_temperature       173(2) 
_diffrn_radiation_wavelength      0.71073 
_diffrn_radiation_type            MoK\a 
_diffrn_radiation_source          'sealed tube' 
_diffrn_radiation_monochromator   graphite 
_diffrn_measurement_device_type   'Bruker-Nonius Apex X8-CCD-
diffractometer'
_diffrn_measurement_method        '\w scans' 
_diffrn_detector_area_resol_mean  ? 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             15044 
_diffrn_reflns_av_R_equivalents   0.0217 
_diffrn_reflns_av_sigmaI/netI     0.0170 
_diffrn_reflns_limit_h_min        -16 
_diffrn_reflns_limit_h_max        20 
_diffrn_reflns_limit_k_min        -10 
_diffrn_reflns_limit_k_max        10 
_diffrn_reflns_limit_l_min        -22 
_diffrn_reflns_limit_l_max        26 
_diffrn_reflns_theta_min          2.59 
_diffrn_reflns_theta_max          27.50 
_diffrn_measured_fraction_theta_max    0.997 
_diffrn_reflns_theta_full              27.50 
_diffrn_measured_fraction_theta_full   0.997 
_reflns_number_total              3003 
_reflns_number_gt                 2463 
_reflns_threshold_expression      >2sigma(I) 
_computing_data_collection        'Bruker Apex v2.0-2' 
_computing_cell_refinement        'Bruker Apex v2.0-2' 
_computing_data_reduction         'Bruker SAINT' 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 1997)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 1997)' 
_computing_molecular_graphics     'ORTEP-3 (Farrugia, 1997)'
_computing_publication_material   'SHELXL-97' 
 
Data for compound 33c (chapter 4): 
 





_chemical_name_common             ? 
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_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum
 'C11 H11 Cl O6' 







 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'Cl'  'Cl'   0.1484   0.1585 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
_symmetry_cell_setting            monoclinic 
_symmetry_space_group_name_H-M    'C 2/c' 
_symmetry_space_group_name_Hall   '-C 2yc' 
_symmetry_Int_Tables_number       15 
# CRYSTAL DATA 
loop_
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, y, -z+1/2' 
 'x+1/2, y+1/2, z' 
 '-x+1/2, y+1/2, -z+1/2' 
 '-x, -y, -z' 
 'x, -y, z-1/2' 
 '-x+1/2, -y+1/2, -z' 
 'x+1/2, -y+1/2, z-1/2' 
_cell_length_a                    21.914(4) 
_cell_length_b                    8.1480(16) 
_cell_length_c                    15.168(3) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  119.34(3) 
_cell_angle_gamma                 90.00 
_cell_volume                      2360.8(8) 
_cell_formula_units_Z             8 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     5466
_cell_measurement_theta_min       5.520 
_cell_measurement_theta_max       72.131 
_exptl_crystal_description        block 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.45 
_exptl_crystal_size_mid           0.45 
_exptl_crystal_size_min           0.35 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.545 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              1136 
_exptl_absorpt_coefficient_mu     0.341 
_exptl_absorpt_correction_type    'multi-scan' 
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_exptl_absorpt_correction_T_min   0.8617 
_exptl_absorpt_correction_T_max   0.8900 
_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 





_diffrn_ambient_temperature       173(2) 
_diffrn_radiation_wavelength      0.71073 
_diffrn_radiation_type            MoK\a 
_diffrn_radiation_source          'sealed tube' 
_diffrn_radiation_monochromator   graphite 
_diffrn_measurement_device_type   'Bruker-Nonius Apex X8-CCD-
diffractometer'
_diffrn_measurement_method        '\w scans' 
_diffrn_detector_area_resol_mean  ? 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             18626 
_diffrn_reflns_av_R_equivalents   0.0157 
_diffrn_reflns_av_sigmaI/netI     0.0144 
_diffrn_reflns_limit_h_min        -35 
_diffrn_reflns_limit_h_max        34 
_diffrn_reflns_limit_k_min        -8 
_diffrn_reflns_limit_k_max        13 
_diffrn_reflns_limit_l_min        -22 
_diffrn_reflns_limit_l_max        25 
_diffrn_reflns_theta_min          2.72 
_diffrn_reflns_theta_max          36.23 
_diffrn_measured_fraction_theta_max    0.918 
_diffrn_reflns_theta_full              36.23 
_diffrn_measured_fraction_theta_full   0.918 
_reflns_number_total              5232 
_reflns_number_gt                 4525 
_reflns_threshold_expression      >2sigma(I) 
_computing_data_collection        'Bruker Apex v2.0-2' 
_computing_cell_refinement        'Bruker Apex v2.0-2' 
_computing_data_reduction         'Bruker SAINT' 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 1997)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 1997)' 
_computing_molecular_graphics     'ORTEP-3 (Farrugia, 1997)'
_computing_publication_material   'SHELXL-97' 
 
Data for compound 33d (chapter 4): 
 





_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          'C11 H11 F O6' 
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_chemical_formula_sum
 'C11 H11 F O6' 







 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'F'  'F'   0.0171   0.0103 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
_symmetry_cell_setting            triclinic 
_symmetry_space_group_name_H-M    'P -1' 
_symmetry_space_group_name_Hall   '-P 1' 
_symmetry_Int_Tables_number       2 
# CRYSTAL DATA 
loop_
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, -y, -z' 
_cell_length_a                    7.5980(15) 
_cell_length_b                    7.7540(16) 
_cell_length_c                    10.764(2) 
_cell_angle_alpha                 107.65(3) 
_cell_angle_beta                  96.61(3) 
_cell_angle_gamma                 109.78(3) 
_cell_volume                      551.6(3) 
_cell_formula_units_Z             2 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     4774
_cell_measurement_theta_min       5.887 
_cell_measurement_theta_max       59.193 
_exptl_crystal_description        block 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.23 
_exptl_crystal_size_mid           0.14 
_exptl_crystal_size_min           0.10 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.554 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              268 
_exptl_absorpt_coefficient_mu     0.138 
_exptl_absorpt_correction_type    'multi-scan' 
_exptl_absorpt_correction_T_min   0.9690 
_exptl_absorpt_correction_T_max   0.9864 
_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 






_diffrn_ambient_temperature       173(2) 
_diffrn_radiation_wavelength      0.71073 
_diffrn_radiation_type            MoK\a 
_diffrn_radiation_source          'sealed tube' 
_diffrn_radiation_monochromator   graphite 
_diffrn_measurement_device_type   'Bruker-Nonius Apex X8-CCD-
diffractometer'
_diffrn_measurement_method        '\w scans' 
_diffrn_detector_area_resol_mean  ? 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             13356 
_diffrn_reflns_av_R_equivalents   0.0227 
_diffrn_reflns_av_sigmaI/netI     0.0179 
_diffrn_reflns_limit_h_min        -9 
_diffrn_reflns_limit_h_max        9 
_diffrn_reflns_limit_k_min        -10 
_diffrn_reflns_limit_k_max        10 
_diffrn_reflns_limit_l_min        -13 
_diffrn_reflns_limit_l_max        13 
_diffrn_reflns_theta_min          2.95 
_diffrn_reflns_theta_max          27.50 
_diffrn_measured_fraction_theta_max    0.995 
_diffrn_reflns_theta_full              27.50 
_diffrn_measured_fraction_theta_full   0.995 
_reflns_number_total              2513 
_reflns_number_gt                 2020 
_reflns_threshold_expression      >2sigma(I) 
_computing_data_collection        'Bruker Apex v2.0-2' 
_computing_cell_refinement        'Bruker Apex v2.0-2' 
_computing_data_reduction         'Bruker SAINT' 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 1997)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 1997)' 
_computing_molecular_graphics     'ORTEP-3 (Farrugia, 1997)'
_computing_publication_material   'SHELXL-97' 
Data for compound 35i (chapter 5): 
 





_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          'C18 H15 N O3 S2' 
_chemical_formula_sum
 'C18 H15 N O3 S2' 








 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0061   0.0033 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'S'  'S'   0.1246   0.1234 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
# CRYSTAL DATA 
_symmetry_cell_setting            monoclinic 
_symmetry_space_group_name_H-M    'P 21/n' 
_symmetry_space_group_name_Hall   '-P 2yn' 
_symmetry_Int_Tables_number       14 
loop_
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x+1/2, y+1/2, -z+1/2' 
 '-x, -y, -z' 
 'x-1/2, -y-1/2, z-1/2' 
_cell_length_a                    9.3830(19) 
_cell_length_b                    5.9990(12) 
_cell_length_c                    29.850(6) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  98.42(3) 
_cell_angle_gamma                 90.00 
_cell_volume                      1662.1(6) 
_cell_formula_units_Z             4 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     2847
_cell_measurement_theta_min       4.409
_cell_measurement_theta_max       54.817 
_exptl_crystal_description        block 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.43 
_exptl_crystal_size_mid           0.20 
_exptl_crystal_size_min           0.05 
_exptl_crystal_density_meas       ? 
_exptl_crystal_density_diffrn     1.428 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              744 
_exptl_absorpt_coefficient_mu     0.336 
_exptl_absorpt_correction_type    'multi-scan' 
_exptl_absorpt_correction_T_min   0.8689 
_exptl_absorpt_correction_T_max   0.9834 
_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 
 
Data for compound 35k (chapter 5): 






_chemical_name_common             ? 
_chemical_melting_point           ? 
_chemical_formula_moiety          ? 
_chemical_formula_sum
 'C20 H21 N O5 S' 







 'C'  'C'   0.0033   0.0016 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'H'  'H'   0.0000   0.0000 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'N'  'N'   0.0061   0.0033 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'O'  'O'   0.0106   0.0060 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
 'S'  'S'   0.1246   0.1234 
 'International Tables Vol C Tables 4.2.6.8 and 6.1.1.4' 
_symmetry_cell_setting            monoclinic 
_symmetry_space_group_name_H-M    'C 2/c' 
_symmetry_space_group_name_Hall   '-C 2yc' 
_symmetry_Int_Tables_number       15 
# CRYSTAL DATA 
loop_
 _symmetry_equiv_pos_as_xyz 
 'x, y, z' 
 '-x, y, -z+1/2' 
 'x+1/2, y+1/2, z' 
 '-x+1/2, y+1/2, -z+1/2' 
 '-x, -y, -z' 
 'x, -y, z-1/2' 
 '-x+1/2, -y+1/2, -z' 
 'x+1/2, -y+1/2, z-1/2' 
_cell_length_a                    26.319(5) 
_cell_length_b                    9.903(2) 
_cell_length_c                    17.239(3) 
_cell_angle_alpha                 90.00 
_cell_angle_beta                  123.40(3) 
_cell_angle_gamma                 90.00 
_cell_volume                      3751.1(13) 
_cell_formula_units_Z             8 
_cell_measurement_temperature     173(2) 
_cell_measurement_reflns_used     7494 
_cell_measurement_theta_min       5.659 
_cell_measurement_theta_max       70.541 
_exptl_crystal_description        block 
_exptl_crystal_colour             colourless 
_exptl_crystal_size_max           0.37 
_exptl_crystal_size_mid           0.25 
_exptl_crystal_size_min           0.21 
_exptl_crystal_density_meas       ? 
 154
_exptl_crystal_density_diffrn     1.372 
_exptl_crystal_density_method     'not measured' 
_exptl_crystal_F_000              1632 
_exptl_absorpt_coefficient_mu     0.204 
_exptl_absorpt_correction_type    'multi-scan' 
_exptl_absorpt_correction_T_min   0.9283 
_exptl_absorpt_correction_T_max   0.9584 
_exptl_absorpt_process_details    '(SADABS; Sheldrick, 2004)' 





_diffrn_ambient_temperature       173(2) 
_diffrn_radiation_wavelength      0.71073 
_diffrn_radiation_type            MoK\a 
_diffrn_radiation_source          'sealed tube' 
_diffrn_radiation_monochromator   graphite 
_diffrn_measurement_device_type   'Bruker-Nonius Apex X8-CCD-
diffractometer'
_diffrn_measurement_method        '\w scans' 
_diffrn_detector_area_resol_mean  ? 
_diffrn_standards_number          ? 
_diffrn_standards_interval_count  ? 
_diffrn_standards_interval_time   ? 
_diffrn_standards_decay_%         ? 
_diffrn_reflns_number             33165 
_diffrn_reflns_av_R_equivalents   0.0223 
_diffrn_reflns_av_sigmaI/netI     0.0184 
_diffrn_reflns_limit_h_min        -36 
_diffrn_reflns_limit_h_max        36 
_diffrn_reflns_limit_k_min        -13 
_diffrn_reflns_limit_k_max        13 
_diffrn_reflns_limit_l_min        -24 
_diffrn_reflns_limit_l_max        19 
_diffrn_reflns_theta_min          2.38 
_diffrn_reflns_theta_max          30.00 
_diffrn_measured_fraction_theta_max    0.999 
_diffrn_reflns_theta_full              30.00 
_diffrn_measured_fraction_theta_full   0.999 
_reflns_number_total              5454 
_reflns_number_gt                 4696 
_reflns_threshold_expression      >2sigma(I) 
_computing_data_collection        'Bruker Apex v2.0-2' 
_computing_cell_refinement        'Bruker Apex v2.0-2' 
_computing_data_reduction         'Bruker SAINT' 
_computing_structure_solution     'SHELXS-97 (Sheldrick, 1997)' 
_computing_structure_refinement   'SHELXL-97 (Sheldrick, 1997)' 
_computing_molecular_graphics     'ORTEP-3 (Farrugia, 1997)'
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